IL301078A

IL301078A - Modified b cells and methods of use thereof

Info

Publication number: IL301078A
Application number: IL301078A
Authority: IL
Original assignee: Walking Fish Therapeutics; Walking Fish Therapeutics Inc
Priority date: 2020-09-02
Filing date: 2021-09-02
Publication date: 2023-05-01
Also published as: CN116829160A; MX2023002603A; JP2023539382A; CA3191390A1; WO2022051556A1; AU2021337680A9; EP4203978A1; KR20230091865A; AU2021337680A1; CL2023000602A1

Description

WO 2022/051556 PCT/US2021/048944 MODIFIED B CELLS AND METHODS OF USE THEREOF BACKGROUND OF THE INVENTION [0001]Most cellular immunotherapies to date have focused in T cells. For example, cancer immunotherapies are primarily focused on modification and administration of T cells - enhancing the killer T cell response to a tumor. Modifying B cells for the treatment of various disease, however, is a technique that has not been extensively studied, despite the critical role of B cells in immune responses. [0002]B cells, also known as B lymphocytes, are a type of white blood cell responsible for, among other things, helping the body resist infection and diseases. They are part of our adaptive immune system, and are capable of various immune responses, for example, secreting antibodies in response to a recognized antigen. Additionally, B cells are capable of presenting antigens, and can also secret cytokines. [0003]Many B cells mature into plasma cells that produce antibodies (proteins) capable of fighting off infections. Other B cells mature into memory B cells. All plasma cells descended from a single B cell produce the same antibody that is directed against the antigen that stimulated it to mature. The same principle holds with memory B cells. Thus, all plasma cells and memory cells "remember" the stimulus that led to their formation. The B cell, or B lymphocyte, is not thymus-dependent, has a short lifespan, and is responsible for the production of immunoglobulins. See e.g., https://www.medicinenet.com/script/main/art.asp?articlekey=2413 . The B cell is thus an immunologically important cell. [0004]B cells appear to be associated with patient outcomes in the treatment of cancer. For example, the presence of tertiary lymphoid structures (TLSs) is associated with better patient outcomes. See, e.g., Helmink, B.A., et al., Nature, 2020, 577(7791), 549-555; Petitprez F et al., Nature, 2020, 577(7791), 556-560. TLSs are aggregates of immune cells (mostly T and B cells) that arise in response to immunological stimuli. While TLSs that surround tumor cells include B cells, the role of B cells in antitumor responses have been unclear. B cells found in tumors can produce inhibitory factors that hinder the function of immune cells. See, e.g., Kessel, A., et al., Autoimmun Rev., 2012, 11(9), 670-677; Khan, A.R., et al., Nature Commun., 2015, 6, 5997. Further, current evidence indicates that B cells impede antitumor responses in most mouse models of cancer. Affara, N.I., et al. Cancer Cell, 2014, 25(6), 809-821; Shalapour, S., et al., Nature, 2017, 551, 340-345; Ammirante, M. et al.. Nature, 2010, 464, 302-305. Yet, the presence of B cells in TLS structures is correlated with positive clinical outcomes to cancer immunotherapy. Petitprez 2020. Intratumoral injection of LPS- activated spleen cells, which include B cells, in combination with checkpoint inhibitors has been shown to produce anti-tumor responses. Soldevilla et al., Oncoimmunology, 2018, 7:8, 61450711. [0005]Given the natural ability of B cells to present antigens and secrete proteins, there is great potential as a cellular therapy for targeting certain diseased cell types and secreting therapeutic1 WO 2022/051556 PCT/US2021/048944 payloads. There thus exists a need for alternative treatments beyond T cell therapies, such as engineered B cells, for the treatment of a variety of diseases and disorders, including cancer, heart disease, inflammatory disease, muscle wasting disease, neurological disease, and the like.

SUMMARY OF THE INVENTION [0006]It has now been found that engineered B cells can be efficacious in the treatment of various diseases and disorders as recited herein. The invention therefore relates to modified B cells. [0007]In certain embodiments, the invention relates to an isolated modified B cell ("CAR-B cell), capable of expressing a chimeric receptor ("CAR-B receptor"), wherein said chimeric receptor comprises (a) an extracellular domain; (b) a transmembrane domain; and (c) a cytoplasmic domain that comprises at least one signaling domain. In various embodiments, the extracellular domain comprises an extracellular binding domain and a hinge domain. In various embodiments, the extracellular binding domain(s) recognizes at least one antigen or protein expressed on the surface of a target cell. In various embodiments the target cell is selected from the group consisting of a tumor cell, cardiac muscle cell, a skeletal muscle cell, a bone cell, a blood cell, a nerve cell, a fat cell, a skin cell, and an endothelial cell. In various embodiments, the B cell expresses more than one CAR-B receptor construct. In various embodiments, the CAR-B receptor comprises more than one extracellular binding domain. In various embodiments, the extracellular binding domain is a single chain variable fragment (scFv), or a full-length antibody, or the extracellular domain of a receptor or ligand. In various embodiments, the extracellular binding domain is capable of binding to an antigen or protein selected from the group consisting of: PSMA, GPC3, ASGR1, ASGR2, Sarcoglycan, Corin and Her2. In various embodiments, the hinge domain is derived from the group consisting of IgG, CD28 and CDS. In various embodiments, the hinge domain is comprised of a nucleic acid sequence selected from the group consisting of SEQ ID Nos. 27, 29, 31. In various embodiments, the cytoplasmic domain comprises at least one signaling domain native to B cell receptors. In various embodiments the cytoplasmic domain comprises a domain that is selected from the group consisting of: CD79a (Immunoglobulin a), CD79b (Immunoglobulin [3), CD40, CD19, CD137, Fcyr2a, MyD88, CD21, Syk, FYN, LYN, PI3K, BTK, PLCy2, and BLNK. In various embodiments, the cytoplasmic domain further comprises a costimulatory domain. [0008]In various embodiments, the invention comprises an isolated modified B cell, wherein said B cell is capable of expressing and secreting a payload, wherein the payload is not naturally expressed in a B cell or is expressed at higher levels than is naturally expressed in a B cell. In various embodiments, the payload is an antibody or fragment thereof. In various embodiments, the antibody is a secreted antibody and can include blocking antibodies (eg anti-PD-1) or agonist antibodies (anti- CD 137, GITR, OX40) engineered to contain native or engineered Fc regions. In various embodiments, the antibody is membrane bound. In various embodiments, the payload is selected from the group consisting of: IL-1, IL-7, IL-8, IL-10, IL-12, IL-13, IL-17, IL18, IL-21, interferon a, WO 2022/051556 PCT/US2021/048944 interferon p, interferon y, TSLP, CCL21, FLT3L, XCL1, LIGHT(TNFSF14), OX40L, CD137L, CD40L, ICOSL, anti-CD3 antibody, CD47, TIM4-FC, CXCL13, CCL21, CD80, CD40L, IFNa A2, LIGHT , 4-1BBL, MDGF (C19orfl0), FGF10, PDGF, agrin, TNF-a, GM-CSF, an anti-FAP antibody, an anti-TGF-P antibody; a TGF- trap, decoy or other inhibitory molecule; an anti-BMP antibody; a BMP trap, decoy or other inhibitory molecule. In various embodiments, the B cell is capable of expressing more than one payload. In various embodiments, the B cell is capable of expressing more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 payloads. [0009]In various embodiments, the invention relates to a method of treating a patient comprising administering the modified B cell of the present invention. In various embodiments, the modified B cell is administered intra-tumorally, intravenously, subcutaneously, or intradermally. In various embodiments, the method further comprises administering a checkpoint inhibitor. In various embodiments, the checkpoint inhibitor to a checkpoint molecule that is selected from the group consisting of PD-1, PD-L1, CTLA-4, LAG3, TIM-3 and NKG2A. In various embodiments, the checkpoint inhibitor is a monoclonal antibody.In various embodiments, the invention relates to an isolated modified B cell, capable of expressing a chimeric receptor, wherein said chimeric receptor comprises (a) an extracellular domain, wherein the extracellular domain comprises an extracellular binding domain and a hinge domain; (b) a transmembrane domain; and (c) a cytoplasmic domain that comprises at least one signaling domain, wherein said modified B cell is further capable of expressing a payload, wherein the payload is not naturally expressed on the surface of a cell. In various embodiments, the extracellular binding domain recognizes an antigen or protein expressed on the surface of a target cell. In various embodiments, the target cell is selected from the group consisting of a tumor cell, a cardiac muscle cell, a skeletal muscle cell, a bone cell, a blood cell, a nerve cell, a fat cell, a skin cell and an endothelial cell. In various embodiments, the B cell expresses more than one CAR-B receptor construct. In various embodiments, the CAR-B receptor comprises more than one extracellular binding domain. In various embodiments, the extracellular binding domain is a single chain variable fragment (scFv), an antibody, or the extracellular domain of a receptor or ligand. In various embodiments, the extracellular binding domain is capable of binding to an antigen or protein selected from the group consisting of PSMA, GP3, ASGR1, ASGR2, Sarcoglycan, Corin and Her2. In various embodiments, the hinge domain is derived from the group consisting of IgG, CDand CD8. In various embodiments, the hinge domain is comprised of a nucleic acid sequence selected from the group consisting of SEQ ID Nos. 27, 29, and 31. In various embodiments, the cytoplasmic domain comprises at least one signaling domain native to B cells. In various embodiments, the cytoplasmic domain comprises a domain selected from the group consisting of: CD79a (Immunoglobulin a), CD79b (Immunoglobulin P), CD40, CD19, CD137, Fcyr2a, MyD88, CD21, Syk, FYN, LYN, PI3K, BTK, PLCy2, and BLNK. In various embodiments, the cytoplasmic domain further comprises a costimulatory domain. In various embodiments, the payload is a secreted or membrane bound antibody or fragment thereof. In various embodiments, the payload is selected WO 2022/051556 PCT/US2021/048944 from the group consisting of: IL-1, IL-7, IL-8, IL-10, IL-12, IL-13, IL-17, IL-18, IL-21, interferon a, interferon p, interferon y, TSLP, CCL21, FLT3L, XCL1, LIGHT(TNFSF14), OX40L, CD137L, CD40L, ICOSL, anti-CD3 antibody, CD47, TIM4-FC, CXCL13, CCL21, CD80, CD40L, IFNa A2, LIGHT , 4-1BBL, MDGF (C19orfl0), FGF10, PDGF, agrin, TNF-a, GM-CSF, an anti-FAP antibody, an anti-TGF-P antibody; a TGF- trap, decoy or other inhibitory molecule; an anti-BMP antibody; a BMP trap, decoy or other inhibitory molecule. In various embodiments, the B cell is capable of expressing more than one payload. In various embodiments, the B cell is capable of expressing more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 payloads. In various embodiments, the modified B cell further encodes at least one protein selected from the group consisting of: the cytoplasmic domains of CD79a, CD79b, CD40, CD19, CD137, Fcyr2a and MyD88. In various embodiments, the intention relates to a method of treating a patient comprising administering the modified B cell. In various embodiments, the method further comprises administering a checkpoint inhibitor. In various embodiments, the checkpoint inhibitor is selected from inhibitors to one or more checkpoint molecules from the group consisting of: PD-1, PD-L1, CTLA-4, LAG3, TIM-3 andNKG2A. In various embodiments, the checkpoint inhibitor is a monoclonal antibody. In various embodiments, the present invention relates to an isolated modified B cell, capable of expressing a chimeric receptor, wherein said chimeric receptor comprises an extracellular domain, wherein said extracellular domain comprises a hinge domain and an extracellular binding domain, wherein said extracellular binding domain is not naturally expressed on a B cell; and wherein said extracellular binding domain is capable of recognizing a target of interest. In various embodiments, the binding domain is a single chain variable fragment (scFv), antibody, ligand or receptor. In various embodiments, the binding domain is an ScFv. In various embodiments, the binding domain is a receptor, a ligand, or a fragment thereof. In various embodiments, the B cell is further capable of expressing a payload. In various embodiments, the invention comprises a method of treating a patient comprising administering the modified B cell to a patient. [0010]In various embodiments, the present invention comprises a nucleic acid capable of expressing a chimeric B cell receptor, wherein said chimeric receptor comprises: (a) an extracellular domain, wherein said extracellular domain comprises an extracellular binding domain and a hinge domain; (b) a transmembrane domain; and (c) a cytoplasmic domain that comprises at least one signaling domain. In various embodiments, the extracellular binding domain, recognizes an antigen or protein expressed on the surface of a target cell. In various embodiments, the extracellular binding domain is a single chain variable fragment (scFv), antibody, receptor or ligand. In various embodiments, the target cell is selected from the group consisting of a tumor cell, a cardiac muscle cell, a skeletal muscle cell, a bone cell, a blood cell, a nerve cell, a fat cell, a skin cell and an endothelial cell. In various embodiments, the vector expresses more than one CAR-B receptor. In various embodiments, the CAR-B receptor expresses more than one extracellular binding domain. In various embodiments, the extracellular binding domain is capable of binding to an antigen or protein selected from the group WO 2022/051556 PCT/US2021/048944 consisting of: PSMA, GP3, ASGR1, ASGR2, Sarcoglycan, Corin, Her2, FAP1, MUC1, CEA153, JAM-1, and LFA-1. In various embodiments, the hinge domain is derived from the group consisting of IgG, CD28 and CDS. In various embodiments, the hinge domain is comprised of a nucleic acid sequence selected from the group consisting of SEQ ID Nos. 27, 29, and 31. In various embodiments, the cytoplasmic domain comprises at least one signaling domain native to B cell receptors. In various embodiments, the cytoplasmic domain comprises a domain selected from the group consisting of: CD79a (Immunoglobulin a), CD79b (Immunoglobulin P), CD40, CD19, CD137, Fcyr2a, MyD88, CD21, Syk, FYN, LYN, PI3K, BTK, PLCy2, and BLNK. In various embodiments, the cytoplasmic domain further comprises a costimulatory domain. [0011]In various embodiments, the invention relates to a vector comprising a nucleic acid capable of expressing a chimeric B cell receptor, wherein said chimeric receptor comprises: (a) an extracellular domain, wherein said extracellular domain comprises an extracellular binding domain and a hinge domain; (b) a transmembrane domain; and (c) a cytoplasmic domain that comprises at least one signaling domain. In various embodiments, the extracellular binding domain recognizes an antigen or protein. In various embodiments, the target cell is selected from the group consisting of a tumor cell, a cardiac muscle cell, a skeletal muscle cell, a bone cell, a blood cell, a nerve cell, a fat cell, a skin cell and an endothelial cell. In various embodiments, the vector expresses more than one CAR-B receptor. In various embodiments, the CAR-B expresses more than one extracellular binding domain. In various embodiments, the extracellular binding domain is a single chain variable fragment (scFv), antibody, receptor or ligand. In various embodiments, the extracellular binding domain is capable of binding to an antigen or protein selected from the group consisting of: PSMA, GPC3, ASGR1, AGSR2, Sarcoglycan, Corin, Her2, FAP1, MUC1, CEA153, JAM-1, and LFA-1. In various embodiments, the hinge domain is derived from the group consisting of IgG, CD28 and CD8. In various embodiments, the hinge domain is comprised of a nucleic acid sequence selected from the group consisting of SEQ ID Nos. 27, 29, and 31. In various embodiments, the cytoplasmic domain comprises at least one signaling domain native to B cells. In various embodiments, the cytoplasmic domain comprises a signaling domain selected from the group consisting of: CD79a (Immunoglobulin a), CD79b (Immunoglobulin p), CD40, CD19, CD137, Fcyr2a, MyD88, CD21, Syk, FYN, LYN, PI3K, BTK, PLCy2, and BLNK. In various embodiments, the cytoplasmic domain further comprises a costimulatory domain. [0012]In various embodiments, the invention relates to an isolated modified B cell, capable of expressing an integrin, a homing antibody, protein, a receptor, or combinations thereof, wherein said integrin, homing antibody, protein, or receptor is not naturally expressed in a B cell or is expressed at higher levels than is naturally expressed in a B cell; and wherein said integrin, homing antibody, protein, receptor, or combinations thereof is attracted to a site or target of interest. In various embodiments, the integrin, homing antibody, protein, and receptor is selected from CLA (PSGL-glycoform), CLA (PSGL-1 glycoform), CCR10, CCR3, CCR4, CCR5, CCR6, CCR9, CD43E, CD44, WO 2022/051556 PCT/US2021/048944 c-Met, CXCR3, CXCR4, LFA-1, LFA-1 (aL02), selectin ligands, VLA-4, VLA-4 (a401), and a4p7, or combinations thereof. In various embodiments, the site of interest is a homing or target tissue, an inflammatory site in a specific location or tissue, or a tumor or tumor microenvironment, where delivery of payloads is desirable. In various embodiments, the homing or target tissue is selected from skin, gut (intestine, colon, mesenteric lymph nodes (mLN), Peyer’s Patch (PP), small intestine), liver, lung, bone marrow, heart, peripheral lymph node (LN), CNS, thymus, and bone marrow. In various embodiments, the target of interest is selected from CXCL16, CCL17, CCL 17(22), CCL(MIP-3a), CCL21, CCL25, CCL27, CCL28, CCL4, CCL5, CD62E, CD62P, CXCL10, CXCL12, CXCL13, CXCL16, CXCL9/CXCL10, CXCR3, E/P-selectin, E-selectin, GPR15L, HGF, Hyaluronate, ICAM-1, ligands for CCR1, 2, 5, MAdCAM, MAdCAM-1, PNAd, VAP-1, VCAM, and VCAM-1, or combinations thereof. In various embodiments, the method comprises treating a patient by administering the isolated modified B cell. In various embodiments, the method involves further administering a compound or a derivative thereof, wherein the compound or derivative thereof is capable of increasing the expression of the integrin, homing antibody, protein, and receptor, or combinations thereof. In various embodiments, the compound or a derivative thereof is capable of altering trafficking of B cells to a site or target of interest in the patient. In various embodiments, the compound is all-trans-retinoic acid (ATRA) or a derivative thereof. [0013]In various embodiments, the invention relates to an isolated modified B cell, capable of expressing an immune inhibitory molecule, wherein said immune inhibitory molecule is not naturally expressed in a B cell or is expressed at higher levels than is naturally expressed in a B cell. In various embodiments, said immune inhibitory molecule is selected from IL-10, TGF-0, PD-L1, PD-L2, LAG- 3, and TIM-3, or combinations thereof. In various embodiments, said immune inhibitory molecule is capable of decreasing inflammation and autoimmune activity of B cells at a site or target of interest in a patient. In various embodiments, the invention relates to a method of treating a patient comprising administering said isolated modified B cell. In various embodiments, said immune inhibitory molecule is selected from IL-10, TGF-0, PD-L1, PD-L2, LAG-3, and TIM-3, or combinations thereof. In various embodiments, said immune inhibitory molecule is capable of decreasing inflammation and autoimmune activity of B cells at a site or target of interest in the patient. In various embodiments, the invention relates to further administering a compound or a derivative thereof capable of increasing the expression of an integrin, a homing antibody, a protein, a receptor, or combinations thereof in the B cell. In various embodiments, said compound or derivative thereof is capable of altering trafficking of B cells to a site or target of interest in the patient. In various embodiments, said compound is all-trans-retinoic acid (ATRA) or a derivative thereof. In various embodiments, the invention relates to an isolated modified B cell, wherein the isolated modified B cell is treated with a compound or a derivative thereof, wherein said compound or derivative thereof is capable of increasing the expression of an integrin, a homing antibody, a protein, a receptor, or combinations thereof in B cells. In various embodiments, said compound or derivative thereof is WO 2022/051556 PCT/US2021/048944 capable of altering trafficking of B cells to a site or target of interest in the patient. In various embodiments, said compound is all-trans-retinoic acid (ATRA) or a derivative thereof. In various embodiments, said compound or derivative thereof is capable of (i) increasing the expression of an integrin, a homing antibody, a protein, a receptor, or combinations thereof in B cells, and (ii) altering trafficking of B cells to a site or target of interest in the patient. In various embodiments, said compound is all-trans-retinoic acid (ATRA) or a derivative thereof. [0014]In various embodiments, the invention relates to an isolated modified B cell, capable of expressing at least one or more of a constitutively active Toll-like receptor (TLR), wherein said TLR is not naturally expressed in a B cell or is expressed at higher levels than is naturally expressed in a B cell. In various embodiments, said TLR is selected from TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9, TLR10, TLR11, TLR12, and TLR13, or combinations thereof. In various embodiments, said TLR is capable of potentiating B cells for increasing immune responses in a patient. In various embodiments, said TLR is capable of producing potent effector B cells for increasing immune responses in a patient. In various embodiments, said immune inhibitory molecule is capable of decreasing inflammation and autoimmune activity of B cells at a site or target of interest in a patient. In various embodiments, said TLR is selected from TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9, TLR10, TLR11, TLR12, and TLR13, or combinations thereof. In various embodiments, said TLR is capable of (i) potentiating B cells, and (ii) producing potent effector B cells, for increasing immune responses in a patient. In various embodiments, at least one or more of a TLR agonist is administered to the patient. In various embodiments, the isolated modified B cell is treated with at least one or more of a TLR agonist. In various embodiments, said TLR agonist is capable of (i) potentiating B cells, and (ii) producing potent effector B cells, for increasing immune responses in a patient. In various embodiments, said TLR agonist binds to one or more TLRs selected from TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9, TLR10, TLR11, TLR12, and TLR13, or combinations thereof. In various embodiments, said TLR agonist is selected from CpG-rich oligonucleotides, double-stranded RNA mimic, polyinosinic acid:polycytidylic acid (poly-I:C). In various embodiments, said TLR agonist comprises CpG oligonucleotides. In various embodiments, said TLR agonist is capable of is capable of (i) potentiating B cells, and (ii) producing potent effector B cells, for increasing immune responses in the patient. In various embodiments, said TLR agonist binds to one or more TLRs selected from TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9, TLR10, TLR11, TLR12, and TLR13, or combinations thereof. In various embodiments, said TLR agonist is selected from CpG-rich oligonucleotides, double-stranded RNA mimic, polyinosinic acid:polycytidylic acid (poly-I:C). In various embodiments, said TLR agonist comprises CpG oligonucleotides. [0015]In various embodiments, the invention relates to an isolated modified B cell, wherein said B cell is electroporated with an mRNA encoding at least one or more of an antigen fused to a targeting signal. In various embodiments, said antigen is (i) not naturally presented by a B cell, (ii) not WO 2022/051556 PCT/US2021/048944 presented by a B cell simultaneously in both HLA class I and class II molecules naturally, or (iii) not presented by a B cell with high efficiencies in both HLA class I and class II molecules naturally. In various embodiments, said targeting signal is targeting signal of a lysosomal protein. In various embodiments, said targeting signal is a targeting signal of lysosome-associated membrane protein-(LAMP1). In various embodiments, said antigen is capable of being targeted to the lysosomes and presented simultaneously and efficiently in both HLA class I and class II molecules. In various embodiments, said B cells is capable of increasing antigen-specific immune responses in a patient. In various embodiments, said antigen is (i) not naturally presented by a B cell, (ii) not presented by a B cell simultaneously in both HLA class I and class II molecules naturally, or (iii) not presented by a B cell with high efficiencies in both HLA class I and class II molecules naturally. In various embodiments, said targeting signal is targeting signal of a lysosomal protein. In various embodiments, said targeting signal is a targeting signal of lysosome-associated membrane protein-(LAMP1). In various embodiments, said antigen is capable of being targeted to the lysosomes and presented simultaneously and efficiently in both HLA class I and class II molecules. In various embodiments, said B cells is capable of increasing antigen-specific immune responses in the patient.

BRIEF DESCRIPTION OF THE FIGURES [0016]FIG. 1 sets forth an example of a chimeric B Cell Receptor (a cBCR or CAR-B) of the present invention. In certain embodiments, the CAR-B construct will comprise an extracellular domain, a transmembrane domain, and a cytoplasmic domain. As depicted in FIG. 1, the extracellular domain may in certain embodiments comprise a binding domain and a hinge region. In certain embodiments, the binding region may be an scFv. CAR-B constructs are cloned into a viral vector for expression. [0017]FIG. 2A-2C shows examples of engineered B cells with homing domains. In various embodiments, the engineered B cells may comprise (a) an scFv binding domain and optional hinge region; (b) an scFv binding domain directly linked to the cell, or (c) a ligand/receptor binding domain directly linked to a cell. [0018]FIG. 3 shows examples of certain CAR-B constructs of the present invention. (A) CAR-B that binds GPC3. (B) CAR-B that binds PSMA. [0019]FIG. 4 shows examples of CAR-B receptors of the present invention capable of binding (A) GPC3 and (B) PSMA. [0020]FIG. 5 sets forth expression of anti-PSMA on the surface of HEK-293 cells. [0021]FIG. 6A-6C sets forth a FACS Plot illustrating binding of anti-PSMA cBCR and of anti- sarcoglycan cBCR to PSMA. B cells expressing pWF391 (anti-PSMA cBCR) bound PSMA whereas the B cells expressing pWF394 (anti-sarcoglycan cBCR) did not bind PSMA. [0022]FIG. 7 illustrates the ability of adenovirus F35 encoding GFP to transduce human B cells. Human B cells were isolated from peripheral blood. The B cells were infected with adenovirus encoding GFP. 0, 1,3, 10 represent the microliter volume of the adenovirus preparation used to infect 8 WO 2022/051556 PCT/US2021/048944 human B cells. [0023]FIG. 8 describes an experiment where BALB/c mice were injected with CT26 bilateral tumors at day zero. At day 12 and day 16, tumor-bearing mice were injected intra-tumorally with payload- expressing cells at a volume of 106 in 50 pL. [0024]FIG. 9 illustrates the effect of 12 different combinations of payloads injected intra-tumorally on tumor volume over 30-35 days as compared to saline and 3T3 cells (without a payload). [0025]FIG. 10 illustrates the effect of 12 different combinations of payloads injected intra-tumorally on tumor volume over 30-35 days as compared to saline and 3T3 cells (without a payload). [0026]FIG. 11A-1 IC illustrates the effect of the top three combinations of pay loads injected intra- tumorally on tumor volume over 30 days as compared to saline and 3T3 cells (without a payload). [0027]FIG. 12 illustrates the abscopal effect of intratumorally injected B cells. B cells were then injected either (i) fresh or (ii) first stimulated for 16-24 hours in growth media (RPMI, 10% FBS, 1% Pen/Strep, 5ng/ml recombinant mouse IL-4, WOuM beta-mercaptoethanol) with 5 ug/ml Lipopolysaccharide. 5X106 B cells were then intratumorally injected into the CT26 mouse model, and anti-tumor responses in the distal (abscopal) tumor where measured. Tumors were implanted at day 0, and at day 6 palpable tumor mass was observed. Treatment was initiated on day intratumorally. [0028]FIG. 13A-13C illustrates expression of CAR-B receptors (also referred to as cBCR receptors) in various cell types 24 hours post transfection. DETAILED DESCRIPTION [0029]The invention disclosed herein relates to several embodiments of engineered or modified B cells:1. B cells that have been modified to home to a site/target of interest, using, e.g., a binding domain such as an scFv, antibody, ligand, receptor, or fragments thereof;2. B cells that have been modified with a homing domain, further comprising an activation, and optionally a costimulatory domain, such that the B cells can home and activate upon interaction with a desired target;3. B cells engineered to be capable of making a desired protein payload, such as an antibody, therapeutic protein, polypeptide, nucleic acid sequence (such as RNAi) or the like;4. Engineered B cells comprising a homing/binding domain, an activating domain, an optional costimulatory domain, and further engineered to express a desire protein payload, such as an antibody, therapeutic protein, polypeptide, nucleic acid sequence (such as RNAi) or the like;5. B cells that have been modified to express an integrin, a homing antibody, protein, or a receptor, such that the B cells are attracted to specific ligands, chemokines, or attractants at a specific site/target of interest (e.g., a homing tissue) and can thereby9 WO 2022/051556 PCT/US2021/048944 home to the site/target of interest, for example, to deliver a desired payload;6. B cells that have been modified to express an immune inhibitory molecule, such that the inflammation and autoimmune activity of B cells localized to a site/target of interest is decreased, thereby leading to a positive therapeutic response;7. B cells that have been treated with a compound or derivatives thereof, such that trafficking of the B cells is altered by expression of specific B cell integrins and/or homing receptors;8. B cells that have been (i) treated with a Toll-like receptor (TLR) agonist, and/or (ii) engineered to express a constitutively active TLR, for potentiating B cells and/or producing potent effector B cells for increasing immune responses in a subject;9. B cells that have been electroporated with an mRNA encoding specific antigens of interest fused to a targeting signal of a lysosomal protein, such that the B cells can simultaneously and efficiently present the specific antigens and/or antigen-derived epitopes of interest in both HLA class I and class II molecules.10. B cells that have been electroporated with a self-amplifying RNA that encodes any items noted heretofore in 1-9. [0030]It is understood that the various embodiments of engineered or modified B cells of the present application are not mutually exclusive and can be combined with each other in any way and without any restriction unless explicitly indicated, for achieving of facilitating any of the results and/or therapeutic responses contemplated herein. [0031] Tumor Antigen.In certain embodiments, the site/target of interest is a tumor antigen. The selection of the antigen-binding domain (moiety) of the invention will depend on the particular type of cancer to be treated. Some tumor antigens may be membrane bound, whereas other may be secreted. For example, a tumor antigen may be secreted and accumulate in the extracellular matrix, or the tumor antigen may be expressed as part of the MHC complex. Tumor antigens are well known in the art and may include, for example, CD 19, KRAS, HGF, CLL, a glioma-associated antigen, carcinoembryonic antigen (CEA); -human chorionic gonadotropin, alphafetoprotein (AFP), lectin- reactive AFP, thyroglobulin, RAGE-1, MN-CA IX, human telomerase reverse transcriptase, RUI, RU2 (AS), intestinal carboxyl esterase, mut hsp70-2, M-CSF, prostase, prostate-specific antigen (PSA), PAP, NY-ESO-1, LAGE-la, p53, protein, PSMA, Her2/neu, survivin and telomerase, prostate-carcinoma tumor antigen-1 (PCTA-1), MAGE, ELF2M, neutrophil elastase, ephrinB2, CD22, insulin growth factor (IGF)-I, IGF-II, IGF-I receptor, mesothelin, EGFR, BCMA, KIT and IL- 13. [0032] Infectious Disease Antigen.In certain embodiments, the site/target of interest is an infectious disease antigen against which an immune response may be desired. Infectious disease antigens are well known in the art and may include, but are not limited to, viruses, bacteria, protists, and parasitic antigens, such as parasites, fungi, yeasts, mycoplasma, viral proteins, bacterial proteins 10 WO 2022/051556 PCT/US2021/048944 and carbohydrates, and fungal proteins and carbohydrates. In addition, the type of infectious disease of the infectious disease antigen is not particularly limited, and may include, but are not limited to, intractable diseases among viral infectious diseases such as AIDS, hepatitis B, Epstein Barr Virus (EBV) infection, HPV infection, HCV infection, etc. Parasitic antigens may include, but are not limited to, the malaria parasite sporozoide protein. [0033]In certain embodiments the modified B cells express an engineered B cell receptor (CAR-B) comprising an extracellular domain, a transmembrane domain and an intracellular domain. In certain embodiments, the extracellular domain comprises a binding domain and a hinge domain. In certain embodiments, the extracellular domain comprises a binding domain, such as an scFv, ligand, antibody, receptor, or fragment thereof which allows the modified B cell to target specific target cells by binding to proteins expressed on the surface of those cells. In certain embodiments, the modified tumor cells target and bind to proteins/antigens expressed on the surface of tumor cells. In certain embodiments, the modified B cell further expresses a payload. In certain embodiments, the payload is capable of increasing the number of cross-presenting dendritic cells (DC) in tumors. In certain embodiments, the payload is capable of activating and attracting T cells into tumors. In certain embodiments, the payload is capable of fomenting the formation of tertiary lymphoid structures (TLS) in tumors. In certain embodiments of the invention, the modified B cell expresses both a CAR- B and a payload. In certain embodiments, the CAR-B comprises stimulatory domains that activate expression of the payload when bound to an antigen or protein expressed on the surface of a tumor cell. 1. Design and domain orientation of Chimeric Antigen Receptors in B Cells (CAR-Bs) [0034]In various embodiments, the invention provides a chimeric B Cell Receptor (CAR-B). It will be appreciated that chimeric B cell receptors (CAR-Bs) are genetically engineered receptors. These engineered receptors can be readily inserted into and expressed by B cells in accordance with techniques known in the art. With a CAR-B, a single receptor can be programmed to both recognize a specific protein or antigen expressed on a tumor cell, and when bound to said protein or antigen elicit an anti-tumor response. In various embodiments, the CAR-Bs serve in part as a homing mechanism to deliver B cells to target tissue. [0035]It will be appreciated that relative to the cell bearing the receptor, the chimeric B cell receptor of the invention will comprise an extracellular domain (which will comprise an antigen-binding domain and may comprise an extracellular signaling domain and/or a hinge domain), a transmembrane domain, and an intracellular domain. The intracellular domain comprises at least an activating domain, preferably comprised of CD79a (Immunoglobulin a), CD79b (Immunoglobulin [3), CD40, CD 19, CD 137, Fcyr2a and/or MyD88. It will further be appreciated that the antigen-binding domain is engineered such that it is located in the extracellular protion of the molecule/construct, such that it is capable of recognizing and binding to its target or targets. [0036]Structurally it will be appreciated that these domains correspond to locations relative to the 11 WO 2022/051556 PCT/US2021/048944 immune cell. Exemplary CAR-B constructs in accordance with the invention are set forth in Table 1: TABLE 1 Construct NameExtracellularDomainHinge 1■ Signal 1 Signal 2 pWF-82 anti-PSMA CD8 CD28 hCD19pWF-83 anti-PSMA CD8 CD28 hCD40pWF-84 anti-PSMA CD8 CD28 hCD40 CD79bpWF-85 anti-PSMA CD8 CD28 hCD40 CD137pWF-86 anti-PSMA CD8 CD28 hCD40 Fcyr2apWF-87 anti-PSMA CD8 CD28 hMyd88 hCD40pWF-88 anti-PSMA CD8 CD28 CD79apWF-89 anti-PSMA CD8 CD28 CD79bpWF-391 anti-PSMA 3x strep II tag CD28 CD79bpWF-394 anti-Sarcoglycan 3x strep II tag CD28 CD79bpWF-396 anti-GPC-3 CD8 CD28 CD79apWF-397 anti-GPC-3 CD8 CD28 CD79bpWF-460 anti-GPC-3 Human IgGl Fc CD28 CD79apWF428 anti-GPC-3 Human LambdaConstant regionHumanLambda ConstantregionpWF429 anti-GPC-3 Human IgGl Fc HumanIgGl FcpWF-521 Anti-GPC3 vL- hclambda constant region- linker-vH-hcHl- cH2-cH3 Human IgGl Fc HumanIgGlEndogenousBCR complex pWF-533 Anti-GPC3-vL-hcHlHuman IgGl (complex with pWF534) EndogenousBCR complex pWF-534 Anti-GPC3-vH- hcKappa-hcH2- cH3 Human IgGl Fc HumanIgGlEndogenousBCR complex WO 2022/051556 PCT/US2021/048944 id="p-37" id="p-37" id="p-37" id="p-37" id="p-37" id="p-37" id="p-37" id="p-37" id="p-37" id="p-37" id="p-37"

[0037]In various embodiments, chimeric B cell receptors are comprised of an extracellular domain, a transmembrane domain and a cytoplasmic domain. In various embodiments, the cytoplasmic domain comprises an activating domain. In various embodiments, the cytoplasmic domain may also comprise a co-stimulatory domain. In various embodiments, the extracellular domain comprises an antigen- binding domain. In various embodiments, the extracellular domain further comprises a hinge region between the antigen-binding domain and the transmembrane domain. FIG. 1 provides a schematic representation of a chimeric B cell receptor of various embodiments of the present invention. [0038] Extracellular Domain.A number of extracellular domains may be used with the present invention. In various embodiments, the extracellular domain comprises an antigen-binding domain. In various embodiments, the extracellular domain may also comprise a hinge region and/or a signaling domain. In various embodiments, the extracellular domains containing IgGl constant domain may also comprise either IgGl (hole) or IgGl (knob) to facilitate directed cBCR formation. [0039] Antigen-Binding Domain and Binding Domain.As used herein, an "antigen binding domain," "antigen-binding domain" or "binding domain" refers to a portion of the B-CAR capable of binding an antigen or protein expressed on the surface of a cell. In some embodiments, the antigen- binding domain binds to an antigen or protein on a cell involved in a hyperproliferative disease. In preferred embodiments, the antigen-binding domain binds to an antigen or protein expressed on the surface of a tumor cell. The antigen-binding molecules will be further understood in view of the definitions and descriptions below. [0040]An antigen-binding domain is said to "specifically bind" its target antigen or protein when the dissociation constant (Kd) is 1x107־ M. The antigen-binding domain specifically binds antigen with "high affinity" when the Kd is l-5xl09־ M, and with "very high affinity" when the Kd is l-5xlO10 M. In one embodiment, the antigen-binding domain has a Kd of 109־ M. In one embodiment, the off-rate is WO 2022/051556 PCT/US2021/048944 epitopes. [0044]The term "antibody" refers to what are known as immunoglobulins, Y-shaped proteins that are produced by the immune system to recognize a particular antigen. The term "antibody fragment" refers to antigen-binding fragments and Fc fragments of antibodies. Types of antigen-binding fragments include: F(ab’)2, Fab, Fab’ and Fv molecules. Fc fragments are generated entirely from the heavy chain constant region of an immunoglobulin. [0045] Extracellular Signaling Domains.The extracellular domain is beneficial for signaling and for an efficient response of lymphocytes to an antigen. Extracellular domains of particular use in this invention may be derived from (i.e., comprise) CD28, CD28T (See e.g., U.S. Patent Application US2017/0283500A1), OX40, 4-1BB/CD137, CD2, CD7, CD27, CD30, CD40, programmed death-(PD-1), inducible T cell costimulator (ICOS), lymphocyte function-associated antigen-1 (LFA-1, CDl-la/CD18), CD3 gamma, CD3 delta, CD3 epsilon, CD247, CD276 (B7-H3), LIGHT, (TNFSF14), NKG2C, CD79a (Immunoglobulin a), CD79b (Immunoglobulin [3), DAP-10, Fc gamma receptor, MHC class 1 molecule, TNF receptor proteins, an Immunoglobulin protein, cytokine receptor, integrins, Signaling Lymphocytic Activation Molecules (SLAM proteins), activating NK cell receptors, BTLA, a Toll ligand receptor, ICAM-1, B7-H3, CDS, ICAM-1, GITR, BAFFR, LIGHT, HVEM (LIGHTR), KIRDS2, SLAMF7, NKp80 (KLRF1), NKp44, NKp30, NKp46, CD19, CD4, CDSalpha, CDSbeta, IL-2R beta, IL-2R gamma, IL-7R alpha, ITGA4, VLA1, CD49a, ITGA4, IA4, CD49D, ITGA6, VLA-6, CD49f, ITGAD, CDlld, ITGAE, CD103, ITGAL, CD1 la, LFA-1, ITGAM, CD1 lb, ITGAX, CDllc, ITGB1, CD29, ITGB2, CD18, LFA-1, ITGB7, NKG2D, TNFR2, TRANCE/RANKL, DNAM1 (CD226), SLAMF4 (CD244, 2B4), CD84, CD96 (Tactile), CEACAM1, CRT AM, Ly9 (CD229), CD160 (BY55), PSGL1, CD100 (SEMA4D), CD69, SLAMF6 (NTB-A, Lyl08), SLAM (SLAMF1, CD150, IPO-3), BLAME (SLAMF8), SELPLG (CD162), LTBR, LAT, GADS, SLP-76, PAG/Cbp, CD 19a, a ligand that specifically binds with CD83, or any combination thereof. The extracellular domain may be derived either from a natural or from a synthetic source. [0046] Hinge Domains.As described herein, extracellular domains often comprise a hinge portion. This is a portion of the extracellular domain proximal to the cell membrane. The extracellular domain may further comprise a spacer region. A variety of hinges can be employed in accordance with the invention, including costimulatory molecules as discussed above, as well as immunoglobulin (Ig) sequences a 3X strep II spacer or other suitable molecules to achieve the desired special distance from the target cell. In some embodiments, the entire extracellular region comprises a hinge region. In some embodiments, the hinge region comprises the extracellular domain of CD28, or CD8 or a portion thereof as described herein. [0047] Transmembrane Domains.The B-CAR can be designed to comprise a transmembrane domain that is fused or otherwise linked to the extracellular domain of the B-CAR. It can similarly be fused to the intracellular domain of the B-CAR. In one embodiment, the transmembrane domain that naturally is associated with one of the domains in a B-CAR is used. In some instances, the 14 WO 2022/051556 PCT/US2021/048944 transmembrane domain can be selected or modified by amino acid substitution to avoid binding of such domains to the transmembrane domains of the same or different surface membrane proteins to minimize interactions with other members of the receptor complex. The transmembrane domain may be derived either from a natural or from a synthetic source. Where the source is natural, the domain may be derived from any membrane-bound or transmembrane protein. Transmembrane regions of particular use in this invention may be derived from (i.e. comprise) CD28, CD28T, OX-40, 4- 1BB/CD137, CD2, CD7, CD27, CD30, CD40, programmed death-1 (PD-1), inducible T cell costimulator (ICOS), lymphocyte function-associated antigen-1 (LFA-1, CDl-la/CD18), CDgamma, CD3 delta, CD3 epsilon, CD247, CD276 (B7-H3), LIGHT, (TNFSF14), NKG2C, CD79a (Immunoglobulin a), CD79b (Immunoglobulin P), DAP-10, Fc gamma receptor, MHC class molecule, TNF receptor proteins, an Immunoglobulin protein, cytokine receptor, integrins, Signaling Lymphocytic Activation Molecules (SLAM proteins), activating NK cell receptors, BTLA, a Toll ligand receptor, ICAM-1, B7-H3, CDS, ICAM-1, GITR, BAFFR, LIGHT, HVEM (LIGHTR), KIRDS2, SLAMF7, NKp80 (KLRF1), NKp44, NKp30, NKp46, CD19, CD4, CD8alpha, CD8beta, IL-2R beta, IL-2R gamma, IL-7R alpha, ITGA4, VLA1, CD49a, ITGA4, IA4, CD49D, ITGA6, VLA- 6, CD49f, ITGAD, CDlld, ITGAE, CD103, ITGAL, CD1 la, LFA-1, ITGAM, CD1 lb, ITGAX, CD1c, ITGB1, CD29, ITGB2, CD18, LFA-1, ITGB7, NKG2D, TNFR2, TRANCE/RANKL, DNAM(CD226), SLAMF4 (CD244, 2B4), CD84, CD96 (Tactile), CEACAM1, CRT AM, Ly9 (CD229), CD 160 (BY55), PSGL1, CD 100 (SEMA4D), CD69, SLAMF6 (NTB-A, Lyl08), SLAM (SLAMF1, CD 150, IPO-3), BLAME (SLAMF8), SELPLG (CD 162), LTBR, LAT, GADS, SLP-76, PAG/Cbp, CD19a, a ligand that specifically binds with CD83, or any combination thereof. [0048]Optionally, short linkers may form linkages between any or some of the extracellular, transmembrane, and intracellular domains of the B-CAR. [0049]In certain embodiments, the transmembrane domain in the B-CAR of the invention is the CD28 transmembrane domain. In one embodiment, the CD28 transmembrane domain comprises the nucleic acid sequence of SEQ ID NO: 1. In one embodiment, the CD28 transmembrane domain comprises the nucleic acid sequence that encodes the amino acid sequence of SEQ ID NO: 2. In one embodiment, the CD28 transmembrane domain comprises the nucleic acid sequence of SEQ ID NO: 3. In another embodiment, the CD28 transmembrane domain comprises the amino acid sequence of SEQ ID NO: 4. [0050]In one embodiment, the transmembrane domain in the B-CAR of the invention is a CDtransmembrane domain. [0051] Intracellular (Cytoplasmic) Domains.The intracellular (IC, or cytoplasmic) domain of the B-CAR receptors of the invention can provide activation of at least one of the normal effector functions of the immune cell. [0052]It will be appreciated that suitable intracellular molecules, include, but are not limited to CD79a (Immunoglobulin a), CD79b (Immunoglobulin P), CD40, CD19, CD137, Fcyr2a and MyD88.15 WO 2022/051556 PCT/US2021/048944 Intraceullar molecules may further include CD28, CD28T, OX-40, 4-1BB/CD137, CD2, CD7, CD27, CD30, CD40, programmed death-1 (PD-1), inducible T cell costimulator (ICOS), lymphocyte function-associated antigen-1 (LFA-1, CDl-la/CD18), CD3 gamma, CD3 delta, CD3 epsilon, CD247, CD276 (B7-H3), LIGHT, (TNFSF14), NKG2C, Ig alpha (CD79a), DAP-10, Fc gamma receptor, MHC class 1 molecule, TNF receptor proteins, an Immunoglobulin protein, cytokine receptor, integrins, Signaling Lymphocytic Activation Molecules (SLAM proteins), activating NK cell receptors, BTLA, a Toll ligand receptor, ICAM-1, B7-H3, CDS, ICAM-1, GITR, BAFFR, LIGHT, HVEM (LIGHTR), KIRDS2, SLAMF7, NKp80 (KLRF1), NKp44, NKp30, NKp46, CD19, CD4, CDSalpha, CDSbeta, IL-2R beta, IL-2R gamma, IL-7R alpha, ITGA4, VLA1, CD49a, ITGA4, IA4, CD49D, ITGA6, VLA-6, CD49f, ITGAD, CDlld, ITGAE, CD103, ITGAL, CD1 la, LFA-1, ITGAM, CD1 lb, ITGAX, CD11c, ITGB1, CD29, ITGB2, CD18, LFA-1, ITGB7, NKG2D, TNFR2, TRANCE/RANKL, DNAM1 (CD226), SLAMF4 (CD244, 2B4), CD84, CD96 (Tactile), CEACAM1, CRT AM, Ly9 (CD229), CD160 (BY55), PSGL1, CD100 (SEMA4D), CD69, SLAMF(NTB-A, Lyl08), SLAM (SLAMF1, CD150, IPO-3), BLAME (SLAMF8), SELPLG (CD162), LTBR, LAT, GADS, SLP-76, PAG/Cbp, CD19a, a ligand that specifically binds with CD83, or any combination thereof. The cytoplasmic signaling sequences within the cytoplasmic signaling portion of the CAR-B of the invention may be linked to each other in a random or specified order. [0053]The term "co-stimulatory" domain or molecule as used herein refers to a heterogenous group of cell surface molecules that act to amplify or counteract initial activating signals of the cell. [0054]In one preferred embodiment, the cytoplasmic domain is designed to comprise the signaling domain of hCD19, wherein the hCD19 domain comprises the nucleic acid sequence set forth in SEQ ID NO. 5. In another embodiment, the cytoplasmic domain is designed to comprise the signaling domain of hCD40, wherein the hCD40 domain comprises the nucleic acid sequence set forth in SEQ ID NO. 7. In another embodiment, the cytoplasmic domain is designed to comprise the signaling domain of hCD40 and hCD79b, wherein the hCD40 domain comprises the nucleic acid sequence set forth in SEQ ID NO. 7 and the hCD79b domain comprises the nucleic acid sequence set forth in SEQ ID NO. 25. In another embodiment, the cytoplasmic domain is designed to comprise the signaling domain of hCD40 and hCD137, wherein the hCD40 domain comprises the nucleic acid sequence set forth in SEQ ID NO. 7 and the hCD137 domain comprises the nucleic acid sequence set forth in SEQ ID NO. 13. In another embodiment, the cytoplasmic domain is designed to comprise the signaling domain of hCD40 and hFcyr2a, wherein the hCD40 domain comprises the nucleic acid sequence set forth in SEQ ID NO. 7 and the hFcyr2a domain comprises the nucleic acid sequence set forth in SEQ ID NO. 17. In another embodiment, the cytoplasmic domain is designed to comprise the signaling domain of hCD40 and hMyd88, wherein the hCD40 domain comprises the nucleic acid sequence set forth in SEQ ID NO. 7 and the hMyd88 domain comprises the nucleic acid sequence set forth in SEQ ID NO. 21. In another embodiment, the cytoplasmic domain is designed to comprise the signaling domain of hCD79a, wherein the hCD79a domain comprises the nucleic acid sequence set forth in WO 2022/051556 PCT/US2021/048944 SEQ ID NO. 23. In another embodiment, the cytoplasmic domain is designed to comprise the signaling domain of hCD79b, wherein the hCD79b domain comprises the nucleic acid sequence set forth in SEQ ID NO. 25. These embodiments are preferably of human origin but may be derived from other species. 2. Modified B Cells [0055] Modified B Cells that Express Payloads.In various embodiments of the present invention a modified B cell is provided that is capable of expressing a payload. As used herein the term "payload" refers to an amino acid sequence, a nucleic acid sequence encoding a peptide or protein, or an RNA molecule, for use as a therapeutic agent. In certain embodiments the payload is for delivery to the tumor or tumor microenvironment. In certain embodiments, it is desirable that the B cell deliver to the tumor or tumor microenvironment a payload capable of, for example, increasing the number of cross-presenting dendritic cells (DCs) in tumors. Cross-presenting DCs will allow for improved presentation of tumor antigens. In various embodiments, the pay load may be capable of activating and attracting T cells into tumors. Activating more T cells in tumors will complement the cross-presenting DCs to remold the tumor environment to have more potent antitumor immune capabilities. Payloads may also foment the formation of tertiary lymphoid structures (TLS) in tumors. Clinical studies have demonstrated that there is a relationship between B cells, TLS and responses to immune checkpoint blockade. [0056]Nonexclusive examples of payloads of the present invention include: IL-1, IL-7, IL-8, IL-10, IL-12, IL-13, IL-17, IL-18, IL-21, interferon a, interferon P, interferon y, TSLP, CCL21, FLT3L, XCL1, LIGHT(TNFSF14), OX40L, CD137L, CD40L, ICOSL, anti-CD3 antibody, CD47, TIM4-FC, CXCL13, CCL21, CD80, CD40L, IFNa A2, LIGHT , 4-1BBL, MDGF (C19orfl0), FGF10, PDGF, agrin, TNF-a, GM-CSF, an anti-FAP antibody, an anti-TGF-P antibody; a TGF-P trap, decoy or other inhibitory molecule; an anti-BMP antibody; a BMP trap, decoy or other inhibitory molecule. [0057] Signaling for Payload Expression.In various embodiments of the present invention, the payload is expressed in the modified B cell as a DNA construct under the control of an activated transcriptional pathway. In certain embodiments, the expression of the payload is controlled of the Nuclear Factor of Activated T cell ("NFAT") pathway. The NFAT pathway is a transcription factor pathway activated during an immune response and is activated by the NFkB. In various embodiments, the modified B cell expresses both a payload and a CAR-B. In various embodiments, where the modified B cell expresses both a payload and a CAR-B, the CAR-B may further encode signaling molecules that induce activation of the NFKB pathway. Such molecules include but are not limited to: CD79a (Immunoglobulin a), CD79b (Immunoglobulin P), CD40, CD19, CD137, Fcyr2a and MyD88. [0058]In various embodiments, the invention relates to isolated B cells that express at least one payload. In various embodiments, the invention relates to isolated B cells that express more than one pay load. In various embodiments, the invention relates to isolated B cells that express 1, 2, 3, 4, 5, 6, 17 WO 2022/051556 PCT/US2021/048944 7, 8, 9, 10, 11 or 12 different payloads. [0059] Modification of B Cells for homing.In various embodiments of the present invention, the engineered B cells can be modified with homing domains (e.g., as illustrated in FIG. 2) such that the B cells can home to a site/target of interest and activate upon interaction with the target. Additionally, B cell homing receptors expressed on B cell membranes that recognize addressins and ligands on target tissues, compound or derivatives thereof that alter the trafficking of B cells to a particular site, and inhibitory molecules inflammation and autoimmune activity of the B cells, can play a role in B cell homing and development of specialized immune responses. [0060] Modified B cells that Express Integrin of Interest.The major homing receptors expressed by lymphocytes are the integrins, which are a large class of molecules characterized by a heterodimeric structure of a and [3 chains. In general, the pairing of specific a and [3 chains of the integrin determines the type of the homing receptor. For example, pairing of the a4 chain with [chain characterizes the major integrin molecule (a4[37) responsible for lymphocyte binding to Mucosal addressin cell adhesion molecule 1 (MAdCAM-1) expressed on high endothelial venules (HEVs) in Peyer’s patches (PP) and gastrointestinal (GI) tract lamina propria endothelial venules (LPVs). Similarly, pairing of the a4 chain with [31 chain characterizes the homing receptor (a4[31) for the skin. [0061] In various embodiments of the present inventions, a B cell to be modified can be selected for in advance, with specific traits that mediate preferred localizations.For example, memory B cells expressing CXCR3 may be enriched for and then subjected to engineering. CXCR3 cells may be attracted to ligands expressed at sites of inflammation. As such, modified B cells can preferentially localize to such sites. [0062]In various embodiments of the present invention, a modified B cell is provided that expresses the a4 and [37 chains of an integrin. It is desirable that expression of the a407 integrin will promote homing of the modified B cell to the colon. In various embodiments, a modified B cell is provided that expresses the a4 and 01 chains of an integrin. It is desirable that expression of the a401 integrin will promote homing of the modified B cell to the skin. In various embodiments, a modified B cell is provided that expresses a desired pairing of an a and a [3 chain of an integrin, such that the expressed integrin promotes homing of the modified B cell to a desired site/target of interest. Accordingly, in various embodiments, any desired combination of the a and [3 chains of an integrin is contemplated for expression in the B cells, such that the modified B cells expressing the specific integrin is targeted to a desired site/target of interest. [0063] Modified B cells that Express Homing Receptors of Interest.B cells have an ability to home to inflammatory tissues and altering their homing receptor expression can complement their native homing tendencies. B cell localization is also driven by expression of attractant molecules (e.g., targets such as ligands and chemokines) at inflammatory sites in specific locations or tissues.

WO 2022/051556 PCT/US2021/048944 Such molecules can also include antibodies, such as the MECA79 antibody that targets cells to peripheral node addressin (PNAd). Bahmani et al., J Clin Invest. 2018; 128(1 !):4770-4786; Azzi et al, Cell Rep. 2016; 15(6): 1202-13. Accordingly, B cells can be engineered to express certain antibodies, proteins, and receptors that facilitate B cell homing to a site/target of interest and interactions of such B cells with the desired target. In certain instances, expression of such receptors redirects the B cells to the tissue of interest. [0064]In various embodiments of the present invention, a modified B cell is provided that is capable of expressing a homing antibody, protein, or a receptor, expression of which is capable of directing the B cell to a specific site/target of interest. Exemplary homing of T cells to specific homing tissues (target tissues) using specific homing receptor/ligand pairs are set forth in Table 2. The same specific homing receptor/ligand pairs are also capable of facilitating homing of B cells to a specific homing tissue (target tissue). Accordingly, in various embodiments of the present invention, homing of the modified B cells to an exemplary homing tissue (target tissue) is facilitated using the corresponding homing receptor/ligand pairs as set forth in Table 2. TABLE 2 Teff cell homing receptors and their cognate ligands mediating organotropic targeting Homing Tissue Type Teff Cell Homing Receptor Cognate Ligand Skin CEA (PSGL-1 glycoform) E/P-selectinCD43E E-selectinVLA-4 (04(31) VCAM-1LFA-1 (aLp2) ICAM-1CCR4 CCL17CCR10 CCL27 Gut (intestine, colon, mLN, PP) a4P7 MAdCAM-1 CCR9a CCL25aCXCR4 CXCL12Selectin ligandsb E/P-selectinbVLA-4b VCAM-lbLFA-lb ICAM-lbCCR6b CCL20 (MIP-3a)b Liver CD44 HyaluronateVLA-4 VCAM-1CCR5 CCL5VAP-1 WO 2022/051556 PCT/US2021/048944 Selectin ligandsb E/P-selectina4p7b MAdCAM-lb Lung LFA-1 ICAM-1CCR3 CCL28CCR4 CCL17CXCR4 CXCL12Selectin ligandsb E/P-selectinbVLA-4b VCAM-lbLFA-lb ICAM-lb Bone Marrow CLA (PSGL-1 glycoform) E/P-selectinCD43E E-selectinVLA-4 VCAM-1LFA-I ICAM-1CXCR4 CXCL12a4p7b MAdCAM-lb Heart CCR5 CCL4, CCL5CCR4?CXCR3 CXCL10c-Met HGF Brain VLA-4b VCAM-lbLFA-lb ICAM-lbCXCR3b CXCL9/CXCL10b Peripheral LNC Selectin ligandsb E/P-selectinbLFA-lb ICAM-lbCXCR3b CXCL9/CXCL10b3Involved in Ten cell homing to the intestine but not colon.1,Inflammatory reactions, tissue injury.‘Under non-inflamed, steady-state conditions, Ten cells typically lose L-selectin and CCR expression and are largely restricted from LN access though may enter during inflammatory reaction! (b) as shown. In contrast, both naive T cells and Tcm cells express L-selectin, CCR7, and CXCRZ and engage PNAd, CCL19/CCL21, and CXCL12, respectively, to undergo T-cell rolling and LEA 1/ICAM-1/2- mediated adhesion and transmigration into LNs. id="p-65" id="p-65" id="p-65" id="p-65" id="p-65" id="p-65" id="p-65" id="p-65" id="p-65" id="p-65" id="p-65"

[0065]Exemplary homing tissue (target tissue) type and ligand or chemokine that enables tissue- restricted B cell homing in accordance with the invention are set forth in Table 3.

WO 2022/051556 PCT/US2021/048944 TABLE 3 Homing Tissue Type Ligand/Chemokines CNS VCAM-1, CD62P, ligands for CCR1,2, 5, CXCR3Liver CD62P, VAP-1,CXCL16Small Intestine MAdCAM, CD62P, CCL25Colon MAdCAM, CD62P, CCL20, GPR15LSkin CD62E, CD62P, CCL 17(22), ICAM-1Thymus VCAM, CD62P, CCL25Peripheral Lymph Node PNAd, CCL21, ICAM-1Peyer’s Patch MAdCAM, CCL21, CXCL13Bone Marrow VCAM, CD62P, CXCL12, ICAM-1 id="p-66" id="p-66" id="p-66" id="p-66" id="p-66" id="p-66" id="p-66" id="p-66" id="p-66" id="p-66" id="p-66"

[0066]In various embodiments of the present invention, a modified B cell is provided that expresses one or more of an antibody, a protein, or a receptor that facilitate homing of the modified B cell to the exemplary target/homing tissues using the specific homing receptor/ligand pairs as set forth in Table 2. In various embodiments of the present invention, a modified B cell is provided that expresses one or more of a homing receptor that facilitate homing of the modified B cell to the exemplary target/homing tissue using the ligand or chemokines are set forth in Tables 2 and/or 3. As used herein, the term "B cell homing" refers to localizing, targeting, trafficking, directing, or redirecting of the B cell of the present application to a site/target of interest, for example, a homing or target tissue, an inflammatory site in a specific location or tissue, or a tumor or tumor microenvironment, where delivery of therapeutic payloads is desirable. As used in the context of B cell homing, the term "antibody", "protein" or a "receptor" refers to an amino acid sequence, a nucleic acid sequence encoding a peptide or protein, or an RNA molecule, for use as a therapeutic agent, which when expressed in a modified B cell of the present invention will direct the B cell to a site/target of interest. [0067]In certain embodiments, the homing antibody, protein, or receptor molecule is for homing/targeting the modified B cell expressing such a molecule to a site/target of interest. In certain embodiments, the homing antibody, protein, or receptor molecule is for homing/targeting the modified B cell expressing such a molecule to inflammatory sites in specific locations or tissues. In certain embodiments, the homing antibody, protein or receptor is for targeting the B cell to a tumor or tumor microenvironment. In certain embodiments, targeting B cells to particular locations is desirable so that the engineered or modified B cells of the present invention can deliver therapeutic payloads to desired locations of interest, for example, a homing or target tissue, an inflammatory site in a specific location or tissue, or a tumor or tumor microenvironment. Accordingly, in certain embodiments, it is desirable that the B cells home to a site/target of interest, for example, a tumor or tumor microenvironment, and deliver to the site/target of interest a payload capable of, for example, 21 WO 2022/051556 PCT/US2021/048944 increasing the number of cross-presenting dendritic cells (DCs) at the site/target of interest (e.g., in tumors). [0068]In various embodiments, the homing antibody, protein, or receptor is expressed in the modified or engineered B cell as a DNA construct. In various embodiments, the homing antibody, protein, or receptor is expressed in the modified B cell as a DNA construct under the control of a constitutively activated transcriptional pathway. In various embodiments, the homing antibody, protein, or receptor involved in the B cell homing/targeting is either not naturally expressed in a B cell or is expressed at higher levels than is naturally expressed in a B cell. Exemplary homing of the modified B cells to specific homing/target tissues using specific homing receptor/ligand pairs in accordance with the present invention is set forth in Table 4. It should be understood that, notwithstanding the exemplary homing tissues, homing receptor, and ligand pairs set forth in Table 4, a modified B cell of the present invention may be engineered to express any homing antibody, protein, or a receptor (e.g., any homing receptor set for in Table 2), such that the modified B cell can be directed to a specific site/target of interest. TABLE 4 Homing Tissue Type Homing Receptor Ligand/Chemokine Liver CXCR6 CXCL16Small Intestine CCR9 CCL25Large Intestine (Colon) CCR6 CCL20Lymph Node CCR7 CCL21Bone Marrow CXCR4 CXCL12Peyer’s Patch CCR7 and CXCR5 CCL21 andCXCL13, respectivelySkin CCR4 CCL 17(22) id="p-69" id="p-69" id="p-69" id="p-69" id="p-69" id="p-69" id="p-69" id="p-69" id="p-69" id="p-69" id="p-69"

[0069]Nonexclusive examples of homing (target) tissue types for the specific homing receptor/ligand pairs of the present invention include: skin, gut (intestine, colon, mesenteric lymph nodes (mLN), Peyer’s Patch (PP), small intestine), liver, lung, bone marrow, heart, peripheral lymph node (LN), CNS, thymus, and bone marrow. [0070]Nonexclusive examples of homing receptors that can be paired with specific or corresponding attractants/ligands/chemokines of the present invention include: CLA (PSGL-1 glycoform), CLA (PSGL-1 glycoform), CCR10, CCR3, CCR4, CCR5, CCR6, CCR9, CD43E, CD44, c-Met, CXCR3, CXCR4, LFA-1, LFA-1 (aLp2), Selectin ligands, VLA-4, VLA-4 (a4pl), and a4p7. [0071]Nonexclusive examples of ligands/chemokines that can be paired with specific or corresponding homing receptors of the present invention include: CXCL16, CCL17, CCL17(22), CCL20 (MIP-3a), CCL21, CCL25, CCL27, CCL28, CCL4, CCL5, CD62E, CD62P, CXCL10, CXCL12, CXCL13, CXCL16, CXCL9/CXCL10, CXCR3, E/P-selectin, E-selectin, GPR15L, HGF, 22 WO 2022/051556 PCT/US2021/048944 Hyaluronate, ICAM-1, ligands for CCR1,2, 5, MAdCAM, MAdCAM-1, PNAd, VAP-1, VCAM, and VCAM-1. [0072]In certain embodiments of the present invention, a modified B cell is provided that express or have increased expression of the exemplary B cell homing receptors (e.g., as set forth in Table 2), such that the modified B cell is targeted to the corresponding homing tissue of interest that expresses the corresponding ligand/chemokines (e.g., as set forth in Tables 2 and/or 3). In certain embodiments of the present invention, a modified B cell is provided that co-expresses an integrin with a specific a and P chain pairing and a specific B cell homing receptor (e.g., as set forth in Tables 2 and/or 3), expression of which integrin and/or homing receptor promote or facilitate homing/targeting of the modified B cell to a site/target of interest. In some embodiments, a modified B cell is provided that co-expresses an a4p7 integrin and CCR9. It is desirable that co-expression of a4p7 and CCR9 will promote small intestine homing of the modified B cells of the present invention. In some embodiments, a modified B cell is provided that co-expresses an a4p 1 integrin and CCR4. It is desirable that co-expression of a4p 1 and CCR4 will promote small intestine homing of the modified B cells of the present invention. [0073] Modified B cells that Express Immune Inhibitory Molecules.B cells are key contributors to many autoimmune diseases. However, B cells can be used therapeutically to antagonize autoimmunity. Specifically, B cells can be engineered to express at least one or more immune inhibitory molecules, which may decrease the autoimmune activity of the B cells, leading to decrease in an autoimmune disease. Immune inhibitory molecules are well known in the art. Such inhibitory molecules may include, but are not limited to, IL-10, TGF־P, PD-L1, PD-L2, LAG-3, and TIM-3. In certain embodiments of the present invention, a modified B cell is provided that is engineered to express at least one or more of an inhibitory molecule selected from IL-10, TGF-P, PD-L1, PD-L2, LAG-3, and TIM-3, or any combinations thereof, such that the inflammation at the site and autoimmune activity of the B cells localized to the site are decreased, thereby leading to a positive therapeutic response. [0074] Compounds that alter B cell Trafficking.In certain embodiments of the present invention, a modified B cell is provided that is treated with at least one or more compound or derivatives thereof that alter the trafficking of B cells by inducing expression of a specific B cell integrin and/or a homing receptor. Compounds or derivatives thereof that alter the trafficking of B cells are well known in the art. In certain embodiments, a modified B cell is provided that is treated with all-trans- retinoic acid (ATRA) or derivatives thereof that promote homing of the B cells to gut (small intestine) due to the increased expression of a4p7 integrin and CCR9 homing receptor. As used herein, the term "compound" refers to a chemical, drug, a therapeutic agent, or derivatives thereof, that alter the trafficking of B cells in a desired manner. [0075]In various embodiments of the present invention, a modified B cell engineered to co-express a specific integrin (e.g., with a specific a and P chain pairing) and a specific B cell homing receptor of 23 WO 2022/051556 PCT/US2021/048944 interest is treated with at least one or more compounds or derivatives thereof that alter the trafficking of the modified B cells and promote homing of the cells to a specific site/target of interest due to the increased expression of the specific integrin and/or the homing receptor. In various embodiments, a B cell modified to co-express an integrin with a specific a and P chain pairings and a specific B cell homing receptor further expresses at least one or more immune inhibitory molecules, such that the autoimmune activity of the modified B cells targeted to a specific site of inflammation is decreased, leading to a decrease in the autoimmune disease. In some embodiments, a modified B cell engineered to express one or more immune inhibitory molecules, for example IL-10, TGF-, PD-L1, PD-L2, LAG-3, and TIM-3, or combinations thereof, is treated with ATRA or derivatives thereof for a specified period of time, such that expression of the a4p7 integrin and CCR9 homing receptor is induced to promote B cell homing to a specific site/target of interest (e.g., the gut), but the inflammation at the site and autoimmune activity of B cells localized to the site are decreased, leading to a positive therapeutic response. In one embodiment, a modified B cell engineered to express one or more immune inhibitory molecules, for example IL-10, TGF-, or combinations thereof, is treated with ATRA or derivatives thereof for a specified period of time, such that expression of the a4pintegrin and CCR9 homing receptor is induced to promote B cell homing to a specific site/target of interest (e.g., the gut), but the inflammation at the site and autoimmune activity of B cells localized to the site are decreased, leading to a positive therapeutic response. [0076]It is understood that, any B cell of the present invention modified to co-express a specific B cell integrin and homing receptor that targets the B cell to a particular homing/target tissue of interest, may be further engineered to express one or more immune inhibitory molecules for reducing inflammation and autoimmune activity of the B cells localized to the site, and/or treated with a compound that alter the homing/targeting of the modified B cells by inducing expression of the specific B cell integrin and/or the homing receptor. [0077] Activation of B cells with TLR agonists and TLRs.B cells have a natural ability to uptake and present antigens recognized by their specific B cell receptors (BCRs). B cells activated by Toll- like receptors (TLRs) result in potent effector B cells in defending the body in an immune response. Expression of or increasing the expression of TLRs in B cells can provide a mechanism for potentiating B cells for innate signals regulating adaptive immune responses. [0078] Activation of B cells with TLR agonists.In various embodiments of the present invention, a B cell is provided, where the B cell is treated in vitro with at least one TLR agonist. In various embodiments, the TLR can be a TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLRS, TLR9, TLR10, TLR11, TLR12, and/or a TLR13. In various embodiments, the TLR agonist preferentially binds to one or more T LR selected from the group consisting of TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLRS, TLR9, TLR10, TLR11, TLR12, and TLR13. TLR agonists are well known in the art and may include, but are not limited to, CpG-rich oligonucleotides and the double-stranded RNA mimic, polyinosinic acid:polycytidylic acid (poly-I:C). In various embodiments, the TLR 24 WO 2022/051556 PCT/US2021/048944 agonist can be CpG oligonucleotides. [0079]In various embodiments, each B cell may be treated with one TLR agonist. In various embodiments, each B cell may be treated with more than one TLR agonist. For example, each B cell may be treated 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 different TLR agonists. Alternatively, the patient may be administered a heterogeneous population of B cells, each B cell treated with a unique TLR agonist or a combination of TLR agonists. In some embodiments, the B cells for use a therapeutic agent is treated with one or more TLR agonists at the same time or in advance of the administration of the B cells to a subject or patient in need thereof. In certain embodiments, treatment with one or more TLR agonist is capable of producing more potent effector B cells for defending the body in an immune response. In certain embodiments, treatment with one or more TLR agonist is capable of potentiating B cells for immune responses. In some embodiments, treating a B cell of the present invention with at least one or more TLR agonists induces expression or activation of one or more TLRs. [0080] Activation of B cells with TLR Expression.In various embodiments of the present invention, a modified B cell is provided that is capable of expressing a constitutively active TLR. In various embodiments, the TLR is expressed in the modified or engineered B cell as a DNA construct under the control of a constitutively activated transcriptional pathway. In various embodiments, the TLR is either not naturally expressed in a B cell or is expressed at higher levels than is naturally expressed in a B cell. In various embodiments, the TLR can be a TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9, TLR10, TLR11, TLR12, and/or a TLR13. [0081]In various embodiments, each B cell may express more than one constitutively active TLR. For example, each B cell may express 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or 13 different constitutively active TLRs. Alternatively, the patient may be administered a heterogeneous population of B cells, each B cell capable of expressing and/or secreting a unique TLR or combination of TLRs, which are constitutively active. In various embodiments, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or 13 different constitutively active TLRs may be administered to the subject or patient through a heterogeneous population of B cells. [0082]In certain embodiments of the present invention, the B cell is a modified B cell that expresses at least one constitutively active TLR. In certain embodiments, the modified B cell that expresses at least one constitutively active TLR is treated with one or more TLR agonist. In certain embodiments, the expression of the constitutively active TLR is capable of producing more potent effector B cells for defending the body in an immune response. In certain embodiments, the expression of the constitutively active TLR is capable of potentiating B cells for immune responses. In certain embodiments, the modified B cell expresses both a TLR that is constitutively active and any CAR-B of the present application. In various embodiments, the modified B cell expressing a TLR that is constitutively active and/or a CAR-B is further treated with one or more TLR agonist at the same time or in advance of the administration of the modified B cells to a subject or patient in need thereof. In 25 WO 2022/051556 PCT/US2021/048944 certain embodiments, B cells may be engineered to express payloads and modifiers, such as TLRs, in the absence of CAR-B, for intratumoral administration. [0083] Modified B Cells that Present Antigens Simultaneously in HLA Class I and Class II Molecules.B cells, in addition to their function in antibody production, also express high level of Human Leukocyte Antigen (HLA) class II molecules and can present antigens to CD4+ T cells. Hong et al., 2018, Immunity 49, 695-708. In various embodiments of the present invention, a modified B cell is provided that is capable of presenting specific antigens and/or antigen-derived epitopes of interest, such as tumor antigens or infectious disease antigens, simultaneously in both HLA class I and class II molecules. Tumor antigens and infectious disease antigens are well known in the art and are described in the foregoing sections. In certain embodiments, a specific antigen of interest, e.g., a tumor antigen or an infectious disease antigen, is fused to a targeting signal of a lysosomal protein that targets the antigen to the lysosomes and presents the antigen simultaneously and efficiently in both HLA class I and class II molecules. In some embodiments, the targeting signal is the targeting signal of lysosome-associated membrane protein-1 (LAMP1). In some embodiments, the targeting signal is capable entering endosomal recycling compartments. The c-terminal sequence of Clec9A is such a targeting moiety. As used herein, a specific tumor antigen or an infectious disease antigen fused to a targeting signal refers to an amino acid sequence, a nucleic acid sequence encoding a peptide or protein, or an RNA molecule (e.g., an mRNA molecule), for use as a therapeutic agent. In one embodiment, a specific tumor antigen or an infectious disease antigen fused to a targeting signal refers to an mRNA molecule for use as a therapeutic agent. In certain embodiments, it is desirable that the specific tumor antigens and/or infectious disease antigens fused to a targeting signal, such as the targeting signal of LAMP 1 or Clec9A, be targeted to the lysosomes or endosomes and presented simultaneously and efficiently in both HLA class I and class II molecules. In certain embodiments, it is desirable that electroporation of B cells (e.g., human B cells), before or after maturation, with an mRNA encoding specific tumor antigens and/or infectious disease antigens of interest fused to a targeting signal, such as the targeting signal of LAMP 1 or Clec9A, be capable of simultaneously and efficiently presenting the specific antigens and/or antigen-derived epitopes in both HLA class I and class II molecules. In various embodiments, the specific tumor antigens and/or infectious disease antigens of interest is either not naturally presented by a B cell, is not presented by a B cell simultaneously in both HLA class I and class II molecules naturally, or is not presented by a B cell with high efficiencies in both HLA class I and class II molecules naturally. It is contemplated that, introduction of such electroporated B cells into a subject, e.g., a human host, will promote development of or potentiate antigen-specific immune responses by presenting specific antigens and/or antigen-derived epitopes of interest simultaneously and efficiently in both HLA class I and class II molecules. [0084]In various embodiments, the invention relates to a nucleic acid sequence, e.g., an mRNA sequence, encoding at least one specific antigen of interest, e.g., a tumor antigen or an infectious WO 2022/051556 PCT/US2021/048944 disease antigen, fused to a targeting signal, such as the targeting signal of LAMP 1, for use as a therapeutic agent in electroporation of B cells for simultaneously and efficiently presenting the specific antigen and/or antigen-derived epitopes in both HLA class I and class II molecules. In various embodiments, the invention relates to nucleic acid sequence, e.g., an mRNA sequence, encoding more than one (e.g., 1, 2, 3, 4, 5, or more) specific tumor antigen and/or an infectious disease antigen of interest fused to a targeting signal. In various embodiments, the invention relates to pools of different nucleic acid sequences, e.g., pools of different mRNA sequences, for use as a therapeutic agent in electroporation of B cells as described above, where each pool encodes at least one specific antigen of interest, e.g., a tumor antigen or an infectious disease antigen, fused to a targeting signal that is different from the other pools of the mRNA sequences. Accordingly, in some embodiments, the subject may be administered a homogeneous population of B cells, where each B cell is electroporated with an mRNA encoding at least one specific antigen of interest fused to a targeting signal. In some embodiments, the subject may be administered a homogeneous a population of B cells, where each B cell is electroporated with an mRNA encoding more than one specific antigen of interest fused to targeting signal. In some embodiments, the subject may be administered a heterogeneous population of B cells, where each B cell is electroporated with a combination of mRNAs each encoding at least one specific antigen of interest fused to a different targeting signal. [0085]In some embodiments, the B cells for use in electroporation as described above me be any of the modified B cells of the present application. In some embodiments, the modified B cell comprises a chimeric antigen receptor for B cells (CAR-B). In various embodiments, the modified B cell can express a CAR-B and simultaneously and efficiently present specific antigen and/or antigen-derived epitopes of interest in both HLA class I and class II molecules. [0086]In various embodiments, the invention relates to a method of administering an isolated B cell to a patient in need thereof. In various embodiments, a population of B cells may be administered to the patient. In various embodiments, each B cell may express more than one payload peptide or protein. For example, each B cell may express 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 different payloads. Alternatively, the patient may be administered a heterogeneous population of B cells, each B cell capable of expressing and/or secreting a unique payload or combination of payloads. In various embodiments, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 different payloads may be administered to the patient through a heterogeneous population of B cells. 3. Methods of Treatment [0087]In some aspects, the invention therefore comprises a method for treating or preventing a tumor or cancerous tissue, comprising administering to a patient in need thereof an effective amount of at least one B-CAR disclosed herein. [0088]Methods are provided for treating diseases or disorders, including cancer. In some embodiments, the invention relates to creating a B cell-mediated immune response in a subject, comprising administering an effective amount of the engineered immune cells of the present 27 WO 2022/051556 PCT/US2021/048944 application to the subject. In some embodiments, the B cell-mediated immune response is directed against a target cell or cells. In some embodiments, the engineered immune cell comprises a chimeric antigen receptor for B cells (B-CAR). In some embodiments, the target cell is a tumor cell. In some aspects, the invention comprises a method for treating or preventing a malignancy, said method comprising administering to a subject in need thereof an effective amount of at least one isolated antigen-binding molecule described herein. In some aspects, the invention comprises a method for treating or preventing a malignancy, said method comprising administering to a subject in need thereof an effective amount of at least one immune cell, wherein the immune cell comprises at least one chimeric antigen receptor. [0089]In some aspects, the invention comprises a pharmaceutical composition comprising at least one antigen-binding molecule as described herein and a pharmaceutically acceptable excipient. In some embodiments, the pharmaceutical composition further comprises an additional active agent. [0090]In some embodiments, the subject is diagnosed with a metastatic disease localized to the liver. In other embodiments, the metastatic disease is a cancer. I n still other embodiments, the cancer metastasized from a primary tumor in the breast, colon, rectum, esophagus, lung, pancreas and/or stomach. In still other embodiments, the subject is diagnosed with unresectable metastatic liver tumors. In yet other embodiments, the subject is diagnosed with unresectable metastatic liver tumors from primary colorectal cancer. In some embodiments, the Subject is diagnosed with hepatocellular carcinoma. [0091]It will be appreciated that target doses for modified B cells can range from 1 xW6-2xlOcells/kg, preferably 2x106 cells/kg, more preferably. It will be appreciated that doses above and below this range may be appropriate for certain subjects, and appropriate dose levels can be determined by the healthcare provider as needed. Additionally, multiple doses of cells can be provided in accordance with the invention. [0092]Also provided are methods for reducing the size of a tumor in a subject, comprising administering to the subject a modified B cell of the present invention, wherein the cell comprises a CAR-B receptor comprising an antigen-binding domain that binds to an antigen on a tumor, a payload or both a CAR-B and a payload. In some embodiments, the subject has a solid tumor, or a blood malignancy such as lymphoma or leukemia. In some embodiments, the modified B cell is delivered to a tumor bed. In some embodiments, the cancer is present in the bone marrow of the subject. [0093]Also provided are methods for homing B cells to a site/target of interest in a subject, comprising administering to the subject a modified B cell of the present invention, wherein the cell comprises an integrin, a homing antibody, protein, or a receptor that is attracted to a ligand, chemokine, or an attractant at the site/target of interest. In some embodiments, the site/target of interest is, for example, a homing or target tissue, an inflammatory site in a specific location or tissue, or a tumor or tumor microenvironment, where delivery of therapeutic payloads is desirable. [0094]Also provided are methods for decreasing inflammation and autoimmune activity of B cells at 28 WO 2022/051556 PCT/US2021/048944 a site/target of interest in a subject, comprising administering to the subject a modified B cell of the present invention, wherein the cell comprises an immune inhibitory molecule. In some embodiments, the site/target of interest is, for example, a homing or target tissue, an inflammatory site in a specific location or tissue, or a tumor or tumor microenvironment, where delivery of therapeutic payloads is desirable. [0095]Also provided are methods for altering trafficking of B cells to a site/target of interest in a subject, comprising treating a B cell of the present invention with a compound or derivatives thereof suitable for altering B cell trafficking, and administering the treated B cell to the subject in need thereof. In some instances, the compound or derivatives thereof alters B cell trafficking by increasing the expression of an integrin, homing antibody, protein, receptor, or combinations thereof, expressed by the B cells. [0096]Also provided are methods for potentiating B cells and/or producing potent effector B cells for increasing immune responses in a subject, comprising treating a B cell of the present invention with at least one or more TLR agonists, and administering the treated B cell to the subject in need thereof. In some embodiments, treating a B cell of the present invention with at least one or more TLR agonists induces expression or activation of one or more TLRs. In some embodiments, the method for potentiating B cells and/or producing potent effector B cells for increasing immune responses in a subject, further comprises administering to the subject a modified B cell of the present invention that expresses at least one or more constitutively active TLRs. Also provided are methods for potentiating B cells and/or producing potent effector B cells for increasing immune responses in a subject, comprising administering to the subject a modified B cell of the present invention, wherein the cell expresses a CAR-B receptor comprising an antigen-binding domain that binds to an antigen on a tumor, a constitutively active TLR or both a CAR-B and a constitutively active TLR, where the cell is treated with at least one or more TLR agonists at the same time or in advance of the administration of the cells to the subject. [0097]Also provided are methods for increasing antigen-specific immune responses in a subject, comprising administering to the subject a modified B cell of the present invention, wherein the cell is electroporated with a nucleic acid sequence, e.g., an mRNA, encoding specific tumor antigens and/or infectious disease antigens fused to a targeting signal, such as the targeting signal of LAMP 1 or Clec9A, for simultaneously and efficiently presenting the specific antigens and/or antigen-derived epitopes in both HLA class I and class II molecules. In some embodiments, the subject has a solid tumor, or a blood malignancy such as lymphoma or leukemia. [0098]It is understood that the various embodiments of the methods of treatment using the engineered or modified B cells of the present application are not mutually exclusive and can be combined with each other in any way and without any restriction unless explicitly indicated, for achieving of facilitating any of the results and/or therapeutic responses contemplated herein. [0099]In some embodiments, the modified B cells are autologous B cells. In some embodiments, the 29 WO 2022/051556 PCT/US2021/048944 modified B cells are allogeneic B cells. In some embodiments, the modified B cells are heterologous B cells. In some embodiments, the modified B cells of the present application are transfected or transduced in vivo. In other embodiments, the engineered cells are transfected or transduced ex vivo. [0100]As used herein, the term "subject" or "patient" means an individual. In some aspect, a subject is a mammal such as a human. In some aspect, a subject can be a non-human primate. Non- human primates include marmosets, monkeys, chimpanzees, gorillas, orangutans, and gibbons, to name a few. The term "subject" also includes domesticated animals, such as cats, dogs, etc., livestock (e.g., llama, horses, cows), wild animals (e.g., deer, elk, moose, etc., laboratory animals (e.g., mouse, rabbit, rat, gerbil, guinea pig, e؛c.) and avian species (e.g., chickens, turkeys, ducks, etc.). Preferably, the subject is a human subject. More preferably, the subject is a human patient. [0101]The methods can further comprise administering one or more chemotherapeutic agents. In certain embodiments, the chemotherapeutic agent is a lymphodepleting (preconditioning) chemotherapeutic. Beneficial preconditioning treatment regimens, along with correlative beneficial biomarkers are described in U.S. Provisional Patent Applications 62/262,143 and 62/167,750, which are hereby incorporated by reference in their entirety herein. These describe, e.g., methods of conditioning a patient in need of a T cell therapy comprising administering to the patient specified beneficial doses of cyclophosphamide (between 200 mg/m2/ day and 2000 mg/m2/day) and specified doses of fludarabine (between 20 mg/m2/day and 900 mg/m2/day). A preferred dose regimen involves treating a patient comprising administering daily to the patient about 500 mg/m2/day of cyclophosphamide and about 60 mg/m2/day of fludarabine for three days prior to administration of a therapeutically effective amount of engineered B cells to the patient. [0102]In other embodiments, the antigen-binding molecule, transduced (or otherwise engineered) cells (such as CARs), and the chemotherapeutic agent are administered each in an amount effective to treat the disease or condition in the subject. [0103]In certain embodiments, compositions comprising CAR-expressing immune effector cells disclosed herein may be administered in conjunction with any number of chemotherapeutic agents. Examples of chemotherapeutic agents include alkylating agents such as thiotepa and cyclophosphamide (CYTOXAN™); alkyl sulfonates such as busulfan, improsulfan and piposulfan; aziridines such as benzodopa, carboquone, meturedopa, and uredopa; ethylenimines and methylamelamines including altretamine, triethylenemelamine, trietylenephosphoramide, triethylenethiophosphaoramide and trimethylolomelamine resume; nitrogen mustards such as chlorambucil, chlornaphazine, cholophosphamide, estramustine, ifosfamide, mechlorethamine, mechlorethamine oxide hydrochloride, melphalan, novembichin, phenesterine, prednimustine, trofosfamide, uracil mustard; nitrosureas such as carmustine, chlorozotocin, fotemustine, lomustine, nimustine, ranimustine; antibiotics such as aclacinomysins, actinomycin, authramycin, azaserine, bleomycins, cactinomycin, calicheamicin, carabicin, carminomycin, carzinophilin, chromomycins, dactinomycin, daunorubicin, detorubicin, 6-diazo-5-oxo-L-norleucine, doxorubicin, epirubicin.

WO 2022/051556 PCT/US2021/048944 esorubicin, idarubicin, marcellomycin, mitomycins, mycophenolic acid, nogalamycin, olivomycins, peplomycin, potfiromycin, puromycin, que-lamycin, rodombicin, streptonigrin, streptozocin, tubercidin, ubenimex, zinostatin, zorubicin; anti-metabolites such as methotrexate and 5-fluorouracil (5-FU); folic acid analogues such as denopterin, methotrexate, pteropterin, trimetrexate; purine analogs such as fludarabine, 6-mercaptopurine, thiamiprine, thioguanine; pyrimidine analogs such as ancitabine, azacitidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine, doxifluridine, enocitabine, floxuridine, 5-FU; androgens such as calusterone, dromostanolone propionate, epitiostanol, mepitiostane, testolactone; anti-adrenals such as aminoglutethimide, mitotane, trilostane; folic acid replenisher such as frolinic acid; aceglatone; aldophosphamide glycoside; aminolevulinic acid; amsacrine; bestrabucil; bisantrene; edatraxate; defofamine; demecolcine; diaziquone; elformithine; elliptinium acetate; etoglucid; gallium nitrate; hydroxyurea; lentinan; lonidamine; mitoguazone; mitoxantrone; mopidamol; nitracrine; pentostatin; phenamet; pirarubicin; podophyllinic acid; 2-ethylhydrazide; procarbazine; PSK®; razoxane; sizofiran; spirogermanium; tenuazonic acid; triaziquone; 2, 2’,2"-trichlorotriethylamine; urethan; vindesine; dacarbazine; mannomustine; mitobronitol; mitolactol; pipobroman; gacytosine; arabinoside ("Ara-C");cyclophosphamide; thiotepa; taxoids, e.g. paclitaxel (Taxol®, Bristol-Myers Squibb) and doxetaxel (Taxotere®, Rhone-Poulenc Rorer); chlorambucil; gemcitabine; 6-thioguanine; mercaptopurine; methotrexate; platinum analogs such as cisplatin and carboplatin; vinblastine; platinum; etoposide (VP-16); ifosfamide; mitomycin C; mitoxantrone; vincristine; vinorelbine; navelbine; novantrone; teniposide; daunomycin; aminopterin; xeloda; ibandronate; CPT-11; topoisomerase inhibitor RFS2000; difluoromethylomithine (DMFO); retinoic acid derivatives such as Targretin™ (bexarotene), Panretin™, (alitretinoin); Ontak™ (denileukin diftitox); esperamicins; capecitabine; and pharmaceutically acceptable salts, acids or derivatives of any of the above. Also included in this definition are anti-hormonal agents that act to regulate or inhibit hormone action on tumors such as anti-estrogens including for example tamoxifen, raloxifene, aromatase inhibiting 4(5)-imidazoles, 4-hydroxytamoxifen, trioxifene, keoxifene, LY117018, onapristone, and toremifene (Fareston); and anti-androgens such as flutamide, nilutamide, bicalutamide, leuprolide, and goserelin; and pharmaceutically acceptable salts, acids or derivatives of any of the above. Combinations of chemotherapeutic agents are also administered where appropriate, including, but not limited to CHOP, i.e., Cyclophosphamide (Cytoxan®) Doxorubicin (hydroxydoxorubicin), Fludarabine, Vincristine (Oncovin®), and Prednisone. [0104]In some embodiments, the chemotherapeutic agent is administered at the same time or within one week after the administration of the engineered cell or nucleic acid. In other embodiments, the chemotherapeutic agent is administered from 1 to 4 weeks or from 1 week to month, 1 week to 2 months, 1 week to 3 months, 1 week to 6 months, 1 week to 9 months, or week to 12 months after the administration of the engineered cell or nucleic acid. In other embodiments, the chemotherapeutic agent is administered at least 1 month before administering the WO 2022/051556 PCT/US2021/048944 cell or nucleic acid. In some embodiments, the methods further comprise administering two or more chemotherapeutic agents. [0105]A variety of additional therapeutic agents may be used in conjunction with the compositions described herein. For example, potentially useful additional therapeutic agents include PD-1 (or PD-L1) inhibitors such as nivolumab (Opdivo®), pembrolizumab (Keytruda@), pembrolizumab, pidilizumab, and atezolizumab (Tecentriq®). [0106]Additional therapeutic agents suitable for use in combination with the invention include, but are not limited to, ibrutinib (Imbruvica®), ofatumumab (Arzerra®), rituximab (Rituxan@), bevacizumab (Avastin®), trastuzumab (Herceptin®), trastuzumab emtansine (KADCYLA®), imatinib (Gleevec®), cetuximab (Erbitux®), panitumumab (Vectibix®), catumaxomab, ibritumomab, ofatumumab, tositumomab, brentuximab, alemtuzumab, gemtuzumab, erlotinib, gefitinib, vandetanib, afatinib, lapatinib, neratinib, axitinib, masitinib, pazopanib, sunitinib, sorafenib, toceranib, lestaurtinib, axitinib, cediranib, lenvatinib, nintedanib, pazopanib, regorafenib, semaxanib, sorafenib, sunitinib, tivozanib, toceranib, vandetanib, entrectinib, cabozantinib, imatinib, dasatinib, nilotinib, ponatinib, radotinib, bosutinib, lestaurtinib, ruxolitinib, pacritinib, cobimetinib, selumetinib, trametinib, binimetinib, alectinib, ceritinib, crizotinib, aflibercept, adipotide, denileukin diftitox, mTOR inhibitors such as Everolimus and Temsirolimus, hedgehog inhibitors such as sonidegib and vismodegib, CDK inhibitors such as CDK inhibitor (palbociclib). [0107]In additional embodiments, the composition comprising CAR-containing immune can be administered with an anti-inflammatory agent. Anti-inflammatory agents or drugs include, but are not limited to, steroids and glucocorticoids (including betamethasone, budesonide, dexamethasone, hydrocortisone acetate, hydrocortisone, hydrocortisone, methylprednisolone, prednisolone, prednisone, triamcinolone), nonsteroidal anti-inflammatory drugs (NSAIDS) including aspirin, ibuprofen, naproxen, methotrexate, sulfasalazine, leflunomide, anti-TNF medications, cyclophosphamide and mycophenolate. Exemplary NSAIDs include ibuprofen, naproxen, naproxen sodium, Cox-2 inhibitors, and sialylates. Exemplary analgesics include acetaminophen, oxycodone, tramadol of proporxyphene hydrochloride. Exemplary glucocorticoids include cortisone, dexamethasone, hydrocortisone, methylprednisolone, prednisolone, or prednisone. Exemplary biological response modifiers include molecules directed against cell surface markers (e.g., CD4, CD5, etc.), cytokine inhibitors, such as the TNF antagonists, (e.g., etanercept (ENBREL®), adalimumab (HUMIRA®) and infliximab (REMICADE®)), chemokine inhibitors and adhesion molecule inhibitors. The biological response modifiers include monoclonal antibodies as well as recombinant forms of molecules. Exemplary DMARDs include azathioprine, cyclophosphamide, cyclosporine, methotrexate, penicillamine, leflunomide, sulfasalazine, hydroxychloroquine, Gold (oral (auranofin) and intramuscular) and minocycline. [0108]In certain embodiments, the compositions described herein are administered in conjunction with a cytokine. "Cytokine " as used herein is meant to refer to proteins released by one cell WO 2022/051556 PCT/US2021/048944 population that act on another cell as intercellular mediators. Examples of cytokines are lymphokines, monokines, and traditional polypeptide hormones. Included among the cytokines are growth hormones such as human growth hormone, N-methionyl human growth hormone, and bovine growth hormone; parathyroid hormone; thyroxine; insulin; proinsulin; relaxin; prorelaxin; glycoprotein hormones such as follicle stimulating hormone (FSH), thyroid stimulating hormone (TSH), and luteinizing hormone (LH); hepatic growth factor (HGF); fibroblast growth factor (FGF); prolactin; placental lactogen; mullerian-inhibiting substance; mouse gonadotropin-associated peptide; inhibin; activin; vascular endothelial growth factor; integrin; thrombopoietin (TPO); nerve growth factors (NGFs) such as NGF-beta; platelet-growth factor; transforming growth factors (TGFs) such as TGF-alpha and TGF-beta; insulin-like growth factor-I and -II; erythropoietin (EPO); osteoinductive factors; interferons such as interferon-alpha, beta, and -gamma; colony stimulating factors (CSFs) such as macrophage-CSF (M-CSF); granulocyte-macrophage-CSF (GM-CSF); and granulocyte-CSF (G-CSF); interleukins (ILs) such as IL-1, IL-1 alpha, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12; IL-15, a tumor necrosis factor such as TNF-alpha or TNF- beta; and other polypeptide factors including LIF and kit ligand (KL). As used herein, the term cytokine includes proteins from natural sources or from recombinant cell culture, and biologically active equivalents of the native sequence cytokines. 4. Methods of Making [0109]A variety of known techniques can be utilized in making the polynucleotides, polypeptides, vectors, antigen-binding molecules, immune cells, compositions, and the like according to the invention. [0110]Prior to the in vitro manipulation or genetic modification of the immune cells described herein, the cells may be obtained from a subject. In some embodiments, the immune cells comprise B cells. B cells can be obtained from a number of sources, including peripheral blood mononuclear cells (PBMCs), bone marrow, lymph nodes tissue, cord blood, thymus tissue, tissue from a site of infection, ascites, pleural effusion, spleen tissue, and tumors. In certain embodiments, B cells can be obtained from a unit of blood collected from the subject using any number of techniques known to the skilled person, such as FICOLLTM separation. Cells may preferably be obtained from the circulating blood of an individual by apheresis. The apheresis product typically contains lymphocytes, including T cells, monocytes, granulocytes, B cells, other nucleated white blood cells, red blood cells, and platelets. In certain embodiments, the cells collected by apheresis may be washed to remove the plasma fraction, and placed in an appropriate buffer or media for subsequent processing. The cells may be washed with PBS. As will be appreciated, a washing step may be used, such as by using a semiautomated flowthrough centrifuge for example, the Cobe™ 2991 cell processor, the Baxter Cyto-MateTM, or the like. After washing, the cells may be resuspended in a variety of biocompatible buffers, or other saline solution with or without buffer. In certain embodiments, the undesired components of the apheresis sample may be removed.

WO 2022/051556 PCT/US2021/048944 id="p-111" id="p-111" id="p-111" id="p-111" id="p-111" id="p-111" id="p-111" id="p-111" id="p-111" id="p-111" id="p-111"

[0111]The immune cells, such as B cells, can be genetically modified following isolation using known methods, or the immune cells can be activated and expanded (or differentiated in the case of progenitors) in vitro prior to being genetically modified. In another embodiment, the immune cells, such as B cells, are genetically modified with the chimeric B cell receptors described herein (e.g., transduced with a viral vector comprising one or more nucleotide sequences encoding a CAR-B) and then are activated and/or expanded in vitro. Methods for activating and expanding B cells are known in the art and are described, for example, in U.S. Pat. Nos. 6,905,874; 6,867,041; 6,797,514; and PCT WO 2012/079000, the contents of which are hereby incorporated by reference in their entirety. Generally, such methods include contacting PBMC or isolated B cells with a stimulatory agent and costimulatory agent generally attached to a bead or other surface, in a culture medium with appropriate cytokines, such as IL-2. [0112]In other embodiments, the B cells may be activated and stimulated to proliferate with feeder cells and appropriate antibodies and cytokines using methods such as those described in U.S. Pat. Nos. 6,040,177; 5,827,642; and WO/2012129514, the contents of which are hereby incorporated by reference in their entirety. [0113]Certain methods for making the constructs and engineered immune cells of the invention are described in PCT application PCT/US2015/14520, the contents of which are hereby incorporated by reference in their entirety. Additional methods of making the constructs and cells can be found in U.S. provisional patent application No. 62/244,036 the contents of which are hereby incorporated by reference in their entirety. [0114]For cloning of polynucleotides, the vector may be introduced into a host cell (an isolated host cell) to allow replication of the vector itself and thereby amplify the copies of the polynucleotide contained therein. The cloning vectors may contain sequence components generally include, without limitation, an origin of replication, promoter sequences, transcription initiation sequences, enhancer sequences, and selectable markers. These elements may be selected as appropriate by a person of ordinary skill in the art. For example, the origin of replication may be selected to promote autonomous replication of the vector in the host cell. [0115]In certain embodiments, the present disclosure provides isolated host cells containing the vector provided herein. The host cells containing the vector may be useful in expression or cloning of the polynucleotide contained in the vector. Suitable host cells can include, without limitation, prokaryotic cells, fungal cells, yeast cells, or higher eukaryotic cells such as mammalian cells. Suitable prokaryotic cells for this purpose include, without limitation, eubacteria, such as Gram- negative or Gram-positive organisms, for example, Enterobactehaceae such as Escherichia, e.g., E. coli, Enterobacter, Erwinia, Klebsiella, Proteus, Salmonella, e.g., Salmonella typhimurium, Serratia, e.g., Serratia marc-escans, and Shigella, as well as Bacilli such as B. subtilis and B. licheniformis, Pseudomonas such as P. aeruginosa, and Streptomyces.

WO 2022/051556 PCT/US2021/048944 id="p-116" id="p-116" id="p-116" id="p-116" id="p-116" id="p-116" id="p-116" id="p-116" id="p-116" id="p-116" id="p-116"

[0116]The vector can be introduced to the host cell using any suitable methods known in the art, including, without limitation, DEAE-dextran mediated delivery, calcium phosphate precipitate method, cationic lipids mediated delivery, liposome mediated transfection, electroporation, microprojectile bombardment, receptor-mediated gene delivery, delivery mediated by poly lysine, histone, chitosan, and peptides. Standard methods for transfection and transformation of cells for expression of a vector of interest are well known in the art. In a further embodiment, a mixture of different expression vectors can be used in genetically modifying a donor population of immune effector cells wherein each vector encodes a different B-CARs as disclosed herein. The resulting transduced immune effector cells form a mixed population of engineered cells, with a proportion of the engineered cells expressing more than one different B-CARs. [0117]In one embodiment, the invention provides a method of storing genetically engineered cells expressing B-CARs that target a protein. This involves cryopreserving the immune cells such that the cells remain viable upon thawing. A fraction of the immune cells expressing the B-CARs can be cryopreserved by methods known in the art to provide a permanent source of such cells for the future treatment of patients afflicted with a malignancy. When needed, the cryopreserved transformed immune cells can be thawed, grown and expanded for more such cells. [0118]As used herein, "cryopreserve" refers to the preservation of cells by cooling to sub-zero temperatures, such as (typically) 77 Kelvin or 196° C. (the boiling point of liquid nitrogen). Cryoprotective agents are often used at sub-zero temperatures to prevent the cells being preserved from damage due to freezing at low temperatures or warming to room temperature.Cryopreservative agents and optimal cooling rates can protect against cell injury. Cryoprotective agents which can be used in accordance with the invention include but are not limited to: dimethyl sulfoxide (DMSO) (Lovelock & Bishop, Nature, 1959, 183, 1394-1395; Ashwood-Smith, Nature, 1961, 190, 1204-1205), glycerol, polyvinylpyrrolidine (Rinfret, Ann. N.Y. Acad. Sci., 1960, 85, 576), and polyethylene glycol (Sloviter & Ravdin, Nature, 1962, 196, 48). The preferred cooling rate is l°-3° C/minute. [0119]The term, "substantially pure," is used to indicate that a given component is present at a high level. The component is desirably the predominant component present in a composition. Preferably it is present at a level of more than 30%, of more than 50%, of more than 75%, of more than 90%, or even of more than 95%, said level being determined on a dry weight/dry weight basis with respect to the total composition under consideration. At very high levels (e.g. at levels of more than 90%, of more than 95% or of more than 99%) the component can be regarded as being in "pure form." Biologically active substances of the present invention (including polypeptides, nucleic acid molecules, antigen-binding molecules, moieties) can be provided in a form that is substantially free of one or more contaminants with which the substance might otherwise be associated. When a composition is substantially free of a given contaminant, the contaminant will be at a low level (e.g., WO 2022/051556 PCT/US2021/048944 at a level of less than 10%, less than 5%, or less than 1% on the dry weight/dry weight basis set out above). [0120]In some embodiments, the cells are formulated by first harvesting them from their culture medium, and then washing and concentrating the cells in a medium and container system suitable for administration (a "pharmaceutically acceptable" carrier) in a treatment-effective amount. Suitable infusion media can be any isotonic medium formulation, typically normal saline, Normosol™M R (Abbott) or Plasma-Lyte™ A (Baxter), but also 5% dextrose in water or Ringer’s lactate can be utilized. The infusion medium can be supplemented with human serum albumin. [0121]Desired treatment amounts of cells in the composition is generally at least 2 cells or is more typically greater than 102 cells, and up to 106, up to and including 108 or 109 cells and can be more than 1010 cells. The number of cells will depend upon the desired use for which the composition is intended, and the type of cells included therein. The density of the desired cells is typically greater than 106 cells/ml and generally is greater than 107 cells/ml, generally 108 cells/ml or greater. The clinically relevant number of immune cells can be apportioned into multiple infusions that cumulatively equal or exceed 105, 106, 107, 108, 109, 1010, 1011, or 1012 cells. In some aspects of the present invention, particularly since all the infused cells will be redirected to a particular target antigen, lower numbers of cells, in the range of 106/kilogram (106-10u per patient) may be administered. B-CAR treatments may be administered multiple times at dosages within these ranges. The cells may be autologous, allogeneic, or heterologous to the patient undergoing therapy. [0122]The B cells of the present invention may be administered either alone, or as a pharmaceutical composition in combination with diluents and/or with other components such as IL- or other cytokines or cell populations. Pharmaceutical compositions of the present invention may comprise a B-CAR expressing cell population, such as B cells, as described herein, in combination with one or more pharmaceutically or physiologically acceptable carriers, diluents or excipients. Such compositions may comprise buffers such as neutral buffered saline, phosphate buffered saline and the like; carbohydrates such as glucose, mannose, sucrose or dextrans, mannitol; proteins; polypeptides or amino acids such as glycine; antioxidants; chelating agents such as EDTA or glutathione; adjuvants (e.g., aluminum hydroxide); and preservatives. Compositions of the present invention are preferably formulated for intravenous administration. Treatment may also include one or more corticosteroid treatment, such as dexamethasone and/or methylprednisolone. [0123]The compositions of the present application can comprise, consist essentially of, or consist of, the components disclosed. [0124]The pharmaceutical compositions of the invention (solutions, suspensions or the like), may include one or more of the following: sterile diluents such as water for injection, saline solution, preferably physiological saline, Ringer’s solution, isotonic sodium chloride, fixed oils such as synthetic mono or diglycerides which may serve as the solvent or suspending medium, polyethylene glycols, glycerin, propylene glycol or other solvents; antibacterial agents such as benzyl alcohol or WO 2022/051556 PCT/US2021/048944 methyl paraben; antioxidants such as ascorbic acid or sodium bisulfate; chelating agents such as ethylene-diaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. The parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic. An injectable pharmaceutical composition is preferably sterile. [0125]It will be appreciated that adverse events may be minimized by transducing the immune cells (containing one or more B-CAR) with a suicide gene. It may also be desired to incorporate an inducible "on" or "accelerator" switch into the immune cells. These techniques may employ the use of dimerization domains and optional activators of such domain dimerization. These techniques include, e.g., those described by Wu et al., Science 2014, 350(6258) utilizing FKBP/Rapalog dimerization systems in certain cells, the contents of which are incorporated by reference herein in their entirety. Additional dimerization technology is described in, e.g., Tegan et al. Chem. Rev.2010, 110, 3315-3336 as well as U.S. Patent Nos. 5,830,462; 5,834,266; 5,869,337; and 6,165,787, the contents of which are also incorporated by reference herein in their entirety. Additional dimerization pairs may include cyclosporine-A/cyclophilin, receptor, estrogen/estrogen receptor (optionally using tamoxifen), glucocorticoids/glucocorticoid receptor, tetracycline/tetracycline receptor, vitamin D/vitamin D receptor. Further examples of dimerization technology can be found in e.g., WO 2014/127261, WO 2015/090229, US 2014/0286987, US 2015/0266973, US 2016/0046700, U.S. Patent No. 8,486,693, US 2014/0171649, and US 2012/0130076, the contents of which are further incorporated by reference herein in their entirety [0126]Suitable techniques include use of inducible caspase-9 (U.S. Appl. Pub. No. 2011/0286980) or a thymidine kinase, before, after or at the same time, as the cells are transduced with the B-CAR construct of the present invention. Additional methods for introducing suicide genes and/or "on" switches include CRISPR, TALENS, MEGATALEN, zinc fingers, RNAi, siRNA, shRNA, antisense technology, and other techniques known in the art. [0127]It will be understood that descriptions herein are exemplary and explanatory only and are not restrictive of the invention as claimed. In this application, the use of the singular includes the plural unless specifically stated otherwise. [0128]The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described. All documents, or portions of documents, cited in this application, including but not limited to patents, patent applications, articles, books, and treatises, are hereby expressly incorporated by reference in their entirety for any purpose. As utilized in accordance with the present disclosure, the following terms, unless otherwise indicated, shall be understood to have the following meanings: [0129]In this application, the use of "or" means "and/or" unless stated otherwise. Furthermore, the use of the term "including", as well as other forms, such as "includes" and "included", is not limiting. Also, terms such as "element" or "component" encompass both elements and components WO 2022/051556 PCT/US2021/048944 comprising one unit and elements and components that comprise more than one subunit unless specifically stated otherwise. [0130]The term "polynucleotide", "nucleotide", or "nucleic acid" includes both single-stranded and double-stranded nucleotide polymers. The nucleotides comprising the polynucleotide can be ribonucleotides or deoxyribonucleotides or a modified form of either type of nucleotide. Said modifications include base modifications such as bromouridine and inosine derivatives, ribose modifications such as 2’, 3’-dideoxyribose, and intemucleotide linkage modifications such as phosphorothioate, phosphorodithioate, phosphoroselenoate, phosphoro-diselenoate, phosphoro- anilothioate, phoshoraniladate and phosphoroamidate. [0131]The term "oligonucleotide" refers to a polynucleotide comprising 200 or fewer nucleotides. Oligonucleotides can be single stranded or double stranded, e.g., for use in the construction of a mutant gene. Oligonucleotides can be sense or antisense oligonucleotides. An oligonucleotide can include a label, including a radiolabel, a fluorescent label, a hapten or an antigenic label, for detection assays. Oligonucleotides can be used, for example, as PCR primers, cloning primers or hybridization probes. [0132]The term "control sequence" refers to a polynucleotide sequence that can affect the expression and processing of coding sequences to which it is ligated. The nature of such control sequences can depend upon the host organism. In particular embodiments, control sequences for prokaryotes can include a promoter, a ribosomal binding site, and a transcription termination sequence. For example, control sequences for eukaryotes can include promoters comprising one or a plurality of recognition sites for transcription factors, transcription enhancer sequences, and transcription termination sequence. "Control sequences" can include leader sequences (signal peptides) and/or fusion partner sequences. [0133]As used herein, "operably linked " means that the components to which the term is applied are in a relationship that allows them to carry out their inherent functions under suitable conditions. [0134]The term "vector" means any molecule or entity (e.g., nucleic acid, plasmid, bacteriophage or virus) used to transfer protein coding information into a host cell. The term "expression vector" or "expression construct" refers to a vector that is suitable for transformation of a host cell and contains nucleic acid sequences that direct and/or control (in conjunction with the host cell) expression of one or more heterologous coding regions operatively linked thereto. An expression construct can include, but is not limited to, sequences that affect or control transcription, translation, and, if introns are present, affect RNA splicing of a coding region operably linked thereto. [0135]The term "host cell" refers to a cell that has been transformed, or is capable of being transformed, with a nucleic acid sequence and thereby expresses a gene of interest. The term includes the progeny of the parent cell, whether or not the progeny is identical in morphology or in genetic make-up to the original parent cell, so long as the gene of interest is present.

WO 2022/051556 PCT/US2021/048944 id="p-136" id="p-136" id="p-136" id="p-136" id="p-136" id="p-136" id="p-136" id="p-136" id="p-136" id="p-136" id="p-136"

[0136]The term "transformation" refers to a change in a cell’s genetic characteristics, and a cell has been transformed when it has been modified to contain new DNA or RNA. For example, a cell is transformed where it is genetically modified from its native state by introducing new genetic material via transfection, transduction, or other techniques. Following transfection or transduction, the transforming DNA can recombine with that of the cell by physically integrating into a chromosome of the cell, or can be maintained transiently as an episomal element without being replicated, or can replicate independently as a plasmid. A cell is considered to have been "stably transformed" when the transforming DNA is replicated with the division of the cell. [0137]The term "transfection" refers to the uptake of foreign or exogenous DNA by a cell. A number of transfection techniques are well known in the art and are disclosed herein. See, e.g., Graham et al., VIROLOGY, 1973, 52:456; Sambrook et al., Molecular Cloning: A Laboratory Manual, 2001, supra; Davis et al., Basic Methods in Molecular Biology, 1986, Elsevier; Chu et al., Gene, 1981, 13:197. [0138]The term "transduction" refers to the process whereby foreign DNA is introduced into a cell via viral vector. See, e.g., Jones et al., Genetics: principles and analysis, 1998, Boston: Jones & Bartlett Publ. [0139]The terms "polypeptide" or "protein" refer to a macromolecule having the amino acid sequence of a protein, including deletions from, additions to, and/or substitutions of one or more amino acids of the native sequence. The terms "polypeptide" and "protein" specifically encompass antigen-binding molecules, antibodies, or sequences that have deletions from, additions to, and/or substitutions of one or more amino acid of antigen-binding protein. The term "polypeptide fragment" refers to a polypeptide that has an amino-terminal deletion, a carboxyl-terminal deletion, and/or an internal deletion as compared with the full-length native protein. Such fragments can also contain modified amino acids as compared with the native protein. Useful polypeptide fragments include immunologically functional fragments of antigen-binding molecules. [0140]The term "isolated" means (i) free of at least some other proteins with which it would normally be found, (ii) is essentially free of other proteins from the same source, e.g., from the same species, (iii) separated from at least about 50 percent of polynucleotides, lipids, carbohydrates, or other materials with which it is associated in nature, (iv) operably associated (by covalent or noncovalent interaction) with a polypeptide with which it is not associated in nature, or (v) does not occur in nature. [0141]A "variant" of a polypeptide (e.g., an antigen-binding molecule) comprises an amino acid sequence wherein one or more amino acid residues are inserted into, deleted from and/or substituted into the amino acid sequence relative to another polypeptide sequence. Variants include fusion proteins. [0142]The term "identity" refers to a relationship between the sequences of two or more polypeptide molecules or two or more nucleic acid molecules, as determined by aligning and WO 2022/051556 PCT/US2021/048944 comparing the sequences. "Percent identity" means the percent of identical residues between the amino acids or nucleotides in the compared molecules and is calculated based on the size of the smallest of the molecules being compared. For these calculations, gaps in alignments (if any) are preferably addressed by a particular mathematical model or computer program (7. e., an "algorithm"). [0143]To calculate percent identity, the sequences being compared are typically aligned in a way that gives the largest match between the sequences. One example of a computer program that can be used to determine percent identity is the GCG program package, which includes GAP (Devereux etal.,Nucl. Acid Res., 1984, 12, 387; Genetics Computer Group, University of Wisconsin, Madison, Wis.). The computer algorithm GAP is used to align the two polypeptides or polynucleotides for which the percent sequence identity is to be determined. The sequences are aligned for optimal matching of their respective amino acid or nucleotide (the "matched span", as determined by the algorithm). In certain embodiments, a standard comparison matrix (see, e.g., Dayhof et al., 1978, Atlas of Protein Sequence and Structure, 1978, 5:345-352 for the PAM 2comparison matrix; Henikoff et al., Proc. Natl. Acad. Sci. U.S.A. 1992, 89, 10915-10919 for the BLO-SUM 62 comparison matrix) is also used by the algorithm. [0144]As used herein, the twenty conventional (e.g., naturally occurring) amino acids and their abbreviations follow conventional usage. See, e.g., Immunology A Synthesis (2nd Edition, Golub and Green, Eds., Sinauer Assoc., Sunderland, Mass. (1991)), which is incorporated herein by reference for any purpose. Stereoisomers (e.g., D-amino acids) of the twenty conventional amino acids, unnatural amino acids such as alpha-, alpha-disubstituted amino acids, N-alkyl amino acids, lactic acid, and other unconventional amino acids can also be suitable components for polypeptides of the present invention. Examples of unconventional amino acids include: 4-hydroxyproline, .gamma.-carboxy-glutamate, epsilon-N,N,N-trimethyllysine, e-N-acetyllysine, O-phosphoserine, N- acetylserine, N-formy !methionine, 3-methylhistidine, 5-hydroxy lysine,. sigma.-N-methylarginine, and other similar amino acids and imino acids (e.g., 4-hydroxyproline). In the polypeptide notation used herein, the left-hand direction is the amino terminal direction and the right-hand direction is the carboxy-terminal direction, in accordance with standard usage and convention. [0145]Conservative amino acid substitutions can encompass non-naturally occurring amino acid residues, which are typically incorporated by chemical peptide synthesis rather than by synthesis in biological systems. These include peptidomimetics and other reversed or inverted forms of amino acid moieties. Naturally occurring residues can be divided into classes based on common side chain properties:a) hydrophobic: norleucine, Met, Ala, Vai, Leu, lie;b) neutral hydrophilic: Cys, Ser, Thr, Asn, Gin;c) acidic: Asp, Glu;d) basic: His, Lys, Arg; WO 2022/051556 PCT/US2021/048944 e) residues that influence chain orientation: Gly, Pro; and f) aromatic: Trp, Tyr, Phe. [0146]For example, non-conservative substitutions can involve the exchange of a member of one of these classes for a member from another class. [0147]In making changes to the antigen-binding molecule, the costimulatory or activating domains of the engineered T cell, according to certain embodiments, the hydropathic index of amino acids can be considered. Each amino acid has been assigned a hydropathic index on the basis of its hydrophobicity and charge characteristics. They are: isoleucine (+4.5); valine (+4.2); leucine (+3.8); phenylalanine (+2.8); cysteine/cystine (+2.5); methionine (+1.9); alanine (+1.8); glycine (- 0.4); threonine (-0.7); serine (-0.8); tryptophan (-0.9); tyrosine (-1.3); proline (-1.6); histidine (-3.2); glutamate (-3.5); glutamine (-3.5); aspartate (-3.5); asparagine (-3.5); lysine (-3.9); and arginine (- 4.5). See, e.g.,Kyte et al., 3. Mol. Biol., 1982,157, 105-131. It is known that certain amino acids can be substituted for other amino acids having a similar hydropathic index or score and still retain a similar biological activity. It is also understood in the art that the substitution of like amino acids can be made effectively on the basis of hydrophilicity, particularly where the biologically functional protein or peptide thereby created is intended for use in immunological embodiments, as in the present case. Exemplary amino acid substitutions are set forth in Table 5. TABLE 5 Original Residues Exemplary Substitutions Preferred Substitutions Ala Val, Leu, lie ValArg Lys, Gin, Asn LysAsn Gin GinAsp Glu GluCys Ser, Ala SerGin Asn AsnGlu Asp AspGly Pro, Ala AlaHis Asn, Gin, Lys, Arg Arglie Leu, Val, Met, Ala, Phe, NorleucineLeu Leu Norleucine, lie, Va, Met, Ala, Phelie Lys Arg, 1, 4 Diamino-butyric Acid, Gin, AsnArg Met Leu, Phe, lie Leu WO 2022/051556 PCT/US2021/048944 Phe Leu, Vai, lie, Ala, Tyr LeuPro Ala GlySer Thr, Ala, Cys ThrThr Ser SerTrp Tyr, Phe TyrTyr Trp, Phe, Thr, Ser PheVai lie, Met, Leu, Phe, Ala, NorleucineLeu id="p-148" id="p-148" id="p-148" id="p-148" id="p-148" id="p-148" id="p-148" id="p-148" id="p-148" id="p-148" id="p-148"

[0148]The term "derivative" refers to a molecule that includes a chemical modification other than an insertion, deletion, or substitution of amino acids (or nucleic acids). In certain embodiments, derivatives comprise covalent modifications, including, but not limited to, chemical bonding with polymers, lipids, or other organic or inorganic moieties. In certain embodiments, a chemically modified antigen-binding molecule can have a greater circulating half-life than an antigen-binding molecule that is not chemically modified. In some embodiments, a derivative antigen-binding molecule is covalently modified to include one or more water soluble polymer attachments, including, but not limited to, polyethylene glycol, polyoxyethylene glycol, or polypropylene glycol. [0149]Peptide analogs are commonly used in the pharmaceutical industry as non-peptide drugs with properties analogous to those of the template peptide. These types of non-peptide compound are termed "peptide mimetics" or "peptidomimetics." Fauchere, J. L., Adv. Drug Res., 1986, 15, 29; Veber, D. F. & Freidinger, R. M., Trends in Neuroscience, 1985, 8, 392-396; and Evans, B. E., et al., J. Med. Chern., 1987, 30, 1229-1239, which are incorporated herein by reference for any purpose. [0150]The term "therapeutically effective amount" refers to the amount of CAR-B cells determined to produce a therapeutic response in a mammal. Such therapeutically effective amounts are readily ascertained by one of ordinary skill in the art. [0151]The terms "patient" and "subject" are used interchangeably and include human and non- human animal subjects as well as those with formally diagnosed disorders, those without formally recognized disorders, those receiving medical attention, those at risk of developing the disorders, etc. [0152]The term "treat" and "treatment" includes therapeutic treatments, prophylactic treatments, and applications in which one reduces the risk that a subject will develop a disorder or other risk factor. Treatment does not require the complete curing of a disorder and encompasses embodiments in which one reduces symptoms or underlying risk factors. The term "prevent" does not require the 100% elimination of the possibility of an event. Rather, it denotes that the likelihood of the occurrence of the event has been reduced in the presence of the compound or method.

WO 2022/051556 PCT/US2021/048944 id="p-153" id="p-153" id="p-153" id="p-153" id="p-153" id="p-153" id="p-153" id="p-153" id="p-153" id="p-153" id="p-153"

[0153]Standard techniques can be used for recombinant DNA, oligonucleotide synthesis, and tissue culture and transformation (e.g., electroporation, lipofection). Enzymatic reactions and purification techniques can be performed according to manufacturer’s specifications or as commonly accomplished in the art or as described herein. The foregoing techniques and procedures can be generally performed according to conventional methods well known in the art and as described in various general and more specific references that are cited and discussed throughout the present specification. See, e.g., Sambrook et al., Molecular Cloning: A Laboratory Manual (2d ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989)), which is incorporated herein by reference for any purpose. 5. Sequences [0154]The following sequences will further exemplify the invention:CD28 transmembrane domain - mouse(SEQIDNO: 1) TTCTGGGCCCTTGTGGTGGTTGCCGGAGTGCTGTTTTGCTATGGGCTCCTGGTTAC CGTTGCCCTTTGTGTGATTTGGACC CD28 transmembrane domain - mouse(SEQ ID NO: 2) FWALVVVAGVLFCYGLLVTVALCVIWT CD28 transmembrane domain - human(SEQ ID NO: 3) TTTTGGGTATTGGTAGTGGTGGGCGGAGTTTTAGCCTGCTACAGCCTCCTGGTAAC AGTGGCTTTTATCATCTTTTGGGTG CD28 transmembrane domain - human(SEQ ID NO: 4) FWVLVVVGGV LACYSLLVTV AFIIFWVCD 19 cytoplasmic domain - human(SEQ ID NO: 5) CAGCGGGCTTTAGTCTTGCGGCGTAAACGTAAAAGAATGACAGATCCAACTCGCA GGTTCTTCAAAGTGACCCCCCCACCTGGGTCCGGACCGCAGAACCAATATGGGAA TGTCCTGTCTCTGCCTACGCCTACAAGTGGACTGGGTAGGGCTCAGAGGTGGGCT GCCGGTCTCGGCGGAACTGCGCCATCTTACGGAAATCCCTCCTCCGACGTTCAGG CAGACGGGGCCCTGGGGTCTCGATCCCCGCCTGGTGTTGGACCAGAAGAGGAAG AGGGCGAGGGCTACGAAGAGCCCGACTCCGAAGAGGACAGTGAGTTTTACGAGA WO 2022/051556 PCT/US2021/048944 ACGACAGCAACCTGGGGCAGGATCAGCTGTCACAGGATGGCTCAGGATATGAAA ACCCTGAGGACGAGCCTTTGGGGCCTGAAGATGAGGACTCCTTTTCTAATGCAGA GTCATATGAGAATGAGGACGAAGAATTGACTCAACCCGTGGCAAGAACAATGGA TTTCCTCAGTCCACACGGGAGTGCATGGGACCCCTCCAGAGAGGCTACTAGCCTC GGTTCTCAAAGCTATGAGGACATGAGGGGTATTCTGTACGCAGCGCCTCAGTTGA GGTCCATCCGCGGCCAGCCAGGCCCAAACCATGAGGAAGATGCCGATTCTTACGA AAACATGGACAACCCCGATGGTCCTGACCCCGCATGGGGGGGCGGCGGGAGGAT GGGCACCTGGTCTACTCGCCD 19 cytoplasmic domain - human(SEQ ID NO: 6) QRALVLRRKRKRMTDPTRRFFKVTPPPGSGPQNQYGNVLSLPTPTSGLGRAQRWAA GLGGTAPSYGNPSSDVQADGALGSRSPPGVGPEEEEGEGYEEPDSEEDSEFYENDSNL GQDQLSQDGSGYENPEDEPLGPEDEDSFSNAESYENEDEELTQPVARTMDFLSPHGS AWDPSREATSLGSQSYEDMRGILYAAPQLRSIRGQPGPNHEEDADSYENMDNPDGPD PAWGGGGRMGTWSTRCD40 cytoplasmic domain - human(SEQ ID NO: 7) AAGAAGGTTGCAAAAAAACCTACTAATAAGGCTCCCCATCCTAAGCAAGAGCCC CAAGAAATTAACTTTCCCGATGATCTTCCGGGTTCTAACACGGCAGCCCCGGTGC AGGAGACCCTGCATGGTTGTCAACCCGTCACTCAGGAGGACGGGAAAGAGTCTC GTATCTCCGTCCAGGAGAGACAGCD40 cytoplasmic domain - human(SEQ ID NO: 8) KKVAKKPTNKAPHPKQEPQEINFPDDLPGSNTAAPVQETLHGCQPVTQEDGKESRISV QERQCD40 + CD79b cytoplasmic domain - human(SEQ ID NO: 9) AAGAAGGTTGCAAAAAAACCTACTAATAAGGCTCCCCATCCTAAGCAAGAGCCC CAAGAAATTAACTTTCCCGATGATCTTCCGGGTTCTAACACGGCAGCCCCGGTGC AGGAGACCCTGCATGGTTGTCAACCCGTCACTCAGGAGGACGGGAAAGAGTCTC GTATCTCCGTCCAGGAGAGACAGGACAAGGACGATAGTAAAGCAGGGATGGAGG AGGACCATACATACGAGGGACTGGATATCGATCAGACAGCCACGTACGAAGACA TTGTGACACTGAGAACTGGCGAGGTGAAGTGGTCAGTGGGAGAACATCCGGGGC AGGAACD40 + CD79b cytoplasmic domain - human(SEQ ID NO: 10) WO 2022/051556 PCT/US2021/048944 KKVAKKPTNK APHPKQEPQE INFPDDLPGS NTAAPVQETL HGCQPVTQED GKESRISVQE RQDKDDSKAG MEEDHTYEGL DIDQTATYED IVTLRTGEVK WSVGEHPGQECD40 + CD 137 cytoplasmic domain - human(SEQIDNO: 11)AAGAAGGTTGCAAAAAAACCTACTAATAAGGCTCCCCATCCTAAGCAAGAGCCC CAAGAAATTAACTTTCCCGATGATCTTCCGGGTTCTAACACGGCAGCCCCGGTGC AGGAGACCCTGCATGGTTGTCAACCCGTCACTCAGGAGGACGGGAAAGAGTCTC GTATCTCCGTCCAGGAGAGACAGAAAAGAGGCCGAAAAAAGCTGCTGTACATCT TCAAACAACCCTTCATGCGACCTGTTCAGACGACACAGGAGGAGGACGGCTGCA GCTGTAGGTTTCCCGAAGAAGAGGAGGGAGGATGCGAACTTCD40 + CD 137 cytoplasmic domain - human(SEQIDNO: 12) KKVAKKPTNKAPHPKQEPQEINFPDDLPGSNTAAPVQETLHGCQPVTQEDGKESRISV QERQKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELCD 137 cytoplasmic domain - human(SEQIDNO: 13) AAAAGAGGCCGAAAAAAGCTGCTGTACATCTTCAAACAACCCTTCATGCGACCTG TTCAGACGACACAGGAGGAGGACGGCTGCAGCTGTAGGTTTCCCGAAGAAGAGG AGGGAGGATGCGAACTT CD 137 cytoplasmic domain - human(SEQIDNO: 14)KRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCEL CD40 and Fc gamma receptor 2a cytoplasmic domain - human(SEQIDNO: 15) AAGAAGGTTGCAAAAAAACCTACTAATAAGGCTCCCCATCCTAAGCAAGAGCCC CAAGAAATTAACTTTCCCGATGATCTTCCGGGTTCTAACACGGCAGCCCCGGTGC AGGAGACCCTGCATGGTTGTCAACCCGTCACTCAGGAGGACGGGAAAGAGTCTC GTATCTCCGTCCAGGAGAGACAGCGCAAAAAACGTATAAGCGCAAACTCTACAG ATCCAGTAAAAGCCGCGCAATTCGAGCCTCCCGGCCGCCAGATGATTGCAATACG GAAACGTCAACTGGAGGAAACTAATAATGACTATGAGACGGCCGACGGTGGATA CATGACCCTTAATCCCCGCGCGCCAACCGACGATGATAAGAACATATATCTGACG CTCCCCCCTAACGATCACGTTAACAGTAATAAT CD40 and Fc gamma receptor 2a cytoplasmic domain - human WO 2022/051556 PCT/US2021/048944 (SEQIDNO: 16) KKVAKKPTNKAPHPKQEPQEINFPDDLPGSNTAAPVQETLHGCQPVTQEDGKESRISV QERQRKKRISANSTDPVKAAQFEPPGRQMIAIRKRQLEETNNDYETADGGYMTLNPR APTDDDKNIYLTLPPNDHVNSNN Fc gamma receptor 2a cytoplasmic domain - human(SEQIDNO: 17) CGCAAAAAACGTATAAGCGCAAACTCTACAGATCCAGTAAAAGCCGCGCAATTC GAGCCTCCCGGCCGCCAGATGATTGCAATACGGAAACGTCAACTGGAGGAAACT AATAATGACTATGAGACGGCCGACGGTGGATACATGACCCTTAATCCCCGCGCGC CAACCGACGATGATAAGAACATATATCTGACGCTCCCCCCTAACGATCACGTTAA CAGTAATAATFc gamma receptor 2a cytoplasmic domain - human (SEQIDNO: 18) RKKRISANSTDPVKAAQFEPPGRQMIAIRKRQLEETNNDYETADGGYMTLNPRAPTD DDKNIYLTLPPNDHVNSNNMyd88 + CD40 cytoplasmic domain - human(SEQIDNO: 19) ATGGCGGCGGGCGGGCCCGGCGCCGGAAGCGCCGCGCCAGTCTCATCTACGTCC AGTCTGCCACTGGCTGCCCTGAACATGAGAGTGAGACGCCGTTTATCCCTCTTCCT GAATGTGCGGACCCAGGTCGCCGCTGATTGGACCGCCCTGGCCGAAGAGATGGA CTTTGAATACTTGGAAATCAGACAGCTGGAAACACAGGCAGACCCAACCGGGAG ACTGCTTGACGCCTGGCAGGGACGCCCAGGGGCAAGTGTTGGTCGGTTACTGGAG CTTTTAACTAAGTTGGGCCGCGATGACGTGCTGTTGGAGTTAGGACCCAGTATCG AGGAGGATTGTCAGAAATACATCTTGAAACAGCAGCAGGAGGAGGCGGAAAAGC CCCTGCAGGTGGCGGCCGTTGACAGCAGTGTACCCAGAACAGCTGAGCTGGCCG GCATCACAACCCTGGATGATCCCCTGGGCCACATGCCTGAGAGGTTCGACGCTTT CATAAAGAAGGTTGCAAAAAAACCTACTAATAAGGCTCCCCATCCTAAGCAAGA GCCCCAAGAAATTAACTTTCCCGATGATCTTCCGGGTTCTAACACGGCAGCCCCG GTGCAGGAGACCCTGCATGGTTGTCAACCCGTCACTCAGGAGGACGGGAAAGAG TCTCGTATCTCCGTCCAGGAGAGACAGMyd88 + CD40 cytoplasmic domain - human(SEQ ID NO: 20) MAAGGPGAGSAAPVSSTSSLPLAALNMRVRRRLSLFLNVRTQVAADWTALAEEMDF EYLEIRQLETQADPTGRLLDAWQGRPGASVGRLLELLTKLGRDDVLLELGPSIEEDCQ KYILKQQQEEAEKPLQVAAVDSSVPRTAELAGITTLDDPLGHMPERFDAFIKKVAKKP WO 2022/051556 PCT/US2021/048944 TNKAPHPKQEPQEINFPDDLPGSNTAAPVQETLHGCQPVTQEDGKESRISVQERQ Myd88 cytoplasmic domain - human(SEQ ID NO: 21) ATGGCGGCGGGCGGGCCCGGCGCCGGAAGCGCCGCGCCAGTCTCATCTACGTCC AGTCTGCCACTGGCTGCCCTGAACATGAGAGTGAGACGCCGTTTATCCCTCTTCCT GAATGTGCGGACCCAGGTCGCCGCTGATTGGACCGCCCTGGCCGAAGAGATGGA CTTTGAATACTTGGAAATCAGACAGCTGGAAACACAGGCAGACCCAACCGGGAG ACTGCTTGACGCCTGGCAGGGACGCCCAGGGGCAAGTGTTGGTCGGTTACTGGAG CTTTTAACTAAGTTGGGCCGCGATGACGTGCTGTTGGAGTTAGGACCCAGTATCG AGGAGGATTGTCAGAAATACATCTTGAAACAGCAGCAGGAGGAGGCGGAAAAGC CCCTGCAGGTGGCGGCCGTTGACAGCAGTGTACCCAGAACAGCTGAGCTGGCCG GCATCACAACCCTGGATGATCCCCTGGGCCACATGCCTGAGAGGTTCGACGCTTT CATA Myd88 cytoplasmic domain - human(SEQ ID NO: 22)MAAGGPGAGSAAPVSSTSSLPLAALNMRVRRRLSLFLNVRTQVAADWTALAEEMDF EYLEIRQLETQADP TGRLLDAWQGRPGASVGRLLELLTKLGRDDVLLELGPSIE EDCQKYILKQQQEEAEKPLQVAAVDSSVPRTAELAGITTLDDPLGHMPERFDAFI CD79a cytoplasmic domain - human(SEQ ID NO: 23) AGGAAACGATGGCAGAACGAGAAGCTCGGGTTGGATGCCGGGGATGAATATGAA GATGAAAACCTTTATGAAGGCCTGAACCTGGACGACTGCTCCATGTATGAGGACA TCTCCCGGGGCCTCCAGGGCACCTACCAGGATGTGGGCAGCCTCAACATAGGAGA TGTCCAGCTGGAGAAGCCGCD79a cytoplasmic domain - human(SEQ ID NO: 24)RKRWQNEKLGLDAGDEYEDENLYEGLNLDDCSMYEDISRGLQGTYQDVGSLNIGDV QLEKPCD79b cytoplasmic domain - human(SEQ ID NO: 25) CTGGACAAGGATGACAGCAAGGCTGGCATGGAGGAAGATCACACCTACGAGGGC CTGGACATTGACCAGACAGCCACCTATGAGGACATAGTGACGCTGCGGACAGGG GAAGTGAAGTGGTCTGTAGGTGAGCACCCAGGCCAGGAGCD79b cytoplasmic domain - human(SEQ ID NO: 26) LDKDDSKAGMEEDHTYEGLDIDQTATYEDIVTLRTGEVKWSVGEHPGQE WO 2022/051556 PCT/US2021/048944 CD 8 hinge domain - human(SEQ ID NO: 27) TTCGTGCCTGTGTTCCTCCCAGCTAAGCCCACTACCACCCCCGCTCCAAGGCCGCC CACGCCCGCTCCTACTATTGCTAGTCAGCCTTTAAGTTTACGACCCGAAGCTTGCA GGCCCGCCGCCGGCGGCGCTGTGCACACCAGGGGGCTTGATTTTGCCTGCGAC CD 8 hinge domain - human(SEQ ID NO: 28) FVPVFLPAKPTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDSpacer with 3X strep II tag(SEQ ID NO: 29)GGCGCTGGTAGTGGCGGTAACTGGAGCCACCCTCAATTTGAGAAGGGCGGGTCA GGCGGATCAGGTGGTAGTGGTGGGTCCAACTGGAGCCATCCGCAATTTGAAAAG GGCGGAAGCGGCGGTTCCGGCGGTTCAGGCGGTAGCAACTGGTCACATCCGCAA TTTGAGAAAGGCGGGTCAGGCGGCGGGSpacer with 3X strep II tag(SEQ ID NO: 30) GAGSGGNWSHPQFEKGGSGGSGGSGGSNWSHPQFEKGGSGGSGGSGGSNWSHPQFE KGGSGGGhuman IgGl Fc (transmembrane form)(SEQ ID NO: 31) CCCAAGAGCTGCGACAAGACCCACACCTGCCCCCCCTGCCCAGCCCCAGAGCTGC TGGGCGGACCCTCCGTGTTCCTGTTCCCCCCCAAGCCCAAGGACACCCTGATGAT CAGCAGGACCCCCGAGGTGACCTGCGTGGTGGTGGACGTGAGCCACGAGGACCC AGAGGTGAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCACAACGCCAAGAC CAAGCCCAGAGAGGAGCAGTACAACAGCACCTACAGGGTGGTGTCCGTGCTGAC CGTGCTGCACCAGGACTGGCTGAACGGCAAGGAATACAAGTGCAAGGTCTCCAA CAAGGCCCTGCCAGCCCCCATCGAAAAGACCATCAGCAAGGCCAAGGGCCAGCC ACGGGAGCCCCAGGTGTACACCCTGCCCCCCTCCCGGGAGGAGATGACCAAGAA CCAGGTGTCCCTGACCTGTCTGGTGAAGGGCTTCTACCCCAGCGACATCGCCGTG GAGTGGGAGAGCAACGGCCAGCCCGAGAACAACTACAAGACCACCCCCCCAGTG CTGGACAGCGACGGCAGCTTCTTCCTGTACAGCAAGCTGACCGTGGACAAGTCCA GGTGGCAGCAGGGCAACGTGTTCAGCTGCAGCGTGATGCACGAGGCCCTGCACAACCACTACACCCAGAAGAGCCTGAGCCTGTCCCCCGAGCTGCAACTGGAGGAGA GCTGTGCGGAGGCGCAGGACGGGGAGCTGGACGGGCTGTGGACGACCATCACCA TCTTCATCACACTCTTCCTGTTAAGCGTGTGCTACAGTGCCACCGTCACCTTCTTC AAGGTGAAGTGGATCTTCTCCTCGGTGGTGGACCTGAAGCAGACCATCATCCCCG WO 2022/051556 PCT/US2021/048944 ACTACAGGAACATGATCGGACAGGGGGCCTGA human IgGl Fc (transmembrane form)(SEQ ID NO: 32) PKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKF NWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALP APIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQP ENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLS PELQLEESCAEAQDGELDGLWTTITIFITLFLLSVCYSATVTFFKVKWIFSSVVDLKQTI IPDYRNMIGQGAanti-huPSMA scFv(SEQ ID NO: 33) GAGGTTCAACTTGTTCAATCTGGGGCAGAAGTGAAGAAGCCCGGGGCATCTGTGA AAGTATCATGCAAAACATCCGGCTATACGTTTACCGAATACACCATTCACTGGGT CAGACAGGCTCCCGGTCAAAGCCTCGAATGGATGGGAAATATTAACCCTAACAAT GGCGGAACCACATATAATCAGAAATTCCAAGGCCGAGTGACGATAACTGTCGAT AAGAGTACGTCCACAGCTTACATGGAACTCAGCTCTTTGAGATCCGAAGACACTG CAGTTTATTATTGTGCAGCTGGATGGAACTTCGACTATTGGGGACAAGGGACTCT TGTTACGGTGTCCAGTGGCAAACCAGGTAGTGGTAAACCCGGAAGCGGCAAGCC CGGGAGCGGTAAACCTGGTAGCGACATCGTCATGACTCAAAGCCCTGACTCACTC GCCGTGAGCCTGGGAGAGCGTGCAACGCTATCTTGTCGGGCCTCTCAGGATGTCG GAACTGCTGTAGACTGGTATCAACAGAAACCTGACCAATCACCAAAACTCCTGAT TTATTGGGCCTCAACACGTCACACAGGAGTGCCAGATAGGTTCACAGGTAGTGGC AGTGGAACTGATTTTACTTTGACAATTAGCAGCCTGCAAGCCGAAGATGTAGCCG TTTACTTCTGTCAACAATATAACTCATACCCACTAACGTTCGGTGCCGGGACGAA GGTAGAGATTAAAanti-huPSMA scFv(SEQ ID NO: 34) EVQLVQSGAE VKKPGASVKV SCKTSGYTFT EYTIHWVRQA PGQSLEWMGN INPNNGGTTY NQKFQGRVTI TVDKSTSTAY MELSSLRSED TAVYYCAAGW NFDYWGQGTL VTVSSGKPGS GKPGSGKPGS GKPGSDIVMT QSPDSLAVSL GERATLSCRA SQDVGTAVDW YQQKPDQSPK LLIYWASTRH TGVPDRFTGS GSGTDFTLTI SSLQAEDVAV YFCQQYNSYP LTFGAGTKVE IKanti-Sarcoglycan scFv(SEQ ID NO: 35) GAAGTCCAATTGGTTGAAAGCGGTGGTGGACTCGTCAAACCTGGCGGTAGCCTTA AACTTTCATGTGCCGCAAGCGGCTTCACGTTTAGTAACTATGCTATGAGTTGGGTC WO 2022/051556 PCT/US2021/048944 CGCCAAAGTCCAGAAAAGCGCCTCGAATGGGTGGCGGAGATCTCTGGAGGAGGA ACATATACATATTATCCAGACACCATGACCGGTAGGTTTACAATCTCAAGAGACA ACGCTAAGAACACCCTGTACCTGGAAATGTCAAGCCTGAGATCAGAAGATACGG CCATGTATTATTGTACGCGCCTACTCGACTATTGGGGTCAAGGAACTTCCGTGAC GGTGTCAAGCGGAGGAGGTGGGAGCGGAGGAGGCGGAAGTGGCGGTGGTGGCTC TGGTGGCGGTGGAAGTGATATAGTGATGACGCAAGCTGCCTTTTCAAACCCTGTT ACTTTGGGGACTAGCGCATCAATCTCCTGTAGGTCCAGCAAATCTTTGCTGCACA GTAATGGAATCACCTATCTTTTCTGGTATTTGCAAAAGCCTGGGCAGAGCCCGCA ACTGCTGATCTATCAAATGTCAAATCTTGCTTCCGGAGTTCCAGACCGCTTCTCAA GTTCCGGGTCCGGCACTGATTTTACCTTGAGAATTTCTAGGGTCGAAGCTGAAGA CGTCGGTGTCTATTATTGCGCGCAAAACCTTGAGCTTCCATACACCTTCGGGGGG GGCACAAAACTTGAGATCAAGanti-Sarcoglycan scFv(SEQ ID NO: 36) EVQLVESGGG LVKPGGSLKL SCAASGFTFS NYAMSWVRQS PEKRLEWVAE ISGGGTYTYY PDTMTGRFTI SRDNAKNTLY LEMSSLRSED TAMYYCTRLL DYWGQGTSVT VSSGGGGSGG GGSGGGGSGG GGSDIVMTQA AFSNPVTLGT SASISCRSSK SLLHSNGITY LFWYLQKPGQ SPQLLIYQMS NLASGVPDRF SSSGSGTDFT LRISRVEAED VGVYYCAQNL ELPYTFGGGT KLEIKanti-hu GPC3 scFv(SEQ ID NO: 37) CAGTCTGTGTTGACGCAGCCGCCCTCAGTGTCTGCGGCCCCAGGACAGAGGGTCA CCATCTCCTGCTCTGGAACCAGGTCCAACATTGGGAGTGATTATGTTTCCTGGTAC CAACACCTCCCAGGAACAGCCCCCAAACTCCTCGTTTATGGCGATAATCTGCGAC CCTCAGGGATTCCTGACCGATTCTCTGCCTCCAAGTCTGGCACGTCAGCCACCCTG GGCATCACCGGACTCCAGACTGGGGACGAGGCCGATTATTACTGCGGCACATGG GATTACACCCTGAATGGTGTGGTGTTCGGCGGAGGGACCAAGCTGACCGTCCTAG GTTCTAGAGGTGGTGGTGGTAGCGGCGGCGGCGGCTCTGGTGGTGGTGGATCCCT CGAGATGGCCCAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTACAGCCTGG GGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTTAGCAGCTATGCCA TGAGCTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTCTCAGTTATTTA TAGCGGTGGTAGTAGCACATACTATGCAGACTCCGTGAAGGGCCGGTTCACCATC TCCAGAGATAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGAGAGCCG AGGACACGGCCGTATATTACTGTGCGCGCACTTCTTACCTGAACCATGGTGATTA CTGGGGTCAAGGTACTCTGGTGACCGTGTCTAGCGCCGCTGCAanti-hu GPC3 scFv(SEQ ID NO: 38) WO 2022/051556 PCT/US2021/048944 QSVLTQPPSV SAAPGQRVTI SCSGTRSNIG SDYVSWYQHL PGTAPKLLVY GDNLRPSGIP DRFSASKSGT SATLGITGLQ TGDEADYYCG TWDYTLNGVV FGGGTKLTVL GSRGGGGSGG GGSGGGGSLE MAQVQLVESG GGLVQPGGSL RLSCAASGFT FSSYAMSWVR QAPGKGLEWV SVIYSGGSST YYADSVKGRF TISRDNSKNT LYLQMNSLRA EDTAVYYCAR TSYLNHGDYW GQGTLVTVSS AAA pWF-82(SEQ ID NO: 39)GAGGTTCAACTTGTTCAATCTGGGGCAGAAGTGAAGAAGCCCGGGGCATCTGTGA AAGTATCATGCAAAACATCCGGCTATACGTTTACCGAATACACCATTCACTGGGT CAGACAGGCTCCCGGTCAAAGCCTCGAATGGATGGGAAATATTAACCCTAACAAT GGCGGAACCACATATAATCAGAAATTCCAAGGCCGAGTGACGATAACTGTCGAT AAGAGTACGTCCACAGCTTACATGGAACTCAGCTCTTTGAGATCCGAAGACACTG CAGTTTATTATTGTGCAGCTGGATGGAACTTCGACTATTGGGGACAAGGGACTCT TGTTACGGTGTCCAGTGGCAAACCAGGTAGTGGTAAACCCGGAAGCGGCAAGCC CGGGAGCGGTAAACCTGGTAGCGACATCGTCATGACTCAAAGCCCTGACTCACTC GCCGTGAGCCTGGGAGAGCGTGCAACGCTATCTTGTCGGGCCTCTCAGGATGTCG GAACTGCTGTAGACTGGTATCAACAGAAACCTGACCAATCACCAAAACTCCTGAT TTATTGGGCCTCAACACGTCACACAGGAGTGCCAGATAGGTTCACAGGTAGTGGC AGTGGAACTGATTTTACTTTGACAATTAGCAGCCTGCAAGCCGAAGATGTAGCCG TTTACTTCTGTCAACAATATAACTCATACCCACTAACGTTCGGTGCCGGGACGAA GGTAGAGATTAAATTCGTGCCTGTGTTCCTCCCAGCTAAGCCCACTACCACCCCC GCTCCAAGGCCGCCCACGCCCGCTCCTACTATTGCTAGTCAGCCTTTAAGTTTACG ACCCGAAGCTTGCAGGCCCGCCGCCGGCGGCGCTGTGCACACCAGGGGGCTTGAT TTTGCCTGCGACTTTTGGGTATTGGTAGTGGTGGGCGGAGTTTTAGCCTGCTACAG CCTCCTGGTAACAGTGGCTTTTATCATCTTTTGGGTGCAGCGGGCTTTAGTCTTGC GGCGTAAACGTAAAAGAATGACAGATCCAACTCGCAGGTTCTTCAAAGTGACCCC CCCACCTGGGTCCGGACCGCAGAACCAATATGGGAATGTCCTGTCTCTGCCTACG CCTACAAGTGGACTGGGTAGGGCTCAGAGGTGGGCTGCCGGTCTCGGCGGAACT GCGCCATCTTACGGAAATCCCTCCTCCGACGTTCAGGCAGACGGGGCCCTGGGGT CTCGATCCCCGCCTGGTGTTGGACCAGAAGAGGAAGAGGGCGAGGGCTACGAAG AGCCCGACTCCGAAGAGGACAGTGAGTTTTACGAGAACGACAGCAACCTGGGGC AGGATCAGCTGTCACAGGATGGCTCAGGATATGAAAACCCTGAGGACGAGCCTTT GGGGCCTGAAGATGAGGACTCCTTTTCTAATGCAGAGTCATATGAGAATGAGGAC GAAGAATTGACTCAACCCGTGGCAAGAACAATGGATTTCCTCAGTCCACACGGGA GTGCATGGGACCCCTCCAGAGAGGCTACTAGCCTCGGTTCTCAAAGCTATGAGGA CATGAGGGGTATTCTGTACGCAGCGCCTCAGTTGAGGTCCATCCGCGGCCAGCCA GGCCCAAACCATGAGGAAGATGCCGATTCTTACGAAAACATGGACAACCCCGAT WO 2022/051556 PCT/US2021/048944 GGTCCTGACCCCGCATGGGGGGGCGGCGGGAGGATGGGCACCTGGTCTACTCGCT AGpWF-82(SEQ ID NO: 40) EVQLVQSGAE VKKPGASVKV SCKTSGYTFT EYTIHWVRQA PGQSLEWMGN INPNNGGTTY NQKFQGRVTI TVDKSTSTAY MELSSLRSED TAVYYCAAGW NFDYWGQGTL VTVSSGKPGS GKPGSGKPGS GKPGSDIVMT QSPDSLAVSL GERATLSCRA SQDVGTAVDW YQQKPDQSPK LLIYWASTRH TGVPDRFTGS GSGTDFTLTI SSLQAEDVAV YFCQQYNSYP LTFGAGTKVE IKFVPVFLPA KPTTTPAPRP PTPAPTIASQ PLSLRPEACR PAAGGAVHTR GLDFACDFWV LVVVGGVLAC YSLLVTVAFI IFWVQRALVL RRKRKRMTDP TRRFFKVTPP PGSGPQNQYGNVLSLPTPTS GLGRAQRWAA GLGGTAPSYGNPSSDVQADG ALGSRSPPGV GPEEEEGEGY EEPDSEEDSE FYENDSNLGQ DQLSQDGSGY ENPEDEPLGP EDEDSFSNAE SYENEDEELT QPVARTMDFL SPHGSAWDPS REATSLGSQS YEDMRGILYA APQLRSIRGQ PGPNHEEDAD SYENMDNPDG PDPAWGGGGR MGTWSTR- pWF-83(SEQ ID NO: 41)GAGGTTCAACTTGTTCAATCTGGGGCAGAAGTGAAGAAGCCCGGGGCATCTGTGA AAGTATCATGCAAAACATCCGGCTATACGTTTACCGAATACACCATTCACTGGGT CAGACAGGCTCCCGGTCAAAGCCTCGAATGGATGGGAAATATTAACCCTAACAAT GGCGGAACCACATATAATCAGAAATTCCAAGGCCGAGTGACGATAACTGTCGAT AAGAGTACGTCCACAGCTTACATGGAACTCAGCTCTTTGAGATCCGAAGACACTG CAGTTTATTATTGTGCAGCTGGATGGAACTTCGACTATTGGGGACAAGGGACTCT TGTTACGGTGTCCAGTGGCAAACCAGGTAGTGGTAAACCCGGAAGCGGCAAGCC CGGGAGCGGTAAACCTGGTAGCGACATCGTCATGACTCAAAGCCCTGACTCACTC GCCGTGAGCCTGGGAGAGCGTGCAACGCTATCTTGTCGGGCCTCTCAGGATGTCG GAACTGCTGTAGACTGGTATCAACAGAAACCTGACCAATCACCAAAACTCCTGAT TTATTGGGCCTCAACACGTCACACAGGAGTGCCAGATAGGTTCACAGGTAGTGGC AGTGGAACTGATTTTACTTTGACAATTAGCAGCCTGCAAGCCGAAGATGTAGCCG TTTACTTCTGTCAACAATATAACTCATACCCACTAACGTTCGGTGCCGGGACGAA GGTAGAGATTAAATTCGTGCCTGTGTTCCTCCCAGCTAAGCCCACTACCACCCCC GCTCCAAGGCCGCCCACGCCCGCTCCTACTATTGCTAGTCAGCCTTTAAGTTTACG ACCCGAAGCTTGCAGGCCCGCCGCCGGCGGCGCTGTGCACACCAGGGGGCTTGAT WO 2022/051556 PCT/US2021/048944 TTTGCCTGCGACTTTTGGGTATTGGTAGTGGTGGGCGGAGTTTTAGCCTGCTACAG CCTCCTGGTAACAGTGGCTTTTATCATCTTTTGGGTGCTGGACAAGGATGACAGC AAGGCTGGCATGGAGGAAGATCACACCTACGAGGGCCTGGACATTGACCAGACA GCCACCTATGAGGACATAGTGACGCTGCGGACAGGGGAAGTGAAGTGGTCTGTA GGTGAGCACCCAGGCCAGGAGTGApWF-83(SEQ ID NO: 42) EVQLVQSGAE VKKPGASVKV SCKTSGYTFT EYTIHWVRQA PGQSLEWMGN INPNNGGTTY NQKFQGRVTI TVDKSTSTAY MELSSLRSED TAVYYCAAGW NFDYWGQGTL VTVSSGKPGS GKPGSGKPGS GKPGSDIVMT QSPDSLAVSL GERATLSCRA SQDVGTAVDW YQQKPDQSPK LLIYWASTRH TGVPDRFTGS GSGTDFTLTI SSLQAEDVAV YFCQQYNSYP LTFGAGTKVE IKFVPVFLPA KPTTTPAPRP PTPAPTIASQ PLSLRPEACR PAAGGAVHTR GLDFACDFWV LVVVGGVLAC YSLLVTVAFIIFWVLDKDDS KAGMEEDHTY EGLDIDQTAT YEDIVTLRTG EVKWSVGEHP GQE-pWF-84:(SEQ ID NO: 43)GAGGTTCAACTTGTTCAATCTGGGGCAGAAGTGAAGAAGCCCGGGGCATCTGTGA AAGTATCATGCAAAACATCCGGCTATACGTTTACCGAATACACCATTCACTGGGT CAGACAGGCTCCCGGTCAAAGCCTCGAATGGATGGGAAATATTAACCCTAACAAT GGCGGAACCACATATAATCAGAAATTCCAAGGCCGAGTGACGATAACTGTCGAT AAGAGTACGTCCACAGCTTACATGGAACTCAGCTCTTTGAGATCCGAAGACACTG CAGTTTATTATTGTGCAGCTGGATGGAACTTCGACTATTGGGGACAAGGGACTCT TGTTACGGTGTCCAGTGGCAAACCAGGTAGTGGTAAACCCGGAAGCGGCAAGCC CGGGAGCGGTAAACCTGGTAGCGACATCGTCATGACTCAAAGCCCTGACTCACTC GCCGTGAGCCTGGGAGAGCGTGCAACGCTATCTTGTCGGGCCTCTCAGGATGTCG GAACTGCTGTAGACTGGTATCAACAGAAACCTGACCAATCACCAAAACTCCTGAT TTATTGGGCCTCAACACGTCACACAGGAGTGCCAGATAGGTTCACAGGTAGTGGC AGTGGAACTGATTTTACTTTGACAATTAGCAGCCTGCAAGCCGAAGATGTAGCCG TTTACTTCTGTCAACAATATAACTCATACCCACTAACGTTCGGTGCCGGGACGAA GGTAGAGATTAAATTCGTGCCTGTGTTCCTCCCAGCTAAGCCCACTACCACCCCC GCTCCAAGGCCGCCCACGCCCGCTCCTACTATTGCTAGTCAGCCTTTAAGTTTACG ACCCGAAGCTTGCAGGCCCGCCGCCGGCGGCGCTGTGCACACCAGGGGGCTTGAT TTTGCCTGCGACTTTTGGGTATTGGTAGTGGTGGGCGGAGTTTTAGCCTGCTACAG CCTCCTGGTAACAGTGGCTTTTATCATCTTTTGGGTGAAGAAGGTTGCAAAAAAA CCTACTAATAAGGCTCCCCATCCTAAGCAAGAGCCCCAAGAAATTAACTTTCCCG WO 2022/051556 PCT/US2021/048944 ATGATCTTCCGGGTTCTAACACGGCAGCCCCGGTGCAGGAGACCCTGCATGGTTG TCAACCCGTCACTCAGGAGGACGGGAAAGAGTCTCGTATCTCCGTCCAGGAGAG ACAGGACAAGGACGATAGTAAAGCAGGGATGGAGGAGGACCATACATACGAGG GACTGGATATCGATCAGACAGCCACGTACGAAGACATTGTGACACTGAGAACTG GCGAGGTGAAGTGGTCAGTGGGAGAACATCCGGGGCAGGAATAApWF-84:(SEQ ID NO: 44) EVQLVQSGAE VKKPGASVKV SCKTSGYTFT EYTIHWVRQA PGQSLEWMGN INPNNGGTTY NQKFQGRVTI TVDKSTSTAY MELSSLRSED TAVYYCAAGW NFDYWGQGTL VTVSSGKPGS GKPGSGKPGS GKPGSDIVMT QSPDSLAVSL GERATLSCRA SQDVGTAVDW YQQKPDQSPK LLIYWASTRH TGVPDRFTGS GSGTDFTLTI SSLQAEDVAV YFCQQYNSYP LTFGAGTKVE IKFVPVFLPA KPTTTPAPRP PTPAPTIASQ PLSLRPEACR PAAGGAVHTR GLDFACDFWV LVVVGGVLAC YSLLVTVAFIIFWVKKVAKK PTNKAPHPKQ EPQEINFPDD LPGSNTAAPV QETLHGCQPV TQEDGKESRI SVQERQDKDD SKAGMEEDHT YEGLDIDQTA TYEDIVTLRT GEVKWSVGEH PGQE- pWF-85:(SEQ ID NO: 45) GAGGTTCAACTTGTTCAATCTGGGGCAGAAGTGAAGAAGCCCGGGGCATCTGTGA AAGTATCATGCAAAACATCCGGCTATACGTTTACCGAATACACCATTCACTGGGT CAGACAGGCTCCCGGTCAAAGCCTCGAATGGATGGGAAATATTAACCCTAACAAT GGCGGAACCACATATAATCAGAAATTCCAAGGCCGAGTGACGATAACTGTCGAT AAGAGTACGTCCACAGCTTACATGGAACTCAGCTCTTTGAGATCCGAAGACACTG CAGTTTATTATTGTGCAGCTGGATGGAACTTCGACTATTGGGGACAAGGGACTCT TGTTACGGTGTCCAGTGGCAAACCAGGTAGTGGTAAACCCGGAAGCGGCAAGCC CGGGAGCGGTAAACCTGGTAGCGACATCGTCATGACTCAAAGCCCTGACTCACTC GCCGTGAGCCTGGGAGAGCGTGCAACGCTATCTTGTCGGGCCTCTCAGGATGTCG GAACTGCTGTAGACTGGTATCAACAGAAACCTGACCAATCACCAAAACTCCTGAT TTATTGGGCCTCAACACGTCACACAGGAGTGCCAGATAGGTTCACAGGTAGTGGC AGTGGAACTGATTTTACTTTGACAATTAGCAGCCTGCAAGCCGAAGATGTAGCCG TTTACTTCTGTCAACAATATAACTCATACCCACTAACGTTCGGTGCCGGGACGAA GGTAGAGATTAAATTCGTGCCTGTGTTCCTCCCAGCTAAGCCCACTACCACCCCC GCTCCAAGGCCGCCCACGCCCGCTCCTACTATTGCTAGTCAGCCTTTAAGTTTACG ACCCGAAGCTTGCAGGCCCGCCGCCGGCGGCGCTGTGCACACCAGGGGGCTTGAT TTTGCCTGCGACTTTTGGGTATTGGTAGTGGTGGGCGGAGTTTTAGCCTGCTACAG CCTCCTGGTAACAGTGGCTTTTATCATCTTTTGGGTGAAGAAGGTTGCAAAAAAA WO 2022/051556 PCT/US2021/048944 CCTACTAATAAGGCTCCCCATCCTAAGCAAGAGCCCCAAGAAATTAACTTTCCCG ATGATCTTCCGGGTTCTAACACGGCAGCCCCGGTGCAGGAGACCCTGCATGGTTG TCAACCCGTCACTCAGGAGGACGGGAAAGAGTCTCGTATCTCCGTCCAGGAGAG ACAGAAAAGAGGCCGAAAAAAGCTGCTGTACATCTTCAAACAACCCTTCATGCG ACCTGTTCAGACGACACAGGAGGAGGACGGCTGCAGCTGTAGGTTTCCCGAAGA AGAGGAGGGAGGATGCGAACTTTAApWF-85:(SEQ ID NO: 46) EVQLVQSGAE VKKPGASVKV SCKTSGYTFT EYTIHWVRQA PGQSLEWMGN INPNNGGTTY NQKFQGRVTI TVDKSTSTAY MELSSLRSED TAVYYCAAGW NFDYWGQGTL VTVSSGKPGS GKPGSGKPGS GKPGSDIVMT QSPDSLAVSL GERATLSCRA SQDVGTAVDW YQQKPDQSPK LLIYWASTRH TGVPDRFTGS GSGTDFTLTI SSLQAEDVAV YFCQQYNSYP LTFGAGTKVE IKFVPVFLPA KPTTTPAPRP PTPAPTIASQ PLSLRPEACR PAAGGAVHTR GLDFACDFWV LVVVGGVLAC YSLLVTVAFIIFWVKKVAKK PTNKAPHPKQ EPQEINFPDD LPGSNTAAPV QETLHGCQPV TQEDGKESRI SVQERQKRGR KKLLYIFKQP FMRPVQTTQE EDGCSCRFPE EEEGGCEL-pWF-86:(SEQ ID NO: 47) EVQLVQSGAE VKKPGASVKV SCKTSGYTFT EYTIHWVRQA PGQSLEWMGN INPNNGGTTY NQKFQGRVTI TVDKSTSTAY MELSSLRSED TAVYYCAAGW NFDYWGQGTL VTVSSGKPGS GKPGSGKPGS GKPGSDIVMT QSPDSLAVSL GERATLSCRA SQDVGTAVDW YQQKPDQSPK LLIYWASTRH TGVPDRFTGS GSGTDFTLTI SSLQAEDVAV YFCQQYNSYP LTFGAGTKVE IKFVPVFLPA KPTTTPAPRP PTPAPTIASQ PLSLRPEACR PAAGGAVHTR GLDFACDFWV LVVVGGVLAC YSLLVTVAFI IFWVKKVAKK PTNKAPHPKQ EPQEINFPDD LPGSNTAAPV QETLHGCQPV TQEDGKESRI SVQERQRKKRISANSTDPVK AAQFEPPGRQ MIAIRKRQLE ETNNDYETAD GGYMTLNPRA PTDDDKNIYL TLPPNDHVNS NN-pWF-87:(SEQ ID NO: 48) GAGGTTCAACTTGTTCAATCTGGGGCAGAAGTGAAGAAGCCCGGGGCATCTGTGA AAGTATCATGCAAAACATCCGGCTATACGTTTACCGAATACACCATTCACTGGGT CAGACAGGCTCCCGGTCAAAGCCTCGAATGGATGGGAAATATTAACCCTAACAAT GGCGGAACCACATATAATCAGAAATTCCAAGGCCGAGTGACGATAACTGTCGAT AAGAGTACGTCCACAGCTTACATGGAACTCAGCTCTTTGAGATCCGAAGACACTG CAGTTTATTATTGTGCAGCTGGATGGAACTTCGACTATTGGGGACAAGGGACTCT WO 2022/051556 PCT/US2021/048944 TGTTACGGTGTCCAGTGGCAAACCAGGTAGTGGTAAACCCGGAAGCGGCAAGCC CGGGAGCGGTAAACCTGGTAGCGACATCGTCATGACTCAAAGCCCTGACTCACTC GCCGTGAGCCTGGGAGAGCGTGCAACGCTATCTTGTCGGGCCTCTCAGGATGTCG GAACTGCTGTAGACTGGTATCAACAGAAACCTGACCAATCACCAAAACTCCTGAT TTATTGGGCCTCAACACGTCACACAGGAGTGCCAGATAGGTTCACAGGTAGTGGC AGTGGAACTGATTTTACTTTGACAATTAGCAGCCTGCAAGCCGAAGATGTAGCCG TTTACTTCTGTCAACAATATAACTCATACCCACTAACGTTCGGTGCCGGGACGAA GGTAGAGATTAAATTCGTGCCTGTGTTCCTCCCAGCTAAGCCCACTACCACCCCC GCTCCAAGGCCGCCCACGCCCGCTCCTACTATTGCTAGTCAGCCTTTAAGTTTACG ACCCGAAGCTTGCAGGCCCGCCGCCGGCGGCGCTGTGCACACCAGGGGGCTTGAT TTTGCCTGCGACTTTTGGGTATTGGTAGTGGTGGGCGGAGTTTTAGCCTGCTACAG CCTCCTGGTAACAGTGGCTTTTATCATCTTTTGGGTGATGGCGGCGGGCGGGCCC GGCGCCGGAAGCGCCGCGCCAGTCTCATCTACGTCCAGTCTGCCACTGGCTGCCC TGAACATGAGAGTGAGACGCCGTTTATCCCTCTTCCTGAATGTGCGGACCCAGGT CGCCGCTGATTGGACCGCCCTGGCCGAAGAGATGGACTTTGAATACTTGGAAATC AGACAGCTGGAAACACAGGCAGACCCAACCGGGAGACTGCTTGACGCCTGGCAG GGACGCCCAGGGGCAAGTGTTGGTCGGTTACTGGAGCTTTTAACTAAGTTGGGCC GCGATGACGTGCTGTTGGAGTTAGGACCCAGTATCGAGGAGGATTGTCAGAAATA CATCTTGAAACAGCAGCAGGAGGAGGCGGAAAAGCCCCTGCAGGTGGCGGCCGT TGACAGCAGTGTACCCAGAACAGCTGAGCTGGCCGGCATCACAACCCTGGATGAT CCCCTGGGCCACATGCCTGAGAGGTTCGACGCTTTCATAAAGAAGGTTGCAAAAA AACCTACTAATAAGGCTCCCCATCCTAAGCAAGAGCCCCAAGAAATTAACTTTCC CGATGATCTTCCGGGTTCTAACACGGCAGCCCCGGTGCAGGAGACCCTGCATGGT TGTCAACCCGTCACTCAGGAGGACGGGAAAGAGTCTCGTATCTCCGTCCAGGAGA GACAGTGApWF-87:(SEQ ID NO: 49)EVQLVQSGAEVKKPGASVKVSCKTSGYTFTEYTIHWVRQAPGQSLEWMGNINPNNG GTTYNQKFQGRVTITVDKSTSTAYMELSSLRSEDTAVYYCAAGWNFDYWGQGTLVT VSSGKPGSGKPGSGKPGSGKPGSDIVMTQSPDSLAVSLGERATLSCRASQDVGTAVD WYQQKPDQSPKLLIYWASTRHTGVPDRFTGSGSGTDFTLTISSLQAEDVAVYFCQQY NSYPLTFGAGTKVEIKFVPVFLPAKPTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGA VHTRGLDFACDFWVLVVVGGVLACYSLLVTVAFIIFWVMAAGGPGAGSAAPVSSTS SLPLAALNMRVRRRLSLFLNVRTQVAADWTALAEEMDFEYLEIRQLETQADPTGRLL DAWQGRPGASVGRLLELLTKLGRDDVLLELGPSIEEDCQKYILKQQQEEAEKPLQVA AVDSSVPRTAELAGITTLDDPLGHMPERFDAFIKKVAKKPTNKAPHPKQEPQEINFPD DLPGSNTAAPVQETLHGCQPVTQEDGKESRISVQERQ- WO 2022/051556 PCT/US2021/048944 pWF-88:(SEQ ID NO: 50) GAGGTTCAACTTGTTCAATCTGGGGCAGAAGTGAAGAAGCCCGGGGCATCTGTGA AAGTATCATGCAAAACATCCGGCTATACGTTTACCGAATACACCATTCACTGGGT CAGACAGGCTCCCGGTCAAAGCCTCGAATGGATGGGAAATATTAACCCTAACAAT GGCGGAACCACATATAATCAGAAATTCCAAGGCCGAGTGACGATAACTGTCGAT AAGAGTACGTCCACAGCTTACATGGAACTCAGCTCTTTGAGATCCGAAGACACTG CAGTTTATTATTGTGCAGCTGGATGGAACTTCGACTATTGGGGACAAGGGACTCT TGTTACGGTGTCCAGTGGCAAACCAGGTAGTGGTAAACCCGGAAGCGGCAAGCC CGGGAGCGGTAAACCTGGTAGCGACATCGTCATGACTCAAAGCCCTGACTCACTC GCCGTGAGCCTGGGAGAGCGTGCAACGCTATCTTGTCGGGCCTCTCAGGATGTCG GAACTGCTGTAGACTGGTATCAACAGAAACCTGACCAATCACCAAAACTCCTGAT TTATTGGGCCTCAACACGTCACACAGGAGTGCCAGATAGGTTCACAGGTAGTGGC AGTGGAACTGATTTTACTTTGACAATTAGCAGCCTGCAAGCCGAAGATGTAGCCG TTTACTTCTGTCAACAATATAACTCATACCCACTAACGTTCGGTGCCGGGACGAA GGTAGAGATTAAATTCGTGCCTGTGTTCCTCCCAGCTAAGCCCACTACCACCCCC GCTCCAAGGCCGCCCACGCCCGCTCCTACTATTGCTAGTCAGCCTTTAAGTTTACG ACCCGAAGCTTGCAGGCCCGCCGCCGGCGGCGCTGTGCACACCAGGGGGCTTGAT TTTGCCTGCGACTTTTGGGTATTGGTAGTGGTGGGCGGAGTTTTAGCCTGCTACAG CCTCCTGGTAACAGTGGCTTTTATCATCTTTTGGGTGAGGAAACGATGGCAGAAC GAGAAGCTCGGGTTGGATGCCGGGGATGAATATGAAGATGAAAACCTTTATGAA GGCCTGAACCTGGACGACTGCTCCATGTATGAGGACATCTCCCGGGGCCTCCAGG GCACCTACCAGGATGTGGGCAGCCTCAACATAGGAGATGTCCAGCTGGAGAAGC CGTGApWF-88:(SEQ ID NO: 51) EVQLVQSGAEVKKPGASVKVSCKTSGYTFTEYTIHWVRQAPGQSLEWMGNINPNNG GTTYNQKFQGRVTITVDKSTSTAYMELSSLRSEDTAVYYCAAGWNFDYWGQGTLVT VSSGKPGSGKPGSGKPGSGKPGSDIVMTQSPDSLAVSLGERATLSCRASQDVGTAVD WYQQKPDQSPKLLIYWASTRHTGVPDRFTGSGSGTDFTLTISSLQAEDVAVYFCQQY NSYPLTFGAGTKVEIKFVPVFLPAKPTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGA VHTRGLDFACDFWVLVVVGGVLACYSLLVTVAFIIFWVRKRWQNEKLGLDAGDEY EDENLYEGLNLDDCSMYEDISRGLQGTYQDVGSLNIGDVQLEKP-pWF-89:(SEQ ID NO: 52) GAGGTTCAACTTGTTCAATCTGGGGCAGAAGTGAAGAAGCCCGGGGCATCTGTGA AAGTATCATGCAAAACATCCGGCTATACGTTTACCGAATACACCATTCACTGGGT WO 2022/051556 PCT/US2021/048944 CAGACAGGCTCCCGGTCAAAGCCTCGAATGGATGGGAAATATTAACCCTAACAAT GGCGGAACCACATATAATCAGAAATTCCAAGGCCGAGTGACGATAACTGTCGAT AAGAGTACGTCCACAGCTTACATGGAACTCAGCTCTTTGAGATCCGAAGACACTG CAGTTTATTATTGTGCAGCTGGATGGAACTTCGACTATTGGGGACAAGGGACTCT TGTTACGGTGTCCAGTGGCAAACCAGGTAGTGGTAAACCCGGAAGCGGCAAGCC CGGGAGCGGTAAACCTGGTAGCGACATCGTCATGACTCAAAGCCCTGACTCACTC GCCGTGAGCCTGGGAGAGCGTGCAACGCTATCTTGTCGGGCCTCTCAGGATGTCG GAACTGCTGTAGACTGGTATCAACAGAAACCTGACCAATCACCAAAACTCCTGAT TTATTGGGCCTCAACACGTCACACAGGAGTGCCAGATAGGTTCACAGGTAGTGGC AGTGGAACTGATTTTACTTTGACAATTAGCAGCCTGCAAGCCGAAGATGTAGCCG TTTACTTCTGTCAACAATATAACTCATACCCACTAACGTTCGGTGCCGGGACGAA GGTAGAGATTAAATTCGTGCCTGTGTTCCTCCCAGCTAAGCCCACTACCACCCCC GCTCCAAGGCCGCCCACGCCCGCTCCTACTATTGCTAGTCAGCCTTTAAGTTTACG ACCCGAAGCTTGCAGGCCCGCCGCCGGCGGCGCTGTGCACACCAGGGGGCTTGAT TTTGCCTGCGACTTTTGGGTATTGGTAGTGGTGGGCGGAGTTTTAGCCTGCTACAG CCTCCTGGTAACAGTGGCTTTTATCATCTTTTGGGTGCTGGACAAGGATGACAGC AAGGCTGGCATGGAGGAAGATCACACCTACGAGGGCCTGGACATTGACCAGACA GCCACCTATGAGGACATAGTGACGCTGCGGACAGGGGAAGTGAAGTGGTCTGTA GGTGAGCACCCAGGCCAGGAGTGApWF-89:(SEQ ID NO: 53) EVQLVQSGAEVKKPGASVKVSCKTSGYTFTEYTIHWVRQAPGQSLEWMGNINPNNG GTTYNQKFQGRVTITVDKSTSTAYMELSSLRSEDTAVYYCAAGWNFDYWGQGTLVT VSSGKPGSGKPGSGKPGSGKPGSDIVMTQSPDSLAVSLGERATLSCRASQDVGTAVD WYQQKPDQSPKLLIYWASTRHTGVPDRFTGSGSGTDFTLTISSLQAEDVAVYFCQQY NSYPLTFGAGTKVEIKFVPVFLPAKPTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGA VHTRGLDFACDFWVLVVVGGVLACYSLLVTVAFIIFWVLDKDDSKAGMEEDHTY EGLDIDQTATYEDIVTLRTGEVKWSVGEHPGQE-pWF-391:(SEQ ID NO: 54) GAGGTTCAACTTGTTCAATCTGGGGCAGAAGTGAAGAAGCCCGGGGCATCTGTGA AAGTATCATGCAAAACATCCGGCTATACGTTTACCGAATACACCATTCACTGGGT CAGACAGGCTCCCGGTCAAAGCCTCGAATGGATGGGAAATATTAACCCTAACAAT GGCGGAACCACATATAATCAGAAATTCCAAGGCCGAGTGACGATAACTGTCGAT AAGAGTACGTCCACAGCTTACATGGAACTCAGCTCTTTGAGATCCGAAGACACTG CAGTTTATTATTGTGCAGCTGGATGGAACTTCGACTATTGGGGACAAGGGACTCT WO 2022/051556 PCT/US2021/048944 TGTTACGGTGTCCAGTGGCAAACCAGGTAGTGGTAAACCCGGAAGCGGCAAGCC CGGGAGCGGTAAACCTGGTAGCGACATCGTCATGACTCAAAGCCCTGACTCACTC GCCGTGAGCCTGGGAGAGCGTGCAACGCTATCTTGTCGGGCCTCTCAGGATGTCG GAACTGCTGTAGACTGGTATCAACAGAAACCTGACCAATCACCAAAACTCCTGAT TTATTGGGCCTCAACACGTCACACAGGAGTGCCAGATAGGTTCACAGGTAGTGGC AGTGGAACTGATTTTACTTTGACAATTAGCAGCCTGCAAGCCGAAGATGTAGCCG TTTACTTCTGTCAACAATATAACTCATACCCACTAACGTTCGGTGCCGGGACGAA GGTAGAGATTAAAGGCGCTGGTAGTGGCGGTAACTGGAGCCACCCTCAATTTGAG AAGGGCGGGTCAGGCGGATCAGGTGGTAGTGGTGGGTCCAACTGGAGCCATCCG CAATTTGAAAAGGGCGGAAGCGGCGGTTCCGGCGGTTCAGGCGGTAGCAACTGG TCACATCCGCAATTTGAGAAAGGCGGGTCAGGCGGCGGGTTTTGGGCTCTCGTGG TGGTGGCTGGAGTGCTTTTCTGCTATGGCCTGCTGGTAACCGTGGCCCTTTGTGTA ATCTGGACCGATAAAGACGATGGAAAAGCCGGGATGGAAGAAGACCATACCTAC GAGGGGCTCAATATTGATCAAACCGCCACGTATGAAGACATTGTAACACTGCGCA CAGGTGAGGTCAAGTGGTCCGTCGGTGAACACCCAGGACAAGAATAA pWF-391:(SEQ ID NO: 55) EVQLVQSGAEVKKPGASVKVSCKTSGYTFTEYTIHWVRQAPGQSLEWMGNINPNNG GTTYNQKFQGRVTITVDKSTSTAYMELSSLRSEDTAVYYCAAGWNFDYWGQGTLVT VSSGKPGSGKPGSGKPGSGKPGSDIVMTQSPDSLAVSLGERATLSCRASQDVGTAVD WYQQKPDQSPKLLIYWASTRHTGVPDRFTGSGSGTDFTLTISSLQAEDVAVYFCQQY NSYPLTFGAGTKVEIKGAGSGGNWSHPQFEKGGSGGSGGSGGSNWSHPQFEKGGSG GSGGSGGSNWSHPQFEKGGSGGGFWALVVVAGVLFCYGLLVTVALCVIWTDKDDG KAGMEEDHTYEGLNIDQTATYEDIVTLRTGEVKWSVGEHPGQE -pWF-394:(SEQ ID NO: 56) GAAGTCCAATTGGTTGAAAGCGGTGGTGGACTCGTCAAACCTGGCGGTAGCCTTA AACTTTCATGTGCCGCAAGCGGCTTCACGTTTAGTAACTATGCTATGAGTTGGGTC CGCCAAAGTCCAGAAAAGCGCCTCGAATGGGTGGCGGAGATCTCTGGAGGAGGA ACATATACATATTATCCAGACACCATGACCGGTAGGTTTACAATCTCAAGAGACA ACGCTAAGAACACCCTGTACCTGGAAATGTCAAGCCTGAGATCAGAAGATACGG CCATGTATTATTGTACGCGCCTACTCGACTATTGGGGTCAAGGAACTTCCGTGACGGTGTCAAGCGGAGGAGGTGGGAGCGGAGGAGGCGGAAGTGGCGGTGGTGGCTC TGGTGGCGGTGGAAGTGATATAGTGATGACGCAAGCTGCCTTTTCAAACCCTGTT ACTTTGGGGACTAGCGCATCAATCTCCTGTAGGTCCAGCAAATCTTTGCTGCACA GTAATGGAATCACCTATCTTTTCTGGTATTTGCAAAAGCCTGGGCAGAGCCCGCA WO 2022/051556 PCT/US2021/048944 ACTGCTGATCTATCAAATGTCAAATCTTGCTTCCGGAGTTCCAGACCGCTTCTCAA GTTCCGGGTCCGGCACTGATTTTACCTTGAGAATTTCTAGGGTCGAAGCTGAAGA CGTCGGTGTCTATTATTGCGCGCAAAACCTTGAGCTTCCATACACCTTCGGGGGG GGCACAAAACTTGAGATCAAGGGCGCTGGGAGCGGCGGGAATTGGAGTCATCCA CAATTCGAAAAGGGTGGGTCCGGCGGCAGTGGTGGAAGCGGCGGGAGTAACTGG TCACATCCCCAGTTTGAGAAAGGCGGTAGTGGTGGCAGCGGCGGTAGTGGTGGC AGTAATTGGAGCCATCCCCAATTCGAAAAGGGCGGTTCCGGCGGCGGATTTTGGG CTCTTGTTGTGGTGGCCGGAGTATTGTTTTGCTATGGCCTGCTCGTTACAGTGGCA TTGTGCGTAATTTGGACTGATAAAGACGACGGCAAAGCCGGGATGGAAGAAGAT CACACCTATGAGGGGCTTAATATAGATCAAACAGCCACATATGAAGATATTGTGA CTCTAAGGACTGGAGAGGTTAAATGGAGTGTGGGTGAGCATCCAGGACAAGAAT AApWF-394:(SEQ ID NO: 57) EVQLVESGGGLVKPGGSLKLSCAASGFTFSNYAMSWVRQSPEKRLEWVAEISGGGT YTYYPDTMTGRFTISRDNAKNTLYLEMSSLRSEDTAMYYCTRLLDYWGQGTSVTVS SGGGGSGGGGSGGGGSGGGGSDIVMTQAAFSNPVTLGTSASISCRSSKSLLHSNGITY LFWYLQKPGQSPQLLIYQMSNLASGVPDRFSSSGSGTDFTLRISRVEAEDVGVYYCAQ NLELPYTFGGGTKLEIKGAGSGGNWSHPQFEKGGSGGSGGSGGSNWSHPQFEKGGS GGSGGSGGSNWSHPQFEKGGSGGGFWALVVVAGVLFCYGLLVTVALCVIWTDKDDGKAGMEEDHTYEGLNIDQTATYEDIVTLRTGEVKWSVGEHPGQE- pWF-396:(SEQ ID NO: 58) CAGTCTGTGTTGACGCAGCCGCCCTCAGTGTCTGCGGCCCCAGGACAGAGGGTCA CCATCTCCTGCTCTGGAACCAGGTCCAACATTGGGAGTGATTATGTTTCCTGGTAC CAACACCTCCCAGGAACAGCCCCCAAACTCCTCGTTTATGGCGATAATCTGCGAC CCTCAGGGATTCCTGACCGATTCTCTGCCTCCAAGTCTGGCACGTCAGCCACCCTG GGCATCACCGGACTCCAGACTGGGGACGAGGCCGATTATTACTGCGGCACATGG GATTACACCCTGAATGGTGTGGTGTTCGGCGGAGGGACCAAGCTGACCGTCCTAG GTTCTAGAGGTGGTGGTGGTAGCGGCGGCGGCGGCTCTGGTGGTGGTGGATCCCT CGAGATGGCCCAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTACAGCCTGG GGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTTAGCAGCTATGCCA TGAGCTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTCTCAGTTATTTA TAGCGGTGGTAGTAGCACATACTATGCAGACTCCGTGAAGGGCCGGTTCACCATC TCCAGAGATAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGAGAGCCG AGGACACGGCCGTATATTACTGTGCGCGCACTTCTTACCTGAACCATGGTGATTA WO 2022/051556 PCT/US2021/048944 CTGGGGTCAAGGTACTCTGGTGACCGTGTCTAGCGCCGCTGCATTCGTGCCTGTGT TCCTCCCAGCTAAGCCCACTACCACCCCCGCTCCAAGGCCGCCCACGCCCGCTCC TACTATTGCTAGTCAGCCTTTAAGTTTACGACCCGAAGCTTGCAGGCCCGCCGCC GGCGGCGCTGTGCACACCAGGGGGCTTGATTTTGCCTGCGACTTTTGGGTATTGG TAGTGGTGGGCGGAGTTTTAGCCTGCTACAGCCTCCTGGTAACAGTGGCTTTTATC ATCTTTTGGGTGAGGAAACGATGGCAGAACGAGAAGCTCGGGTTGGATGCCGGG GATGAATATGAAGATGAAAACCTTTATGAAGGCCTGAACCTGGACGACTGCTCCA TGTATGAGGACATCTCCCGGGGCCTCCAGGGCACCTACCAGGATGTGGGCAGCCT CAACATAGGAGATGTCCAGCTGGAGAAGCCGTGApWF-396:(SEQ ID NO: 59) QSVLTQPPSVSAAPGQRVTISCSGTRSNIGSDYVSWYQHLPGTAPKLLVYGDNLRPSG IPDRFSASKSGTSATLGITGLQTGDEADYYCGTWDYTLNGVVFGGGTKLTVLGSRGG GGSGGGGSGGGGSLEMAQVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQ APGKGLEWVSVIYSGGSSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYC ARTSYLNHGDYWGQGTLVTVSSAAAFVPVFLPAKPTTTPAPRPPTPAPTIASQPLSLRP EACRPAAGGAVHTRGLDFACDFWVLVVVGGVLACYSLLVTVAFIIFWVRKRWQNEKLGLDAGDEYEDENLYEGLNLDDCSMYEDISRGLQGTYQDVGSLNIGDVQLEKP-pWF-397:(SEQ ID NO: 60) CAGTCTGTGTTGACGCAGCCGCCCTCAGTGTCTGCGGCCCCAGGACAGAGGGTCA CCATCTCCTGCTCTGGAACCAGGTCCAACATTGGGAGTGATTATGTTTCCTGGTAC CAACACCTCCCAGGAACAGCCCCCAAACTCCTCGTTTATGGCGATAATCTGCGAC CCTCAGGGATTCCTGACCGATTCTCTGCCTCCAAGTCTGGCACGTCAGCCACCCTG GGCATCACCGGACTCCAGACTGGGGACGAGGCCGATTATTACTGCGGCACATGG GATTACACCCTGAATGGTGTGGTGTTCGGCGGAGGGACCAAGCTGACCGTCCTAG GTTCTAGAGGTGGTGGTGGTAGCGGCGGCGGCGGCTCTGGTGGTGGTGGATCCCT CGAGATGGCCCAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTACAGCCTGG GGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTTAGCAGCTATGCCA TGAGCTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTCTCAGTTATTTA TAGCGGTGGTAGTAGCACATACTATGCAGACTCCGTGAAGGGCCGGTTCACCATC TCCAGAGATAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGAGAGCCG AGGACACGGCCGTATATTACTGTGCGCGCACTTCTTACCTGAACCATGGTGATTA CTGGGGTCAAGGTACTCTGGTGACCGTGTCTAGCGCCGCTGCATTCGTGCCTGTGT TCCTCCCAGCTAAGCCCACTACCACCCCCGCTCCAAGGCCGCCCACGCCCGCTCC TACTATTGCTAGTCAGCCTTTAAGTTTACGACCCGAAGCTTGCAGGCCCGCCGCC GGCGGCGCTGTGCACACCAGGGGGCTTGATTTTGCCTGCGACTTTTGGGTATTGG WO 2022/051556 PCT/US2021/048944 TAGTGGTGGGCGGAGTTTTAGCCTGCTACAGCCTCCTGGTAACAGTGGCTTTTATC ATCTTTTGGGTGCTGGACAAGGATGACAGCAAGGCTGGCATGGAGGAAGATCAC ACCTACGAGGGCCTGGACATTGACCAGACAGCCACCTATGAGGACATAGTGACG CTGCGGACAGGGGAAGTGAAGTGGTCTGTAGGTGAGCACCCAGGCCAGGAGTGA pWF-397:(SEQ ID NO: 61) QSVLTQPPSVSAAPGQRVTISCSGTRSNIGSDYVSWYQHLPGTAPKLLVYGDNLRPSG IPDRFSASKSGTSATLGITGLQTGDEADYYCGTWDYTLNGVVFGGGTKLTVLGSRGG GGSGGGGSGGGGSLEMAQVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQ APGKGLEWVSVIYSGGSSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYC ARTSYLNHGDYWGQGTLVTVSSAAAFVPVFLPAKPTTTPAPRPPTPAPTIASQPLSLRP EACRPAAGGAVHTRGLDFACDFWVLVVVGGVLACYSLLVTVAFIIFWVLDKDDSKA GMEEDHTYEGLDIDQTATYEDIVTLRTGEVKWSVGEHPGQEpWF-460:(SEQ ID NO: 62) CAGTCTGTGTTGACGCAGCCGCCCTCAGTGTCTGCGGCCCCAGGACAGAGGGTCA CCATCTCCTGCTCTGGAACCAGGTCCAACATTGGGAGTGATTATGTTTCCTGGTAC CAACACCTCCCAGGAACAGCCCCCAAACTCCTCGTTTATGGCGATAATCTGCGAC CCTCAGGGATTCCTGACCGATTCTCTGCCTCCAAGTCTGGCACGTCAGCCACCCTG GGCATCACCGGACTCCAGACTGGGGACGAGGCCGATTATTACTGCGGCACATGG GATTACACCCTGAATGGTGTGGTGTTCGGCGGAGGGACCAAGCTGACCGTCCTAG GTTCTAGAGGTGGTGGTGGTAGCGGCGGCGGCGGCTCTGGTGGTGGTGGATCCCT CGAGATGGCCCAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTACAGCCTGG GGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTTAGCAGCTATGCCA TGAGCTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTCTCAGTTATTTA TAGCGGTGGTAGTAGCACATACTATGCAGACTCCGTGAAGGGCCGGTTCACCATC TCCAGAGATAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGAGAGCCG AGGACACGGCCGTATATTACTGTGCGCGCACTTCTTACCTGAACCATGGTGATTA CTGGGGTCAAGGTACTCTGGTGACCGTGTCTAGCCCCAAGAGCTGCGACAAGACC CACACCTGCCCCCCCTGCCCAGCCCCAGAGCTGCTGGGCGGACCCTCCGTGTTCC TGTTCCCCCCCAAGCCCAAGGACACCCTGATGATCAGCAGGACCCCCGAGGTGAC CTGCGTGGTGGTGGACGTGAGCCACGAGGACCCAGAGGTGAAGTTCAACTGGTA CGTGGACGGCGTGGAGGTGCACAACGCCAAGACCAAGCCCAGAGAGGAGCAGTA CAACAGCACCTACAGGGTGGTGTCCGTGCTGACCGTGCTGCACCAGGACTGGCTG AACGGCAAGGAATACAAGTGCAAGGTCTCCAACAAGGCCCTGCCAGCCCCCATC GAAAAGACCATCAGCAAGGCCAAGGGCCAGCCACGGGAGCCCCAGGTGTACACC CTGCCCCCCTCCCGGGAGGAGATGACCAAGAACCAGGTGTCCCTGACCTGTCTGG WO 2022/051556 PCT/US2021/048944 TGAAGGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAACGGCCAGC CCGAGAACAACTACAAGACCACCCCCCCAGTGCTGGACAGCGACGGCAGCTTCTT CCTGTACAGCAAGCTGACCGTGGACAAGTCCAGGTGGCAGCAGGGCAACGTGTT CAGCTGCAGCGTGATGCACGAGGCCCTGCACAACCACTACACCCAGAAGAGCCT GAGCCTGTCCCCCGAGCTGCAACTGGAGGAGAGCTGTGCGGAGGCGCAGGACGG GGAGCTGGACGGGCTGTGGACGACCATCACCATCTTCATCACACTCTTCCTGTTA AGCGTGTGCTACAGTGCCACCGTCACCTTCTTCAAGGTGAAGTGGATCTTCTCCTC GGTGGTGGACCTGAAGCAGACCATCATCCCCGACTACAGGAACATGATCGGACA GGGGGCCTGApWF-460:(SEQ ID NO: 63) QSVLTQPPSVSAAPGQRVTISCSGTRSNIGSDYVSWYQHLPGTAPKLLVYGDNLRPSG IPDRFSASKSGTSATLGITGLQTGDEADYYCGTWDYTLNGVVFGGGTKLTVLGSRGG GGSGGGGSGGGGSLEMAQVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQ APGKGLEWVSVIYSGGSSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYC ARTSYLNHGDYWGQGTLVTVSSPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTL MISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLT VLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVS LTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGN VFSCSVMHEALHNHYTQKSLSLSPELQLEESCAEAQDGELDGLWTTITIFITLFLLSVC YSATVTFFKVKWIFSSVVDLKQTIIPDYRNMIGQGApWF-428:(SEQ ID NO: 64) CAGTCTGTGTTGACGCAGCCGCCCTCAGTGTCTGCGGCCCCAGGACAGAGGGTCA CCATCTCCTGCTCTGGAACCAGGTCCAACATTGGGAGTGATTATGTTTCCTGGTAC CAACACCTCCCAGGAACAGCCCCCAAACTCCTCGTTTATGGCGATAATCTGCGAC CCTCAGGGATTCCTGACCGATTCTCTGCCTCCAAGTCTGGCACGTCAGCCACCCTG GGCATCACCGGACTCCAGACTGGGGACGAGGCCGATTATTACTGCGGCACATGG GATTACACCCTGAATGGTGTGGTGTTCGGCGGAGGGACCAAGCTGACCGTCCTAG GTCAGCCCAAGGCCAACCCCACTGTCACTCTGTTCCCGCCCTCCTCTGAGGAGCTC CAAGCCAACAAGGCCACACTAGTGTGTCTGATCAGTGACTTCTACCCGGGAGCTG TGACAGTGGCCTGGAAGGCAGATGGCAGCCCCGTCAAGGCGGGAGTGGAGACCA CCAAACCCTCCAAACAGAGCAACAACAAGTACGCGGCCAGCAGCTACCTGAGCC TGACGCCCGAGCAGTGGAAGTCCCACAGAAGCTACAGCTGCCAGGTCACGCATG AAGGGAGCACCGTGGAGAAGACAGTGGCCCCTACAGAATGTTCApWF-428:(SEQ ID NO: 65) WO 2022/051556 PCT/US2021/048944 QSVLTQPPSVSAAPGQRVTISCSGTRSNIGSDYVSWYQHLPGTAPKLLVYGDNLRPSG IPDRFSASKSGTSATLGITGLQTGDEADYYCGTWDYTLNGVVFGGGTKLTVLGQPKA NPTVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADGSPVKAGVETTKPSKQS NNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECSpWF-429:(SEQ ID NO: 66) CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTG AGACTCTCCTGTGCAGCCTCTGGATTCACCTTTAGCAGCTATGCCATGAGCTGGGT CCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTCTCAGTTATTTATAGCGGTGGT AGTAGCACATACTATGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCAGAGATA ATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGAGAGCCGAGGACACGG CCGTATATTACTGTGCGCGCACTTCTTACCTGAACCATGGTGATTACTGGGGTCAA GGTACTCTGGTGACCGTGTCTAGCGCCTCCACCAAGGGCCCATCGGTCTTCCCCCT GGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGTC AAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCA GCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGC AGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACG TGAACCACAAGCCCAGCAACACCAAGGTGGACAAGAGAGTGGAGCCCAAGAGCT GCGACAAGACCCACACCTGCCCCCCCTGCCCAGCCCCAGAGCTGCTGGGCGGACC CTCCGTGTTCCTGTTCCCCCCCAAGCCCAAGGACACCCTGATGATCAGCAGGACC CCCGAGGTGACCTGCGTGGTGGTGGACGTGAGCCACGAGGACCCAGAGGTGAAG TTCAACTGGTACGTGGACGGCGTGGAGGTGCACAACGCCAAGACCAAGCCCAGA GAGGAGCAGTACAACAGCACCTACAGGGTGGTGTCCGTGCTGACCGTGCTGCACC AGGACTGGCTGAACGGCAAGGAATACAAGTGCAAGGTCTCCAACAAGGCCCTGC CAGCCCCCATCGAAAAGACCATCAGCAAGGCCAAGGGCCAGCCACGGGAGCCCC AGGTGTACACCCTGCCCCCCTCCCGGGAGGAGATGACCAAGAACCAGGTGTCCCT GACCTGTCTGGTGAAGGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGC AACGGCCAGCCCGAGAACAACTACAAGACCACCCCCCCAGTGCTGGACAGCGAC GGCAGCTTCTTCCTGTACAGCAAGCTGACCGTGGACAAGTCCAGGTGGCAGCAGG GCAACGTGTTCAGCTGCAGCGTGATGCACGAGGCCCTGCACAACCACTACACCCA GAAGAGCCTGAGCCTGTCCCCCGAGCTGCAACTGGAGGAGAGCTGTGCGGAGGC GCAGGACGGGGAGCTGGACGGGCTGTGGACGACCATCACCATCTTCATCACACTC TTCCTGTTAAGCGTGTGCTACAGTGCCACCGTCACCTTCTTCAAGGTGAAGTGGAT CTTCTCCTCGGTGGTGGACCTGAAGCAGACCATCATCCCCGACTACAGGAACATGATCGGACAGGGGGCCTGApWF-429:(SEQ ID NO: 67) WO 2022/051556 PCT/US2021/048944 QVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSVIYSGGSS TYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARTSYLNHGDYWGQGTL VTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTF PAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPP CPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVH NAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKG QPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVL DSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPELQLEESCAE AQDGELDGLWTTITIFITLFLLSVCYSATVTFFKVKWIFSSVVDLKQTIIPDYRNMIGQ GA-muCXCL13(SEQ ID NO: 68) ATGAGACTTTCAACAGCAACACTCCTCCTGTTGCTGGCTTCATGTCTGAGCCCTGG TCATGGTATTTTGGAGGCCCACTATACAAATCTCAAATGTCGGTGTTCAGGCGTA ATATCCACCGTAGTCGGCCTGAACATTATCGATAGGATTCAGGTTACACCCCCCG GGAACGGATGTCCTAAGACCGAGGTGGTGATTTGGACCAAGATGAAGAAGGTCA TTTGTGTGAACCCACGGGCTAAATGGCTGCAGCGTCTTTTGCGACACGTGCAGTC CAAGAGCTTGTCCAGCACACCTCAGGCCCCAGTTAGCAAGCGACGTGCAGCCmuCXCL13(SEQ ID NO: 69) MRLSTATLLLLLASCLSPGHGILEAHYTNLKCRCSGVISTVVGLNIIDRIQVTPPGNGC PKTEVVIWTKMKKVICVNPRAKWLQRLLRHVQSKSLSSTPQ APVSKRRAAmu FLT3LG(SEQ ID NO: 70) ATGACAGTGCTGGCCCCCGCGTGGTCTCCCAATAGCTCACTCCTCCTCTTGCTGCT ACTGCTCAGCCCATGCCTCAGGGGCACCCCCGATTGTTACTTCAGCCACAGCCCA ATCTCCTCCAACTTCAAAGTGAAATTTAGGGAACTGACCGACCACCTGCTGAAAG ATTATCCTGTGACTGTGGCAGTGAACCTGCAAGACGAAAAGCATTGTAAGGCGCT ATGGAGCCTCTTTCTTGCCCAACGATGGATTGAGCAACTCAAAACTGTAGCCGGA AGCAAAATGCAGACGCTACTGGAGGACGTGAATACTGAGATTCACTTCGTTACCA GTTGTACTTTCCAGCCACTGCCAGAGTGTCTCAGGTTTGTGCAGACTAATATCAGC CACCTGCTGAAGGATACTTGCACCCAGCTCCTGGCTCTCAAGCCTTGTATAGGCA AGGCTTGTCAAAATTTTAGCAGGTGTCTCGAAGTCCAGTGCCAGCCAGATTCATC CACACTGCTGCCGCCCCGAAGCCCTATCGCACTCGAAGCGACAGAGTTGCCAGAG CCTCGTCCCAGACAGCTTCTGCTGCTGCTACTTCTGCTGCTGCCGCTAACTCTGGT GCTACTTGCTGCCGCCTGGGGCCTCAGATGGCAACGCGCCAGACGCCGAGGCGA ACTCCACCCTGGGGTGCCACTGCCATCCCACCCA WO 2022/051556 PCT/US2021/048944 mu FLT3LG(SEQ ID NO: 71)MTVLAPAWSPNSSLLLLLLLLSPCLRGTPDCYFSHSPISSNFKVKFRELTDHLLKDYPV TVAVNLQDEKHCKALWSLFLAQRWIEQLKTVAGSKMQTLLEDVNTEIHFVTSCTFQP LPECLRFVQTNISHLLKDTCTQLLALKPCIGKACQNFSRCLEVQCQPDSSTLLPPRSPIA LEATELPEPRPRQLLLLLLLLLPLTLVLLAAAWGLRWQRARRRGELHPGVPLPS HP mu XCL1(SEQ ID NO: 72)ATGCGACTCTTGTTGTTGACTTTTCTCGGAGTGTGCTGCCTGACACCCTGGGTCGT AGAGGGAGTTGGCACTGAAGTACTAGAAGAGTCCTCCTGCGTTAACCTGCAGACA CAGCGGCTCCCAGTCCAGAAAATTAAGACCTACATTATATGGGAAGGAGCAATG CGAGCGGTGATTTTTGTGACCAAGAGGGGTCTCAAGATTTGCGCGGACCCTGAGG CCAAGTGGGTCAAAGCAGCTATTAAGACAGTAGACGGAAGAGCCTCCACCAGGA AGAATATGGCAGAAACTGTACCGACCGGTGCGCAGCGGTCAACATCTACCGCAA TCACACTCACCGGCmu XCL 1(SEQ ID NO: 73)MRLLLLTFLGVCCLTPWVVEGVGTEVLEESSCVNLQTQRLPVQKIKTYIIWEGAMRA VIFVTKRGLKICADPEAKWVKAAIKTVDGRASTRKNMAETVPTGAQRSTSTAI TLTG mu Tim4(ECD)-muIgG2a Fc(SEQ ID NO: 74) ATGAGCAAGGGCCTTCTCCTGCTGTGGCTAGTAACTGAATTGTGGTGGTTGTACCT GACACCTGCCGCTAGTGAGGACACCATCATTGGTTTCCTTGGGCAGCCCGTCACC CTCCCTTGCCATTACCTAAGCTGGAGCCAGTCACGGAACTCTATGTGCTGGGGAAAGGGGTCATGCCCTAATTCCAAGTGCAACGCCGAGCTGTTGCGCACGGACGGCAC CAGAATAATCTCAAGAAAGTCCACCAAGTATACGCTGCTCGGCAAGGTGCAATTC GGTGAAGTGAGCTTGACCATAAGTAACACCAACCGCGGTGACTCCGGAGTTTATT GTTGCAGGATCGAAGTGCCAGGCTGGTTTAACGACGTGAAGAAAAACGTGCGGC TGGAACTGAGGAGGGCAACTACGACCAAGAAACCAACAACCACGACGAGACCTA CCACCACTCCTTACGTGACAACCACGACACCGGAGCTGTTGCCAACTACCGTCAT GACAACATCTGTGTTGCCAACTACCACCCCCCCCCAAACGCTCGCGACAACTGCC TTTTCCACAGCCGTTACCACATGTCCTTCCACCACCCCAGGCTCTTTTTCTCAAGA AACTACCAAGGGATCAGCTTTTACCACCGAGTCTGAAACTCTCCCAGCAAGTAAT CACTCACAGCGGTCAATGATGACCATCAGCACAGACATCGCTGTCTTGAGACCTA CTGGCAGCAATCCAGGCATTCTGCCCTCCACTTCACAGCTGACTACCCAAAAGAC TACACTAACCACCAGCGAAAGTCTGCAGAAAACTACAAAGAGCCATCAAATAAA CTCCCGGCAGACTCCCAGAGGGCCCACAATCAAGCCCTGTCCTCCATGCAAATGC WO 2022/051556 PCT/US2021/048944 CCAGCACCTAACCTCTTGGGTGGACCATCCGTCTTCATCTTCCCTCCAAAGATCAA GGATGTACTCATGATCTCCCTGAGCCCCATAGTCACATGTGTGGTGGTGGATGTG AGCGAGGATGACCCAGATGTCCAGATCAGCTGGTTTGTGAACAACGTGGAAGTA CACACAGCTCAGACACAAACCCATAGAGAGGATTACAACAGTACTCTCCGGGTG GTCAGTGCCCTCCCCATCCAGCACCAGGACTGGATGAGTGGCAAGGAGTTCAAAT GCAAGGTCAACAACAAAGACCTCCCAGCGCCCATCGAGAGAACCATCTCAAAAC CCAAAGGGTCAGTAAGAGCTCCACAGGTATATGTCTTGCCTCCACCAGAAGAAGA GATGACTAAGAAACAGGTCACTCTGACCTGCATGGTCACAGACTTCATGCCTGAA GACATTTACGTGGAGTGGACCAACAACGGGAAAACAGAGCTAAACTACAAGAAC ACTGAACCAGTCCTGGACTCTGATGGTTCTTACTTCATGTACAGCAAGCTGAGAG TGGAAAAGAAGAACTGGGTGGAAAGAAATAGCTACTCCTGTTCAGTGGTCCACG AGGGTCTGCACAATCACCACACGACTAAGAGCTTCTCCCGGACTCCGGGTAAAmu Tim4(ECD)-muIgG2a Fc(SEQ ID NO: 75)MSKGLLLLWLVTELWWLYLTPAASEDTIIGFLGQPVTLPCHYLSWSQSRNSMCWGK GSCPNSKCNAELLRTDGTRIISRKSTKYTLLGKVQFGEVSLTISNTNRGDSGVYCCRIE VPGWFNDVKKNVRLELRRATTTKKPTTTTRPTTTPYVTTTTPELLPTTVMTTSVLPTT TPPQTLATTAFSTAVTTCPSTTPGSFSQETTKGSAFTTESETLPASNHSQRSMMTISTDI AVLRPTGSNPGILPSTSQLTTQKTTLTTSESLQKTTKSHQINSRQTPRGPTIKPCPPCKC PAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQ TQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRA PQVYVLPPPEEEMTKKQVTLTCMVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSD GSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGKmu 4-1BB-L(SEQ ID NO: 76) ATGGATCAGCATACACTGGACGTGGAAGATACAGCCGATGCCAGACACCCTGCT GGAACGTCCTGTCCCAGCGACGCTGCCCTGCTCAGAGACACCGGGCTGCTCGCAG ATGCTGCTCTGCTGAGTGATACCGTTCGGCCAACTAACGCGGCCCTACCCACAGA TGCCGCATATCCCGCGGTAAATGTCAGGGACCGGGAAGCTGCCTGGCCACCGGCC CTCAATTTCTGCTCTAGACATCCGAAACTGTACGGTCTGGTCGCACTGGTACTGCT GCTACTTATAGCAGCTTGTGTTCCCATATTTACCCGCACTGAACCCAGACCCGCTC TCACTATTACAACTTCACCAAACTTGGGCACACGTGAAAACAATGCAGATCAGGT TACCCCTGTAAGTCATATTGGATGCCCCAACACCACACAACAGGGAAGTCCGGTG TTTGCAAAACTCCTTGCTAAGAATCAGGCTTCACTGTGTAACACTACTCTTAATTG GCACTCACAAGACGGGGCCGGGAGTAGCTATCTCAGCCAAGGTCTCCGCTATGAA GAAGATAAGAAAGAGTTGGTGGTGGACAGCCCAGGACTCTACTACGTCTTCCTGG AGCTAAAACTAAGCCCCACTTTTACTAACACTGGACATAAGGTCCAAGGTTGGGT WO 2022/051556 PCT/US2021/048944 GTCCCTCGTACTTCAAGCTAAACCCCAGGTGGACGACTTCGATAACCTGGCGTTG ACAGTTGAGCTCTTTCCTTGCTCTATGGAAAATAAGCTCGTGGATCGGAGCTGGT CTCAACTGTTGCTGCTTAAAGCCGGTCATCGTCTGTCTGTTGGACTACGCGCATAC TTGCATGGAGCCCAGGACGCATATCGTGATTGGGAACTGAGCTACCCGAATACCA CTAGCTTTGGACTATTTCTTGTTAAACCAGATAATCCTTGGGAGmu 4-1BB-L(SEQ ID NO: 77) MDQHTLDVEDTADARHPAGTSCPSDAALLRDTGLLADAALLSDTVRPTNAALPTDA AYPAVNVRDREAAWPPALNFCSRHPKLYGLVALVLLLLIAACVPIFTRTEPRPALTITT SPNLGTRENNADQVTPVSHIGCPNTTQQGSPVFAKLLAKNQASLCNTTLNWHSQDGA GSSYLSQGLRYEEDKKELVVDSPGLYYVFLELKLSPTFTNTGHKVQGWVSLVLQAKP QVDDFDNLALTVELFPCSMENKLVDRSWSQLLLLKAGHRLSVGLRAYLHGAQDAYR DWELSYPNTTSFGLFLVKPDNPWEmu LIGHT (cleavage-deficient mutant)(SEQ ID NO: 78) ATGGAGAGCGTAGTGCAACCCAGCGTATTTGTGGTGGATGGACAGACCGACATCC CATTCAGACGCTTGGAACAGAACCACCGAAGAAGGCGGTGCGGCACCGTCCAGG TGTCCCTCGCTCTCGTGCTGCTGCTTGGTGCTGGCCTCGCAACACAAGGGTGGTTT CTTTTGAGACTCCATCAACGCTTGGGAGACATAGTGGCCCACCTGCCTGATGGTG GGAAGGGCTCTTGGCAGGACCAGCGATCACACCAGGCTAACCCCGCCGCTCACCT GACAGGGGCGAATGCCAGCTTGATCGGAATAGGTGGGCCGCTGCTGTGGGAAAC TAGGCTTGGACTTGCCTTTCTGAGAGGGCTTACATACCATGACGGAGCCCTCGTA ACAATGGAGCCTGGTTATTACTACGTGTACAGTAAGGTGCAGCTTTCTGGAGTCG GGTGTCCCCAGGGGCTGGCTAACGGACTGCCCATCACTCATGGACTATACAAACG CACATCCAGATATCCTAAAGAGCTGGAACTGTTGGTGTCCCGTAGGAGCCCGTGT GGCAGGGCCAACTCTTCCCGTGTGTGGTGGGACTCCTCTTTTCTGGGCGGCGTGGT CCATCTGGAAGCTGGTGAGGAAGTCGTCGTAAGAGTACCTGGAAACCGTCTGGTT CGCCCCCGCGATGGCACCAGGTCCTACTTCGGAGCTTTCATGGTAmu LIGHT (cleavage-deficient mutant) (SEQ ID NO: 79) MESVVQPSVFVVDGQTDIPFRRLEQNHRRRRCGTVQVSLALVLLLGAGLATQGWFL LRLHQRLGDIVAHLPDGGKGSWQDQRSHQANPAAHLTGANASLIGIGGPLLWETRL GLAFLRGLTYHDGALVTMEPGYYYVYSKVQLSGVGCPQGLANGLPITHGLYKRTSR YPKELELLVSRRSPCGRANSSRVWWDSSFLGGVVHLEAGEEVVVRVPGNRLVRPRD GTRSYFGAFMVmu IL 12 (transmembrane form) WO 2022/051556 PCT/US2021/048944 (SEQ ID NO: 80) ATGTGCCCACAGAAACTCACAATTTCTTGGTTCGCAATCGTCCTGCTGGTGTCACC CCTGATGGCAATGTGGGAGTTGGAAAAGGATGTATACGTCGTCGAGGTCGACTGG ACACCTGACGCTCCGGGTGAAACTGTCAACCTCACTTGCGATACTCCTGAAGAGG ACGACATCACGTGGACGAGCGACCAGCGACATGGAGTGATAGGGTCTGGCAAGA CGCTTACTATCACGGTTAAGGAATTTCTCGACGCAGGGCAGTACACATGTCACAA GGGCGGCGAGACTCTGAGCCACTCCCATTTGCTGCTGCACAAGAAGGAGAATGGT ATCTGGTCTACCGAAATCCTGAAGAATTTTAAGAACAAGACTTTTCTGAAATGCG AGGCCCCAAATTATTCCGGACGTTTCACTTGCAGTTGGCTCGTTCAAAGAAATAT GGACTTGAAATTTAACATTAAATCCAGCTCTTCATCTCCTGACAGCAGGGCCGTA ACTTGTGGAATGGCTTCATTGTCAGCTGAGAAAGTTACGCTTGACCAAAGGGATT ATGAGAAATACAGCGTGAGTTGCCAGGAAGATGTGACATGTCCAACGGCAGAGG AAACGTTGCCAATTGAGCTCGCTTTGGAAGCTCGTCAACAAAACAAGTATGAAAA CTATAGTACTAGCTTCTTCATACGGGACATCATCAAACCAGATCCACCTAAGAAT TTGCAGATGAAGCCTCTGAAGAATTCACAAGTCGAGGTATCCTGGGAATACCCAG ATTCATGGTCCACTCCTCATAGTTACTTTAGCCTGAAATTCTTTGTACGCATACAG CGGAAGAAGGAGAAAATGAAGGAGACGGAAGAAGGCTGCAATCAGAAAGGCGC TTTTCTTGTTGAAAAGACGAGCACTGAGGTTCAATGCAAAGGCGGGAATGTATGT GTTCAAGCCCAAGATAGGTATTATAATAGCTCCTGCTCTAAGTGGGCTTGCGTAC CATGCAGAGTTAGAAGTGGCTCAACCTCAGGCTCCGGAAAACCTGGTTCCGGTGA AGGTTCCACAAAAGGGCGTGTGATTCCTGTGTCCGGCCCAGCTAGGTGTCTCTCC CAGTCACGGAATCTCCTGAAAACCACGGATGACATGGTAAAGACAGCTAGGGAG AAACTCAAGCACTACTCCTGCACAGCTGAGGATATCGATCATGAGGACATCACCA GGGACCAGACATCCACTCTGAAAACTTGCCTGCCTTTGGAACTCCACAAGAACGA ATCTTGTCTGGCAACGCGTGAAACGAGTTCTACTACAAGAGGGTCCTGTCTTCCC CCTCAAAAGACAAGCCTTATGATGACCTTGTGTCTCGGTAGCATTTATGAGGACC TAAAGATGTATCAAACCGAGTTTCAGGCTATCAATGCAGCGCTCCAGAATCATAA CCATCAGCAGATCATTCTTGACAAAGGAATGCTCGTGGCCATTGATGAACTAATG CAGAGCCTAAACCACAATGGCGAGACTCTTCGACAGAAACCGCCTGTGGGCGAG GCCGATCCATATAGAGTCAAAATGAAACTGTGTATTCTCCTGCATGCATTTAGTA CTCGTGTAGTGACTATTAACAGAGTGATGGGTTACCTTTCCTCAGCTAATACACTT GTCCTCTTTGGCGCTGGGTTCGGCGCCGTCATAACGGTTGTTGTCATCGTGGTAAT AATCAAGTGCTTTTGCAAGCACAGGTCTTGTTTTCGCAGGAATGAAGCCTCTAGA GAAACAAATAATTCACTGACCTTTGGCCCCGAAGAAGCTCTTGCAGAGCAAACGG TGTTTCTC mu IL 12 (transmembrane form) WO 2022/051556 PCT/US2021/048944 (SEQ ID NO: 81) MCPQKLTISWFAIVLLVSPLMAMWELEKDVYVVEVDWTPDAPGETVNLTCDTPEED DITWTSDQRHGVIGSGKTLTITVKEFLDAGQYTCHKGGETLSHSHLLLHKKENGIWST EILKNFKNKTFLKCEAPNYSGRFTCSWLVQRNMDLKFNIKSSSSSPDSRAVTCGMASL SAEKVTLDQRDYEKYSVSCQEDVTCPTAEETLPIELALEARQQNKYENYSTSFFIRDII KPDPPKNLQMKPLKNSQVEVSWEYPDSWSTPHSYFSLKFFVRIQRKKEKMKETEEGC NQKGAFLVEKTSTEVQCKGGNVCVQAQDRYYNSSCSKWACVPCRVRSGSTSGSGKP GSGEGSTKGRVIPVSGPARCLSQSRNLLKTTDDMVKTAREKLKHYSCTAEDIDHEDIT RDQTSTLKTCLPLELHKNESCLATRETSSTTRGSCLPPQKTSLMMTLCLGSIYEDLKMYQTEFQAINAALQNHNHQQIILDKGMLVAIDELMQSLNHNGETLRQKPPVGEADPYR VKMKLCILLHAFSTRVVTINRVMGYLSSANTLVLFGAGFGAVITVVVIVVIIKCFCKH RSCFRRNEASRETNNSLTFGPEEALAEQTVFLmu IL 12 (secreted form)(SEQ ID NO: 82) ATGTGTCAGTCACGCTATCTTCTCTTCCTTGCTACTCTGGCCTTGCTCAATCACTTG TCCCTTGCTCGTGTGATTCCTGTGTCCGGCCCAGCTAGGTGTCTCTCCCAGTCACG GAATCTCCTGAAAACCACGGATGACATGGTAAAGACAGCTAGGGAGAAACTCAA GCACTACTCCTGCACAGCTGAGGATATCGATCATGAGGACATCACCAGGGACCAG ACATCCACTCTGAAAACTTGCCTGCCTTTGGAACTCCACAAGAACGAATCTTGTCT GGCAACGCGTGAAACGAGTTCTACTACAAGAGGGTCCTGTCTTCCCCCTCAAAAG ACAAGCCTTATGATGACCTTGTGTCTCGGTAGCATTTATGAGGACCTAAAGATGT ATCAAACCGAGTTTCAGGCTATCAATGCAGCGCTCCAGAATCATAACCATCAGCA GATCATTCTTGACAAAGGAATGCTCGTGGCCATTGATGAACTAATGCAGAGCCTA AACCACAATGGCGAGACTCTTCGACAGAAACCGCCTGTGGGCGAGGCCGATCCA TATAGAGTCAAAATGAAACTGTGTATTCTCCTGCATGCATTTAGTACTCGTGTAGT GACTATTAACAGAGTGATGGGTTACCTTTCCTCAGCTGGAAGCGGCGCCACCAAC TTCTCCCTGCTGAAGCAGGCCGGCGACGTGGAGGAGAACCCCGGCCCCATGTGCC CACAGAAACTCACAATTTCTTGGTTCGCAATCGTCCTGCTGGTGTCACCCCTGATG GCAATGTGGGAGTTGGAAAAGGATGTATACGTCGTCGAGGTCGACTGGACACCT GACGCTCCGGGTGAAACTGTCAACCTCACTTGCGATACTCCTGAAGAGGACGACA TCACGTGGACGAGCGACCAGCGACATGGAGTGATAGGGTCTGGCAAGACGCTTA CTATCACGGTTAAGGAATTTCTCGACGCAGGGCAGTACACATGTCACAAGGGCGG CGAGACTCTGAGCCACTCCCATTTGCTGCTGCACAAGAAGGAGAATGGTATCTGG TCTACCGAAATCCTGAAGAATTTTAAGAACAAGACTTTTCTGAAATGCGAGGCCC CAAATTATTCCGGACGTTTCACTTGCAGTTGGCTCGTTCAAAGAAATATGGACTTG AAATTTAACATTAAATCCAGCTCTTCATCTCCTGACAGCAGGGCCGTAACTTGTG GAATGGCTTCATTGTCAGCTGAGAAAGTTACGCTTGACCAAAGGGATTATGAGAA WO 2022/051556 PCT/US2021/048944 ATACAGCGTGAGTTGCCAGGAAGATGTGACATGTCCAACGGCAGAGGAAACGTT GCCAATTGAGCTCGCTTTGGAAGCTCGTCAACAAAACAAGTATGAAAACTATAGT ACTAGCTTCTTCATACGGGACATCATCAAACCAGATCCACCTAAGAATTTGCAGA TGAAGCCTCTGAAGAATTCACAAGTCGAGGTATCCTGGGAATACCCAGATTCATG GTCCACTCCTCATAGTTACTTTAGCCTGAAATTCTTTGTACGCATACAGCGGAAGA AGGAGAAAATGAAGGAGACGGAAGAAGGCTGCAATCAGAAAGGCGCTTTTCTTG TTGAAAAGACGAGCACTGAGGTTCAATGCAAAGGCGGGAATGTATGTGTTCAAG CCCAAGATAGGTATTATAATAGCTCCTGCTCTAAGTGGGCTTGCGTACCATGCAG AGTTAGAAGTmu IL 12 (secreted form)(SEQ ID NO: 83)MCQSRYLLFLATLALLNHLSLARVIPVSGPARCLSQSRNLLKTTDDMVKTAREKLKH YSCTAEDIDHEDITRDQTSTLKTCLPLELHKNESCLATRETSSTTRGSCLPPQKTSLMM TLCLGSIYEDLKMYQTEFQAINAALQNHNHQQIILDKGMLVAIDELMQSLNHNGETL RQKPPVGEADPYRVKMKLCILLHAFSTRVVTINRVMGYLSSAGSGATNFSLLKQAGD VEENPGPMCPQKLTISWFAIVLLVSPLMAMWELEKDVYVVEVDWTPDAPGETVNLT CDTPEEDDITWTSDQRHGVIGSGKTLTITVKEFLDAGQYTCHKGGETLSHSHLLLHKK ENGIWSTEILKNFKNKTFLKCEAPNYSGRFTCSWLVQRNMDLKFNIKSSSSSPDSRAV TCGMASLSAEKVTLDQRDYEKYSVSCQEDVTCPTAEETLPIELALEARQQNKYENYS TSFFIRDIIKPDPPKNLQMKPLKNSQVEVSWEYPDSWSTPHSYFSLKFFVRIQRKKEKM KETEEGCNQKGAFLVEKTSTEVQCKGGNVCVQ AQDRYYNSSCSKWACVPCRV RS mu IFN alpha A2(SEQ ID NO: 84)ATGGCCAGGCTTTGCGCTTTTCTCGTCATGCTGATCGTCATGAGTTACTGGTCCAT TTGCAGCCTCGGATGTGATCTGCCCCACACCTACAACCTGCGCAACAAACGAGCT CTCAAAGTGTTGGCCCAAATGAGGCGGTTGCCCTTCCTTTCCTGTCTCAAAGACA GGCAAGATTTTGGATTTCCACTAGAGAAAGTAGACAATCAACAGATACAGAAAG CTCAAGCTATCCCCGTGTTGAGGGACTTGACTCAACAGACGTTGAATCTATTTACT AGCAAGGCCAGCTCTGCTGCTTGGAATGCCACCCTTCTTGACTCATTTTGCAATGA CCTACATCAACAACTGAATGATCTCCAAACATGTTTGATGCAGCAGGTAGGTGTC CAAGAACCCCCGCTTACTCAGGAAGACGCCCTTCTGGCTGTCCGCAAGTACTTTC ACAGAATCACAGTGTACCTGCGCGAAAAGAAACACTCCCCCTGCGCTTGGGAAGT GGTCAGGGCCGAGGTTTGGCGAGCCCTGAGTAGCTCCGTCAATCTCCTTCCTCGG TTGTCCGAGGAGAAAGAGmu IFN alpha A2(SEQ ID NO: 85)MARLCAFLVMLIVMSYWSICSLGCDLPHTYNLRNKRALKVLAQMRRLPFLSCLKDR WO 2022/051556 PCT/US2021/048944 QDFGFPLEKVDNQQIQKAQAIPVLRDLTQQTLNLFTSKASSAAWNATLLDSFCNDLH QQLNDLQTCLMQQVGVQEPPLTQEDALLAVRKYFHRITVYLREKKHSPCAWEVVRA EVWRALS S S VNLLPRLSEEKE mu CD80(SEQ ID NO: 86) ATGGCTTGCAACTGTCAGCTCATGCAAGATACTCCCCTGCTTAAGTTTCCCTGCCC TAGACTCATTCTCCTCTTCGTCCTTCTCATTCGCCTAAGCCAGGTGAGTTCCGATG TGGATGAACAACTGAGTAAATCTGTCAAGGATAAAGTTCTGCTCCCATGCCGCTA CAATAGCCCCCATGAGGACGAGTCCGAAGATAGGATTTACTGGCAGAAACATGA TAAGGTGGTGCTATCCGTCATTGCCGGTAAATTGAAGGTGTGGCCCGAATATAAG AATAGAACCCTGTATGACAACACAACTTATAGCCTAATCATCCTCGGTCTCGTAC TGAGCGACCGAGGTACTTACTCATGCGTTGTGCAGAAGAAGGAGCGCGGAACAT ACGAAGTCAAGCACCTTGCATTGGTGAAATTGTCAATAAAAGCTGACTTTTCAAC TCCTAATATTACTGAATCAGGTAACCCTTCCGCAGACACTAAAAGAATTACATGC TTCGCCTCTGGCGGGTTTCCCAAACCACGGTTCTCTTGGCTAGAGAATGGGAGAG AACTTCCAGGTATCAATACAACCATCTCTCAAGACCCAGAATCAGAACTGTACAC CATCTCCAGCCAACTCGATTTCAATACCACAAGAAATCATACAATAAAATGTCTG ATAAAGTACGGAGATGCACATGTCTCTGAAGATTTCACATGGGAGAAACCACCA GAGGACCCGCCAGACAGCAAGAATACACTTGTCCTCTTTGGCGCTGGGTTCGGCG CCGTCATAACGGTTGTTGTCATCGTGGTAATAATCAAGTGCTTTTGCAAGCACAG GTCTTGTTTTCGCAGGAATGAAGCCTCTAGAGAAACAAATAATTCACTGACCTTT GGCCCCGAAGAAGCTCTTGCAGAGCAAACGGTGTTTCTCmu CD80(SEQ ID NO: 87)MACNCQLMQDTPLLKFPCPRLILLFVLLIRLSQVSSDVDEQLSKSVKDKVLLPCRYNS PHEDESEDRIYWQKHDKVVLSVIAGKLKVWPEYKNRTLYDNTTYSLIILGLVLSDRG TYSCVVQKKERGTYEVKHLALVKLSIKADFSTPNITESGNPSADTKRITCFASGGFPKP RFSWLENGRELPGINTTISQDPESELYTISSQLDFNTTRNHTIKCLIKYGDAHVSE DFTWEKPPEDPPDSKNTLVLFGAGFGAVITVVVIVVIIKCFCKHRSCFRR NEASRETNNS LTFGPEEALAEQTVFLmu CD40-L(SEQ ID NO: 88)ATGATCGAAACTTATTCCCAACCCTCACCGCGCTCAGTAGCAACTGGCCTACCAG CCAGCATGAAGATATTCATGTACCTCTTGACTGTATTCTTGATCACGCAAATGATT GGTAGTGTTTTGTTCGCCGTTTATCTCCACAGGCGCCTGGATAAAGTTGAAGAAG AGGTTAATCTCCATGAAGACTTCGTGTTCATTAAGAAACTCAAAAGATGTAACAA WO 2022/051556 PCT/US2021/048944 AGGTGAGGGATCTCTGTCTCTTCTGAACTGTGAGGAGATGCGACGGCAATTCGAG GACCTCGTAAAAGACATAACTCTCAACAAAGAAGAGAAGAAAGAAAACTCTTTC GAGATGCAACGGGGCGACGAGGACCCTCAAATTGCCGCACATGTCGTTTCTGAAG CGAATTCCAATGCCGCGTCCGTGCTCCAGTGGGCGAAGAAGGGATACTACACGAT GAAGAGCAACCTTGTGATGCTTGAAAATGGCAAGCAGCTCACAGTTAAACGCGA GGGACTCTACTATGTATACACCCAAGTGACCTTTTGTTCCAACCGGGAGCCAAGT AGCCAACGCCCGTTCATCGTTGGGCTGTGGCTCAAGCCTTCTTCAGGGAGTGAAC GAATCCTTCTCAAGGCAGCCAACACGCATTCCAGCAGCCAACTGTGTGAGCAACA ATCCGTGCATCTTGGCGGGGTCTTTGAGCTGCAAGCGGGCGCCTCTGTGTTCGTG AATGTTACCGAAGCCAGCCAGGTTATCCACCGCGTGGGTTTCAGTAGTTTTGGCC TGCTCAAGCTGmu CD40-L(SEQ ID NO: 89) MIETYSQPSPRSVATGLPASMKIFMYLLTVFLITQMIGSVLFAVYLHRRLDKVEEEVN LHEDFVFIKKLKRCNKGEGSLSLLNCEEMRRQFEDLVKDITLNKEEKKENSFEMQRG DEDPQIAAHVVSEANSNAASVLQWAKKGYYTMKSNLVMLENGKQLTVKREGLYYV YTQVTFCSNREPSSQRPFIVGLWLKPSSGSERILLKAANTHSSSQLCEQQSVHLGGVFE LQAGASVFVNVTEASQVIHRVGFSSFGLLKLmu IL21(SEQ ID NO: 90) ATGGAGCGTACTCTGGTCTGCCTTGTTGTGATATTCTTGGGGACAGTTGCACACAA ATCATCACCCCAAGGACCGGATAGACTCCTCATACGCCTGCGCCATCTGATTGAC ATTGTCGAGCAGTTGAAGATTTATGAGAACGACCTGGACCCTGAACTATTGAGCG CGCCTCAAGACGTCAAAGGGCATTGCGAGCATGCTGCATTTGCATGTTTTCAGAA AGCTAAGCTCAAACCAAGTAATCCCGGTAACAATAAAACATTCATCATCGACCTG GTGGCCCAACTAAGACGCCGGTTGCCGGCGCGCCGGGGTGGTAAGAAACAGAAA CATATTGCTAAATGCCCCTCTTGCGACTCTTACGAGAAAAGGACACCTAAGGAAT TCCTCGAACGATTGAAATGGTTGTTGCAGAAGATGATCCATCAACATCTGAGCmu IL21(SEQ ID NO: 91) MERTLVCLVVIFLGTVAHKSSPQGPDRLLIRLRHLIDIVEQLKIYENDLDPELLSAPQD V KGHCEHAAFA CFQKAKLKPSNPGNNKTFIIDLVAQLRRRLPARRGGKKQKHIAKCPSCDSYEKRTPKEFLERLKWLLQKM IHQHLS mu CCL21(SEQ ID NO: 92) ATGGCACAAATGATGACACTGTCCCTACTTAGTCTAGTTCTAGCTTTGTGTATTCC CTGGACTCAAGGCAGTGACGGAGGAGGACAAGACTGCTGCCTCAAATATTCTCA WO 2022/051556 PCT/US2021/048944 AAAGAAAATCCCTTATTCTATAGTCCGAGGTTACCGTAAGCAAGAACCGAGTCTA GGTTGTCCTATCCCCGCAATCCTCTTTCTACCACGGAAACATAGCAAACCAGAAT TGTGCGCCAACCCAGAAGAGGGTTGGGTCCAAAATTTGATGAGGCGCCTTGACCA ACCACCGGCCCCGGGTAAACAATCACCGGGGTGTCGGAAGAATAGGGGTACATC CAAATCCGGGAAGAAAGGGAAGGGGAGTAAGGGCTGTAAGAGAACGGAACAAA CTCAACCTAGCAGAGGTmu CCL21(SEQ ID NO: 93)MAQMMTLSLLSLVLALCIPWTQGSDGGGQDCCLKYSQKKIPYSIVRGYRKQEPSLGC PIPAILFLPRKHSKPELCANPEEGWVQNLMRRLDQPPAPGKQSPGCRKNRGTSKSGKK GKGSKGCKRTEQTQPSRGanti-mu CD3 scFv-transmembrane(SEQ ID NO: 94) ATGGAAACCGACACATTGCTCCTCTGGGTTCTCCTTCTATGGGTCCCCGGTTCCAC CGGAGATATCCAAATGACACAATCACCCAGCAGCCTGCCTGCCTCTCTGGGCGAC CGCGTTACCATCAATTGTCAAGCTTCCCAAGATATAAGTAATTATCTCAACTGGTA CCAGCAAAAGCCCGGTAAAGCGCCTAAATTGCTGATTTATTATACTAATAAACTC GCAGATGGAGTTCCTAGTAGATTTTCTGGTTCAGGGAGTGGACGGGACTCCAGTT TTACCATATCAAGTCTGGAATCCGAGGATATCGGCAGCTACTATTGCCAGCAATA TTATAATTACCCTTGGACTTTTGGACCCGGGACTAAACTTGAGATCAAAAGAGGC GGAGGAGGCAGTGGTGGTGGTGGATCAGGCGGCGGTGGTAGTGAGGTACAACTC GTGGAATCAGGCGGCGGACTGGTCCAACCCGGCAAGAGCCTTAAACTCTCTTGTG AGGCCAGTGGATTTACATTCAGCGGTTATGGAATGCACTGGGTGAGACAAGCTCC CGGCAGGGGCCTAGAATCAGTGGCGTACATCACCAGCTCATCAATAAACATTAAA TACGCTGATGCAGTCAAGGGCCGGTTTACTGTATCCCGCGACAACGCTAAGAATC TTCTCTTTCTGCAAATGAACATACTTAAGAGCGAGGATACTGCCATGTATTATTGT GCCCGCTTCGATTGGGATAAGAATTATTGGGGACAAGGCACCATGGTTACCGTTA GTAGTCCAAACATCACATCAAATAATAGCAACCCCGTGGAAGGGGACGACTCTGT TTCACTCACCTGTGATTCCTATACCGATCCTGATAATATCAACTATCTATGGTCTC GTAACGGTGAAAGTCTCAGCGAAGGCGACCGGTTGAAACTCTCCGAAGGTAACA GAACCCTTACGCTTCTGAACGTCACCCGGAACGATACCGGGCCCTATGTTTGCGA AACTAGGAACCCTGTTAGCGTGAATCGTAGCGACCCTTTCTCCCTAAATAATACT CTAGTGCTATTCGGAGCGGGATTCGGTGCCGTCATCACAGTAGTCGTTATTGTAGT CATTATTAAATGCTTTTGTAAACATAGGTCTTGCTTCAGAAGAAATGAGGCCAGC CGTGAAACTAATAATTCCCTGACCTTTGGGCCCGAAGAAGCTTTGGCTGAACAGA CTGTGTTTCTCanti-mu CD3 scFv-transmembrane WO 2022/051556 PCT/US2021/048944 (SEQ ID NO: 95) METDTLLLWVLLLWVPGSTGDIQMTQSPSSLPASLGDRVTINCQASQDISNYLNWYQ QKPGKAPKLLIYYTNKLADGVPSRFSGSGSGRDSSFTISSLESEDIGSYYCQQYYNYP WTFGPGTKLEIKRGGGGSGGGGSGGGGSEVQLVESGGGLVQPGKSLKLSCEASGFTF SGYGMHWVRQAPGRGLESVAYITSSSINIKYADAVKGRFTVSRDNAKNLLFLQMNIL KSEDTAMYYCARFDWDKNYWGQGTMVTVSSPNITSNNSNPVEGDDSVSLTCDSYTD PDNINYLWSRNGESLSEGDRLKLSEGNRTLTLLNVTRNDTGPYVCETRNPVSVNRSD PFSLNNTLVLFGAGFGAVITVVVIVVIIKCFCKHRSCFRRNEASRETNNSLTFGPEEAL AEQTVFLmu TSLP(SEQ ID NO: 96) ATGGTTCTTCTCAGGAGCCTCTTCATCCTGCAAGTACTAGTACGGATGGGGCTAA CTTACAACTTTTCTAACTGCAACTTCACGTCAATTACGAAAATATATTGTAACATA ATTTTTCATGACCTGACTGGAGATTTGAAAGGGGCTAAGTTCGAGCAAATCGAGG ACTGTGAGAGCAAGCCAGCTTGTCTCCTGAAAATCGAGTACTATACTCTCAATCC TATCCCTGGCTGCCCTTCACTCCCCGACAAAACATTTGCCCGGAGAACAAGAGAA GCCCTCAATGACCACTGCCCAGGCTACCCTGAAACTGAGAGAAATGACGGTACTC AGGAAATGGCACAAGAAGTCCAAAACATCTGCCTGAATCAAACCTCACAAATTCT AAGATTGTGGTATTCCTTCATGCAATCTCCAGAAmu TSLP(SEQ ID NO: 97) MVLLRSLFILQVLVRMGLTYNFSNCNFTSITKIYCNIIFHDLTGDLKGAKFEQIEDCES KPACLLKIEYYTLNPIPGCPSLPDKTFARRTREALNDHCPGYPETERNDGTQEMAQEV QNICLNQTSQILRLWYSFMQSPEmu GM-CSF(SEQ ID NO: 98) ATGTGGCTGCAGAATTTACTTTTCCTGGGCATTGTGGTCTACAGCCTCTCAGCACC CACCCGCTCACCCATCACTGTCACCCGGCCTTGGAAGCATGTAGAGGCCATCAAA GAAGCCCTGAACCTCCTGGATGACATGCCTGTCACGTTGAATGAAGAGGTAGAAG TCGTCTCTAACGAGTTCTCCTTCAAGAAGCTAACATGTGTGCAGACCCGCCTGAA GATATTCGAGCAGGGTCTACGGGGCAATTTCACCAAACTCAAGGGCGCCTTGAAC ATGACAGCCAGCTACTACCAGACATACTGCCCCCCAACTCCGGAAACGGACTGTG AAACACAAGTTACCACCTATGCGGATTTCATAGACAGCCTTAAAACCTTTCTGAC TGATATCCCCTTTGAATGCAAAAAACCAGGCCAAAAAmu GM-CSF(SEQ ID NO: 99)MWLQNLLFLGIVVYSLSAPTRSPITVTRPWKHVEAIKEALNLLDDMPVTLNEEVEVV WO 2022/051556 PCT/US2021/048944 SNEFSFKKLTCVQTRLKIFEQGLRGNFTKLKGALNMTASYYQTYCPPTPETDCETQVT TYADFIDSLKTFLTDIPFECKKPGQK mu IFN gamma(SEQIDNO: 100) ATGAACGCTACACACTGCATCTTGGCTTTGCAGCTCTTCCTCATGGCTGTTTCTGG CTGTTACTGCCACGGCACAGTCATTGAAAGCCTAGAAAGTCTGAATAACTATTTT AACTCAAGTGGCATAGATGTGGAAGAAAAGAGTCTCTTCTTGGATATCTGGAGGA ACTGGCAAAAGGATGGTGACATGAAAATCCTGCAGAGCCAGATTATCTCTTTCTA CCTCAGACTCTTTGAAGTCTTGAAAGACAATCAGGCCATCAGCAACAACATAAGC GTCATTGAATCACACCTGATTACTACCTTCTTCAGCAACAGCAAGGCGAAAAAGG ATGCATTCATGAGTATTGCCAAGTTTGAGGTCAACAACCCACAGGTCCAGCGCCA AGCATTCAATGAGCTCATCCGAGTGGTCCACCAGCTGTTGCCGGAATCCAGCCTC AGGAAGCGGAAAAGGAGTCGCTGCmu IFN gamma(SEQIDNO: 101) MNATHCILALQLFLMAVSGCYCHGTVIESLESLNNYFNSSGIDVEEKSLFLDIWRNWQ KDGDMKILQSQIISFYLRLFEVLKDNQAISNNISVIESHLITTFFSNSKAKKDAFMSIAK FEVNNPQVQRQAFNELIRVVHQLLPESSLRKRKRSRCmu IL 7(SEQIDNO: 102) ATGTTCCATGTTTCTTTTAGATATATCTTTGGAATTCCTCCACTGATCCTTGTTCTG CTGCCTGTCACATCATCTGAGTGCCACATTAAAGACAAAGAAGGTAAAGCATATG AGAGTGTACTGATGATCAGCATCGATGAATTGGACAAAATGACAGGAACTGATA GTAATTGCCCGAATAATGAACCAAACTTTTTTAGAAAACATGTATGTGATGATAC AAAGGAAGCTGCTTTTCTAAATCGTGCTGCTCGCAAGTTGAAGCAATTTCTTAAA ATGAATATCAGTGAAGAATTCAATGTCCACTTACTAACAGTATCACAAGGCACAC AAACACTGGTGAACTGCACAAGTAAGGAAGAAAAAAACGTAAAGGAACAGAAA AAGAATGATGCATGTTTCCTAAAGAGACTACTGAGAGAAATAAAAACTTGTTGGA ATAAAATTTTGAAGGGCAGTATAmu IL 7(SEQIDNO: 103) MFHVSFRYIFGIPPLILVLLPVTSSECHIKDKEGKAYESVLMISIDELDKMTGTDSNCPN NEPNFFRKHVCDDTKEAAFLNRAARKLKQFLKMNISEEFNVHLLTVSQGTQTLVNCT SKEEKNVKEQKKNDACFLKRLLREIKTCWNKILKGSImu ICOS-L(SEQIDNO: 104) WO 2022/051556 PCT/US2021/048944 ATGCAGCTAAAGTGTCCCTGTTTTGTGTCCTTGGGAACCAGGCAGCCTGTTTGGA AGAAGCTCCATGTTTCTAGCGGGTTCTTTTCTGGTCTTGGTCTGTTCTTGCTGCTGT TGAGCAGCCTCTGTGCTGCCTCTGCAGAGACTGAAGTCGGTGCAATGGTGGGCAG CAATGTGGTGCTCAGCTGCATTGACCCCCACAGACGCCATTTCAACTTGAGTGGT CTGTATGTCTATTGGCAAATCGAAAACCCAGAAGTTTCGGTGACTTACTACCTGC CTTACAAGTCTCCAGGGATCAATGTGGACAGTTCCTACAAGAACAGGGGCCATCT GTCCCTGGACTCCATGAAGCAGGGTAACTTCTCTCTGTACCTGAAGAATGTCACC CCTCAGGATACCCAGGAGTTCACATGCCGGGTATTTATGAATACAGCCACAGAGT TAGTCAAGATCTTGGAAGAGGTGGTCAGGCTGCGTGTGGCAGCAAACTTCAGTAC ACCTGTCATCAGCACCTCTGATAGCTCCAACCCGGGCCAGGAACGTACCTACACC TGCATGTCCAAGAATGGCTACCCAGAGCCCAACCTGTATTGGATCAACACAACGG ACAATAGCCTAATAGACACGGCTCTGCAGAATAACACTGTCTACTTGAACAAGTT GGGCCTGTATGATGTAATCAGCACATTAAGGCTCCCTTGGACATCTCGTGGGGAT GTTCTGTGCTGCGTAGAGAATGTGGCTCTCCACCAGAACATCACTAGCATTAGCC AGGCAGAAAGTTTCACTGGAAATAACACAAAGAACCCACAGGAAACCCACAATA ATGAGTTAAAAGTCCTTGTCCCCGTCCTTGCTGTACTGGCGGCAGCGGCATTCGTT TCCTTCATCATATACAGACGCACGCGTCCCCACCGAAGCTATACAGGACCCAAGA CTGTACAGCTTGAACTTACAGACCACGCCmu ICOS-L(SEQIDNO: 105)MQLKCPCFVSLGTRQPVWKKLHVSSGFFSGLGLFLLLLSSLCAASAETEVGAMVGSN VVLSCIDPHRRHFNLSGLYVYWQIENPEVSVTYYLPYKSPGINVDSSYKNRGHLSLDS MKQGNFSLYLKNVTPQDTQEFTCRVFMNTATELVKILEEVVRLRVAANFSTPVISTSD SSNPGQERTYTCMSKNGYPEPNLYWINTTDNSLIDTALQNNTVYLNKLGLYDVISTLR LPWTSRGDVLCCVENVALHQNITSISQAESFTGNNTKNPQETHNNELKVLVPVLAVL AAAAFVSFIIYRRTRPHRSYTGPKTVQLELTD HAmu CD47(SEQIDNO: 106) ATGTGGCCCTTGGCGGCGGCGCTGTTGCTGGGCTCCTGCTGCTGCGGTTCAGCTCA ACTACTGTTTAGTAACGTCAACTCCATAGAGTTCACTTCATGCAATGAAACTGTG GTCATCCCTTGCATCGTCCGTAATGTGGAGGCGCAAAGCACCGAAGAAATGTTTG TGAAGTGGAAGTTGAACAAATCGTATATTTTCATCTATGATGGAAATAAAAATAG CACTACTACAGATCAAAACTTTACCAGTGCAAAAATCTCAGTCTCAGACTTAATC AATGGCATTGCCTCTTTGAAAATGGATAAGCGCGATGCCATGGTGGGAAACTACA CTTGCGAAGTGACAGAGTTATCCAGAGAAGGCAAAACAGTTATAGAGCTGAAAA ACCGCACGGTTTCGTGGTTTTCTCCAAATGAAAAGATCCTCATTGTTATTTTCCCA WO 2022/051556 PCT/US2021/048944 ATTTTGGCTATACTCCTGTTCTGGGGAAAGTTTGGTATTTTAACACTCAAATATAA ATCCAGCCATACGAATAAGAGAATCATTCTGCTGCTCGTTGCCGGGCTGGTGCTC ACAGTCATCGTGGTTGTTGGAGCCATCCTTCTCATCCCAGGAGAAAAGCCCGTGA AGAATGCTTCTGGACTTGGCCTCATTGTAATCTCTACGGGGATATTAATACTACTT CAGTACAATGTGTTTATGACAGCTTTTGGAATGACCTCTTTCACCATTGCCATATT GATCACTCAAGTGCTGGGCTACGTCCTTGCTTTGGTCGGGCTGTGTCTCTGCATCA TGGCATGTGAGCCAGTGCACGGCCCCCTTTTGATTTCAGGTTTGGGGATCATAGCT CTAGCAGAACTACTTGGATTAGTTTATATGAAGTTTGTCGCTTCCAACCAGAGGA CTATCCAACCTCCTAGGAATAGGmu CD47(SEQIDNO: 107) MWPLAAALLLGSCCCGSAQLLFSNVNSIEFTSCNETVVIPCIVRNVEAQSTEEMFVKW KLNKSYIFIYDGNKNSTTTDQNFTSAKISVSDLINGIASLKMDKRDAMVGNYTCEVTE LSREGKTVIELKNRTVSWFSPNEKILIVIFPILAILLFWGKFGILTLKYKSSHTNKRIILLL VAGLVLTVIVVVGAILLIPGEKPVKNASGLGLIVISTGILILLQYNVFMTAFGMTSFTIA ILITQVLGYVLALVGLCLCIMACEPVHGPLLISGLGIIALAELLGLVYMKFVASNQRTI QPPRNRMu Sarcoglycan alpha:(SEQIDNO: 108)ATGGCAGCAGCAGTAACTTGGATACCTCTCCTGGCAGGTCTCCTGGCAGGACTGA GGGACACCAAGGCCCAGCAGACAACTTTACACCTACTTGTGGGTCGTGTGTTTGT GCATCCTTTGGAACATGCCACCTTCCTGCGCCTTCCAGAACACGTTGCGGTGCCAC CCACTGTCCGACTCACCTACCACGCTCACCTCCAGGGACATCCAGACCTGCCCAG GTGGCTGCACTACACACAGCGCAGTCCCTATAACCCTGGCTTCCTCTACGGCTCCC CCACTCCAGAAGATCGTGGGTACCAAGTCATCGAGGTCACAGCCTACAATCGAGA CAGTTTTGACACCACTAGACAGAGGCTGCTGCTGCTGATTGGGGACCCCGAAGGT CCCCGGTTGCCATACCAAGCTGAGTTCCTGGTGCGCAGCCATGATGTGGAGGAGG TGCTGCCCACCACACCTGCCAACCGCTTCCTCACCGCCTTGGGGGGACTGTGGGA GCCAGGAGAGCTTCAGCTGCTCAACATCACTTCCGCCTTGGACCGGGGAGGCCGA GTCCCTCTTCCTATTGAGGGACGGAAGGAAGGGGTATACATTAAGGTAGGCTCTG CCACACCCTTCTCCACCTGCCTGAAGATGGTGGCGTCGCCCGACAGCTATGCCCG TTGTGCCCAGGGACAGCCTCCACTACTGTCCTGCTACGACACTTTGGCACCCCACT TCCGCGTTGACTGGTGCAATGTGTCTCTGGTAGACAAGTCAGTACCCGAGCCCCT GGATGAGGTACCTACTCCAGGCGATGGGATCTTGGAGCACGACCCGTTCTTCTGC CCACCCACTGAAGCCACAGACCGAGACTTCCTGACAGATGCCTTGGTGACCCTCT TGGTGCCTTTGTTGGTGGCTCTGCTGCTTACTCTGTTGCTGGCTTACATCATGTGCT TTCGGCGTGAAGGACGGCTGAAGAGAGACATGGCCACCTCTGACATCCAGATGTT WO 2022/051556 PCT/US2021/048944 TCACCACTGTTCCATCCATGGGAATACAGAAGAGCTTCGGCAGATGGCAGCCAGC CGAGAGGTGCCCCGGCCTCTTTCCACCTTGCCCATGTTTAATGTTCGTACAGGAGA GCGGTTACCTCCCCGAGTAGACAGCGCACAGATGCCTCTTATCCTGGACCAGCACMu Sarcoglycan alpha:(SEQIDNO: 109) MAAAVTWIPLLAGLLAGLRDTKAQQTTLHLLVGRVFVHPLEHATFLRLPEHVAVPPT VRLTYHAHLQGHPDLPRWLHYTQRSPYNPGFLYGSPTPEDRGYQVIEVTAYNRDSFD TTRQRLLLLIGDPEGPRLPYQAEFLVRSHDVEEVLPTTPANRFLTALGGLWEPGELQL LNITSALDRGGRVPLPIEGRKEGVYIKVGSATPFSTCLKMVASPDSYARCAQGQPPLL SCYDTLAPHFRVDWCNVSLVDKSVPEPLDEVPTPGDGILEHDPFFCPPTEATDRDFLT DALVTLLVPLLVALLLTLLLAYIMCFRREGRLKRDMATSDIQMFHHCSIHGNTEELRQ MAASREVPRPLSTLPMFNVRTGERLPPRVDSAQM PLILDQHMuFGFlO(SEQIDNO: 110)ATGTGGAAATGGATACTGACACATTGTGCCTCAGCCTTTCCCCACCTGCCGGGCT GCTGTTGCTGCTTCTTGTTGCTCTTTTTGGTGTCTTCGTTCCCTGTCACCTGCCAAG CTCTTGGTCAGGACATGGTGTCACAGGAGGCCACCAACTGCTCTTCTTCCTCCTCG TCCTTCTCCTCTCCTTCCAGTGCGGGAAGGCATGTGCGGAGCTACAATCACCTCCA AGGAGATGTCCGCTGGAGAAGGCTGTTCTCCTTCACCAAGTACTTTCTCACGATT GAGAAGAACGGCAAGGTCAGCGGGACCAAGAATGAAGACTGTCCGTACAGTGTC CTGGAGATAACATCAGTGGAAATCGGAGTTGTTGCCGTCAAAGCCATCAACAGCA ACTATTACTTAGCCATGAACAAGAAGGGGAAACTCTATGGCTCAAAAGAGTTTAA CAACGACTGTAAGCTGAAAGAGAGAATAGAGGAAAATGGATACAACACCTATGC ATCTTTTAACTGGCAGCACAATGGCAGGCAAATGTATGTGGCATTGAATGGAAAA GGAGCTCCCAGGAGAGGACAAAAAACAAGAAGGAAAAACACCTCTGCTCACTTC CTCCCCATGACGATCCAAACAMuFGFlO(SEQIDNO: 111)MWKWILTHCASAFPHLPGCCCCFLLLFLVSSFPVTCQALGQDMVSQEATNCSSSSSSF SSPSSAGRHVRSYNHLQGDVRWRRLFSFTKYFLTIEKNGKVSGTKNEDCPYSVLEITS VEIGVVAVKAINSNYYLAMNKKGKLYGSKEFNNDCKLKERIEENGYNTYASFNWQH NGRQMYVALNGKGAPRRGQKTRRKNTSAHFLPMTIQTMu Agrin(SEQIDNO: 112)ATGCCTCCTCTGCCACTGGAACACAGACCCAGGCAGCAGCCTGGTGCCTCCGTGC TGGTTCGGTACTTCATGATCCCCTGCAACATCTGCTTGATCCTCTTGGCTACTTCT WO 2022/051556 PCT/US2021/048944 ACGTTGGGCTTTGCGGTGCTGCTTTTCCTCAGCAACTACAAACCTGGGATCCACTT CACAGCAGCGCCTTCTATGCCTCCTGATGTGTGCAGGGGAATGTTATGTGGCTTTG GTGCTGTGTGTGAACCTAGTGTTGAGGATCCAGGCCGGGCCTCCTGTGTGTGCAA GAAGAATGTCTGCCCTGCTATGGTAGCTCCTGTGTGTGGCTCAGATGCTTCCACCT ATAGCAACGAGTGTGAGCTACAGCGTGCACAGTGCAACCAGCAACGGCGCATCC GCCTACTCCGCCAAGGGCCATGTGGGTCCCGGGACCCCTGTGCCAATGTGACCTG CAGTTTCGGTAGTACCTGTGTACCTTCAGCCGATGGACAGACCGCCTCGTGTCTGT GTCCTACAACCTGCTTTGGGGCCCCTGATGGCACAGTGTGTGGCAGTGATGGTGT TGACTACCCTAGTGAGTGCCAGCTGCTCCGTCATGCCTGTGCCAACCAGGAGCAC ATCTTTAAGAAGTTCGATGGTCCTTGTGACCCCTGCCAGGGCAGCATGTCAGACC TGAATCATATTTGCCGGGTGAACCCACGTACACGGCACCCAGAAATGCTTCTGCG GCCTGAGAACTGCCCCGCCCAACACACACCTATCTGTGGAGATGATGGGGTCACC TATGAAAACGACTGTGTCATGAGCCGTATAGGTGCAGCCCGTGGCCTGCTTCTCC AGAAAGTGCGCTCTGGTCAATGCCAGACTCGAGACCAGTGCCCGGAGACCTGCC AGTTTAACTCTGTATGCCTGTCCCGCCGCGGCCGTCCCCACTGTTCCTGCGATCGC GTCACCTGTGATGGGGCTTACAGGCCAGTGTGTGCCCAGGATGGGCACACGTATG ACAATGACTGTTGGCGCCAACAGGCCGAGTGTCGACAACAGCAGACCATTCCCCC CAAGCACCAGGGCCCGTGTGACCAGACCCCATCCCCGTGCCGTGGAGCGCAGTGT GCATTTGGGGCAACATGCACAGTGAAGAATGGGAAAGCTGTGTGCGAGTGCCAG CGGGTGTGCTCGGGCGGCTACGATCCTGTGTGCGGCAGTGATGGTGTCACTTACG GCAGTGTGTGCGAGCTGGAATCCATGGCCTGTACCCTTGGGCGGGAAATCCGAGT GGCCCGCAGAGGACCGTGTGACCGATGTGGGCAGTGCCGGTTTGGATCCTTGTGC GAGGTGGAGACTGGACGCTGTGTGTGCCCCTCTGAGTGTGTGGAGTCAGCCCAGC CCGTATGTGGCTCTGACGGACACACATATGCTAGTGAATGTGAGCTGCATGTCCA CGCCTGTACACACCAGATCAGCCTATACGTGGCCTCAGCCGGACACTGCCAGACC TGTGGAGAAACAGTTTGTACCTTTGGGGCTGTGTGCTCAGCTGGACAGTGTGTAT GTCCCCGTTGTGAGCACCCCCCACCTGGCCCTGTGTGCGGCAGTGATGGCGTCAC CTACCTCAGTGCCTGTGAGCTCCGAGAGGCTGCCTGTCAGCAGCAGGTACAAATT GAGGAGGCCCGTGCAGGGCCGTGTGAGCCGGCTGAGTGTGGCTCAGGGGGCTCT GGGTCTGGGGAAGACAATGCGTGTGAGCAGGAGCTGTGTCGGCAGCATGGTGGT GTCTGGGATGAGGACTCAGAAGACGGGCCGTGTGTCTGTGACTTTAGTTGCCAGA GTGTCCTTAAAAGCCCAGTGTGTGGCTCAGATGGAGTCACCTATAGCACGGAGTG CCATCTGAAGAAGGCCAGATGTGAAGCGCGGCAAGAGCTGTACGTCGCTGCTCA GGGAGCCTGCCGGGGCCCTACCTTGGCTCCACTGCTACCTATGGCCTCCCCACAC TGTGCCCAAACCCCCTATGGCTGCTGCCAGGACAATGTCACTGCTGCCCAGGGTG TGGGCTTGGCTGGCTGTCCCAGCACCTGCCATTGCAACCCACACGGCTCCTATAG CGGCACTTGTGACCCAGTCACAGGGCAGTGCTCCTGCCGACCAGGTGTAGGAGGC WO 2022/051556 PCT/US2021/048944 CTCAGGTGTGATCGCTGTGAGCCTGGCTTCTGGAACTTCCGTGGCATTGTCACCGA TGGACATAGTGGTTGCACTCCCTGCAGCTGTGACCCTCGGGGTGCTGTAAGAGAT GACTGTGAGCAGATGACTGGATTGTGTTCCTGTAGACCTGGTGTGGCTGGTCCCA AGTGTGGGCAGTGTCCAGATGGTCAAGCCCTGGGCCATCTTGGCTGTGAAGCAGA TCCCACAACACCAGTGACTTGTGTGGAAATGCACTGTGAGTTTGGCGCCTCCTGC GTAGAGGAGGCTGGTTTTGCCCAGTGTGTCTGCCCAACTCTCACATGTCCAGAGG CTAACTCTACCAAGGTCTGTGGATCAGATGGTGTCACATACGGCAATGAATGCCA GCTGAAGACCATTGCCTGCCGCCAGCGTCTGGACATCTCCATTCAGAGTCTTGGT CCATGCCGGGAGAGTGTTGCTCCTGGGGTTTCCCCTACATCTGCATCTATGACCAC CCCAAGGCATATCCTGAGCAGGACACTGGCGTCTCCCCACAGCAGCCTTCCTCTG TCTCCCAGCACTACTGCCCATGATTGGCCCACCCCATTACCCACATCACCTCAGAC CGTAGTCGGCACCCCCAGGAGCACTGCAGCCACACCCTCTGATGTGGCCAGTCTT GCTACAGCGATCTTCAGGGAATCTGGCAGCACCAACGGCAGTGGCGATGAGGAG CTCAGTGGCGATGAGGAGGCCAGTGGGGGCGGGTCTGGGGGACTTGAGCCCCCG GTGGGCAGCGTTGTGGTGACCCACGGGCCACCCATCGAGAGGGCTTCCTGTTACA ACTCACCTTTGGGCTGCTGCTCAGATGGCAAGACACCCTCACTGGACTCAGAAGG CTCCAACTGTCCAGCTACCAAGGCATTCCAGGGCGTGCTGGAGCTTGAGGGGGTC GAGGGACAGGAACTGTTCTACACACCAGAGATGGCTGACCCCAAGTCAGAGTTG TTTGGGGAGACTGCAAGGAGCATTGAGAGCACGCTGGACGACCTGTTCCGGAATT CGGATGTTAAGAAGGACTTCTGGAGCATCCGCCTACGGGAACTGGGGCCTGGCA AATTAGTCCGTGCCATTGTGGATGTTCACTTTGACCCCACCACAGCCTTCCAGGCA CCAGATGTGGGTCAGGCCTTGCTCCAACAGATCCAGGTATCCAGGCCGTGGGCCC TGGCAGTGAGGAGGCCTCTGCGGGAGCATGTGCGATTCTTGGACTTTGACTGGTT TCCCACTTTTTTTACGGGAGCTGCAACAGGAACCACAGCTGCTGTGGCCACAGCC AGAGCCACCACTGTGAGCCGACTGTCTGCCTCTTCTGTCACCCCACGAGTCTACCC CAGTTACACCAGCCGGCCTGTTGGCAGAACTACGGCACCGCTAACCACTCGCCGG CCACCAACCACTACCGCCAGTATTGACCGACCTCGGACTCCAGGCCCGCAACGGC CCCCAAAGTCCTGTGATTCCCAGCCTTGCCTCCACGGAGGTACCTGCCAGGACCT GGATTCTGGCAAGGGTTTCAGCTGCAGCTGTACTGCAGGCAGGGCTGGCACTGTC TGTGAGAAAGTGCAGCTCCCCTCTGTGCCAGCTTTTAAGGGCCACTCCTTCTTGGC CTTCCCCACCCTCCGAGCCTACCACACGCTGCGTCTGGCACTAGAATTCCGGGCG CTGGAGACAGAGGGACTGCTGCTCTACAATGGCAATGCACGTGGCAAAGATTTCC TGGCTCTGGCTCTGTTGGATGGTCATGTACAGTTCAGGTTCGACACGGGCTCAGG GCCGGCGGTGCTAACAAGCTTAGTGCCAGTGGAACCGGGACGGTGGCACCGCCT CGAGTTGTCACGGCATTGGCGGCAGGGCACACTTTCTGTGGATGGCGAGGCTCCT GTTGTAGGTGAAAGTCCGAGTGGCACTGATGGCCTCAACTTGGACACGAAGCTCT ATGTGGGTGGTCTCCCAGAAGAACAAGTTGCCACGGTGCTTGATCGGACCTCTGT WO 2022/051556 PCT/US2021/048944 GGGCATCGGCCTGAAAGGATGCATTCGTATGTTGGACATCAACAACCAGCAGCTG GAGCTGAGCGATTGGCAGAGGGCTGTGGTTCAAAGCTCTGGTGTGGGGGAATGC GGAGACCATCCCTGCTCACCTAACCCCTGCCATGGCGGGGCCCTCTGCCAGGCCC TGGAGGCTGGCGTGTTCCTCTGTCAGTGCCCACCTGGCCGCTTTGGCCCAACTTGT GCAGATGAAAAGAACCCCTGCCAACCGAACCCCTGCCACGGGTCAGCCCCCTGCC ATGTGCTTTCCAGGGGTGGGGCCAAGTGTGCGTGCCCCCTGGGACGCAGTGGTTC CTTCTGTGAGACAGTCCTGGAGAATGCTGGCTCCCGGCCCTTCCTGGCTGACTTTA ATGGCTTCTCCTACCTGGAACTGAAAGGCTTGCACACCTTCGAGAGAGACCTAGG GGAGAAGATGGCGCTGGAGATGGTGTTCTTGGCTCGTGGGCCCAGTGGCTTACTC CTCTACAATGGGCAGAAGACGGATGGCAAGGGGGACTTTGTATCCCTGGCCCTGC ATAACCGGCACCTAGAGTTCCGCTATGACCTTGGCAAGGGGGCTGCAATCATCAG GAGCAAAGAGCCCATAGCCCTGGGCACCTGGGTTAGGGTATTCCTGGAACGAAA TGGCCGCAAGGGTGCCCTTCAAGTGGGTGATGGGCCCCGTGTGCTAGGGGAATCT CCGAAATCCCGCAAGGTCCCGCACACCATGCTCAACCTCAAGGAGCCCCTCTATG TGGGGGGAGCTCCTGACTTCAGCAAGCTGGCTCGGGGCGCTGCAGTGGCCTCCGG CTTTGATGGTGCCATCCAGCTGGTGTCTCTAAGAGGCCATCAGCTGCTGACTCAG GAGCATGTGTTGCGGGCAGTAGATGTAGCGCCTTTTGCAGGCCACCCTTGTACCC AGGCCGTGGACAACCCCTGCCTTAATGGGGGCTCCTGTATCCCGAGGGAAGCCAC TTATGAGTGCCTGTGTCCTGGGGGCTTCTCTGGGCTGCACTGCGAGAAGGGGATA GTTGAGAAGTCAGTGGGGGACCTAGAAACACTGGCCTTTGATGGGCGGACCTAC ATCGAGTACCTCAATGCTGTGACTGAGAGCGAGCTGACCAATGAGATCCCAGCCC CCGAAACTCTGGATTCCCGGGCCCTTTTCAGTGAGAAAGCGCTGCAGAGCAACCA CTTTGAGCTGAGCTTACGCACTGAGGCCACGCAGGGGCTGGTGCTGTGGATTGGA AAGGTTGGAGAACGTGCAGACTACATGGCTCTGGCCATTGTGGATGGGCACCTAC AACTGAGCTATGACCTAGGCTCCCAGCCAGTTGTGCTGCGCTCCACTGTGAAGGT CAACACCAACCGCTGGCTTCGAGTCAGGGCTCACAGGGAGCACAGGGAAGGTTC CCTTCAGGTGGGCAATGAAGCCCCTGTGACTGGCTCTTCCCCGCTGGGTGCCACA CAATTGGACACAGATGGAGCCCTGTGGCTTGGAGGCCTACAGAAGCTTCCTGTGG GGCAGGCTCTCCCCAAGGCCTATGGCACGGGTTTTGTGGGCTGTCTGCGGGACGT GGTAGTGGGCCATCGCCAGCTGCATCTGCTGGAGGACGCTGTCACCAAACCAGAG CTAAGACCCTGCCCCACTCTCTGAMu Agrin(SEQIDNO: 113) MPPLPLEHRPRQQPGASVLVRYFMIPCNICLILLATSTLGFAVLLFLSNYKPGIHFTAAP SMPPDVCRGMLCGFGAVCEPSVEDPGRASCVCKKNVCPAMVAPVCGSDASTYSNEC ELQRAQCNQQRRIRLLRQGPCGSRDPCANVTCSFGSTCVPSADGQTASCLCPTTCFGA PDGTVCGSDGVDYPSECQLLRHACANQEHIFKKFDGPCDPCQGSMSDLNHICRVNPR WO 2022/051556 PCT/US2021/048944 TRHPEMLLRPENCPAQHTPICGDDGVTYENDCVMSRIGAARGLLLQKVRSGQCQTRD QCPETCQFNSVCLSRRGRPHCSCDRVTCDGAYRPVCAQDGHTYDNDCWRQQAECR QQQTIPPKHQGPCDQTPSPCRGAQCAFGATCTVKNGKAVCECQRVCSGGYDPVCGS DGVTYGSVCELESMACTLGREIRVARRGPCDRCGQCRFGSLCEVETGRCVCPSECVE SAQPVCGSDGHTYASECELHVHACTHQISLYVASAGHCQTCGETVCTFGAVCSAGQ CVCPRCEHPPPGPVCGSDGVTYLSACELREAACQQQVQIEEARAGPCEPAECGSGGS GSGEDNACEQELCRQHGGVWDEDSEDGPCVCDFSCQSVLKSPVCGSDGVTYSTECH LKKARCEARQELYVAAQGACRGPTLAPLLPMASPHCAQTPYGCCQDNVTAAQGVG LAGCPSTCHCNPHGSYSGTCDPVTGQCSCRPGVGGLRCDRCEPGFWNFRGIVTDGHS GCTPCSCDPRGAVRDDCEQMTGLCSCRPGVAGPKCGQCPDGQALGHLGCEADPTTP VTCVEMHCEFGASCVEEAGFAQCVCPTLTCPEANSTKVCGSDGVTYGNECQLKTIAC RQRLDISIQSLGPCRESVAPGVSPTSASMTTPRHILSRTLASPHSSLPLSPSTTAHDWPT PLPTSPQTVVGTPRSTAATPSDVASLATAIFRESGSTNGSGDEELSGDEEASGGGSGGL EPPVGSVVVTHGPPIERASCYNSPLGCCSDGKTPSLDSEGSNCPATKAFQGVLELEGV EGQELFYTPEMADPKSELFGETARSIESTLDDLFRNSDVKKDFWSIRLRELGPGKLVR AIVDVHFDPTTAFQAPDVGQALLQQIQVSRPWALAVRRPLREHVRFLDFDWFPTFFT GAATGTTAAVATARATTVSRLSASSVTPRVYPSYTSRPVGRTTAPLTTRRPPTTTASID RPRTPGPQRPPKSCDSQPCLHGGTCQDLDSGKGFSCSCTAGRAGTVCEKVQLPSVPAF KGHSFLAFPTLRAYHTLRLALEFRALETEGLLLYNGNARGKDFLALALLDGHVQFRF DTGSGPAVLTSLVPVEPGRWHRLELSRHWRQGTLSVDGEAPVVGESPSGTDGLNLDT KLYVGGLPEEQVATVLDRTSVGIGLKGCIRMLDINNQQLELSDWQRAVVQSSGVGEC GDHPCSPNPCHGGALCQALEAGVFLCQCPPGRFGPTCADEKNPCQPNPCHGSAPCHV LSRGGAKCACPLGRSGSFCETVLENAGSRPFADFNGFSYLELKGLHTFERDLGEKMA LEMVFLARGPSGLLLYNGQKTDGKGDFVSLALHNRHLEFRYDLGKGAAIIRSKEPIAL GTWVRVFLERNGRKGALQVGDGPRVLGESPKSRKVPHTMLNLKEPLYVGGAPDFSK LARGAAVASGFDGAIQLVSLRGHQLLTQEHVLRAVDVAPFAGHPCTQAVDNPCLNG GSCIPREATYECLCPGGFSGLHCEKGIVEKSVGDLETLAFDGRTYIEYLNAVTESELTN EIPAPETLDSRALFSEKALQSNHFELSLRTEATQGLVLWIGKVGERADYMALAIVDGH LQLSYDLGSQPVVLRSTVKVNTNRWLRVRAHREHREGSLQVGNEAPVTGSSPLGAT QLDTDGALWLGGLQKLPVGQALPKAYGTGFVGCLRDVVVGHRQLHLLEDAVTKPE LRPCPTLMu IL 10(SEQIDNO: 114) ATGCCTGGCTCAGCACTGCTATGCTGCCTGCTCTTACTGACTGGCATGAGGATCA GCAGGGGCCAGTACAGCCGGGAAGACAATAACTGCACCCACTTCCCAGTCGGCC AGAGCCACATGCTCCTAGAGCTGCGGACTGCCTTCAGCCAGGTGAAGACTTTCTT WO 2022/051556 PCT/US2021/048944 TCAAACAAAGGACCAGCTGGACAACATACTGCTAACCGACTCCTTAATGCAGGAC TTTAAGGGTTACTTGGGTTGCCAAGCCTTATCGGAAATGATCCAGTTTTACCTGGT AGAAGTGATGCCCCAGGCAGAGAAGCATGGCCCAGAAATCAAGGAGCATTTGAA TTCCCTGGGTGAGAAGCTGAAGACCCTCAGGATGCGGCTGAGGCGCTGTCATCGA TTTCTCCCCTGTGAAAATAAGAGCAAGGCAGTGGAGCAGGTGAAGAGTGATTTTA ATAAGCTCCAAGACCAAGGTGTCTACAAGGCCATGAATGAATTTGACATCTTCAT CAACTGCATAGAAGCATACATGATGATCAAAATGAAAAGCTAA Mu IL 10(SEQIDNO: 115)MPGSALLCCLLLLTGMRISRGQYSREDNNCTHFPVGQSHMLLELRTAFSQVKTFFQT KDQLDNILLTDSLMQDFKGYLGCQALSEMIQFYLVEVMPQAEKHGPEIKEHLNSLGE KLKTLRMRLRRCHRFLPCENKSKAVEQVKSDFNKLQDQGVYKAMNEFDIFINCIEAY MMIKMKSMu MYDGF (C19orfl0)(SEQIDNO: 116) ATGGCAGCCCCCAGCGGAGGCTTCTGGACTGCGGTGGTCCTGGCGGCCGCAGCGC TGAAATTGGCCGCCGCTGTGTCCGAGCCCACCACCGTGCCATTTGACGTGAGGCC CGGAGGGGTCGTGCATTCGTTCTCCCAGGACGTAGGACCCGGGAACAAGTTTACA TGTACATTCACCTACGCTTCCCAAGGAGGGACCAACGAGCAATGGCAGATGAGCC TGGGGACAAGTGAAGACAGCCAGCACTTTACCTGTACCATCTGGAGGCCCCAGG GGAAATCCTACCTCTACTTCACACAGTTCAAGGCTGAGTTGCGAGGTGCTGAGAT CGAGTATGCCATGGCCTACTCCAAAGCCGCATTTGAGAGAGAGAGTGATGTCCCC CTGAAAAGTGAGGAGTTTGAAGTGACCAAGACAGCAGTGTCTCACAGGCCTGGG GCCTTCAAAGCTGAGCTCTCCAAGCTGGTGATCGTAGCCAAGGCGGCACGCTCGG AGCTGTGA Mu MYDGF (C19orfl0)(SEQIDNO: 117) MAAPSGGFWTAVVLAAAALKLAAAVSEPTTVPFDVRPGGVVHSFSQDVGPGNKFTC TFTYASQGGTNEQWQMSLGTSEDSQHFTCTIWRPQGKSYLYFTQFKAELRGAEIEYA MAYSKAAFERESDVPLKSEEFEVTKTAVSHRPGAFKAELSKLVIVAKAARSELpWF-521(SEQIDNO: 118) CAGTCTGTGTTGACGCAGCCGCCCTCAGTGTCTGCGGCCCCAGGACAGAGGGTCA CCATCTCCTGCTCTGGAACCAGGTCCAACATTGGGAGTGATTATGTTTCCTGGTAC CAACACCTCCCAGGAACAGCCCCCAAACTCCTCGTTTATGGCGATAATCTGCGAC WO 2022/051556 PCT/US2021/048944 CCTCAGGGATTCCTGACCGATTCTCTGCCTCCAAGTCTGGCACGTCAGCCACCCTG GGCATCACCGGACTCCAGACTGGGGACGAGGCCGATTATTACTGCGGCACATGG GATTACACCCTGAATGGTGTGGTGTTCGGCGGAGGGACCAAGCTGACCGTCCTAG GTCAGCCCAAGGCCAACCCCACTGTCACTCTGTTCCCGCCCTCCTCTGAGGAGCTC CAAGCCAACAAGGCCACACTAGTGTGTCTGATCAGTGACTTCTACCCGGGAGCTG TGACAGTGGCCTGGAAGGCAGATGGCAGCCCCGTCAAGGCGGGAGTGGAGACCA CCAAACCCTCCAAACAGAGCAACAACAAGTACGCGGCCAGCAGCTACCTGAGCC TGACGCCCGAGCAGTGGAAGTCCCACAGAAGCTACAGCTGCCAGGTCACGCATG AAGGGAGCACCGTGGAGAAGACAGTGGCCCCTACAGAATGTTCAGGCGCCGGAT CTGGTGGAAACTGGAGTCATCCCCAATTCGAGAAGGGCGGAAGCGGTGGGAGTG GCGGGTCCGGTGGAAGCAACTGGTCACACCCACAATTCGAGAAAGGCGGTTCTG GCGGATCTGGTGGATCTGGCGGAAGTAACTGGTCTCATCCTCAATTCGAAAAGGG CGGAAGCGGTGGCGGCAGGCTAGGTGGAGGCTCAGTGCAGGTGCAGCTGGTGGA GTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCC TCTGGATTCACCTTTAGCAGCTATGCCATGAGCTGGGTCCGCCAGGCTCCAGGGA AGGGGCTGGAGTGGGTCTCAGTTATTTATAGCGGTGGTAGTAGCACATACTATGC AGACTCCGTGAAGGGCCGGTTCACCATCTCCAGAGATAATTCCAAGAACACGCTG TATCTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCCGTATATTACTGTGCGC GCACTTCTTACCTGAACCATGGTGATTACTGGGGTCAAGGTACTCTGGTGACCGT GTCTAGCGCCTCCACCAAGGGCCCATCGGTCTTCCCCCTGGCACCCTCCTCCAAG AGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCG AACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTT CCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTG CCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAACCACAAGCCCA GCAACACCAAGGTGGACAAGAGAGTGGAGCCCAAGAGCTGCGACAAGACCCACA CCTGCCCCCCCTGCCCAGCCCCAGAGCTGCTGGGCGGACCCTCCGTGTTCCTGTTC CCCCCCAAGCCCAAGGACACCCTGATGATCAGCAGGACCCCCGAGGTGACCTGC GTGGTGGTGGACGTGAGCCACGAGGACCCAGAGGTGAAGTTCAACTGGTACGTG GACGGCGTGGAGGTGCACAACGCCAAGACCAAGCCCAGAGAGGAGCAGTACAAC AGCACCTACAGGGTGGTGTCCGTGCTGACCGTGCTGCACCAGGACTGGCTGAACG GCAAGGAATACAAGTGCAAGGTCTCCAACAAGGCCCTGCCAGCCCCCATCGAAA AGACCATCAGCAAGGCCAAGGGCCAGCCACGGGAGCCCCAGGTGTACACCCTGC CCCCCTCCCGGGAGGAGATGACCAAGAACCAGGTGTCCCTGACCTGTCTGGTGAA GGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAACGGCCAGCCCGA GAACAACTACAAGACCACCCCCCCAGTGCTGGACAGCGACGGCAGCTTCTTCCTG TACAGCAAGCTGACCGTGGACAAGTCCAGGTGGCAGCAGGGCAACGTGTTCAGC TGCAGCGTGATGCACGAGGCCCTGCACAACCACTACACCCAGAAGAGCCTGAGC WO 2022/051556 PCT/US2021/048944 CTGTCCCCCGAGCTGCAACTGGAGGAGAGCTGTGCGGAGGCGCAGGACGGGGAG CTGGACGGGCTGTGGACGACCATCACCATCTTCATCACACTCTTCCTGTTAAGCGT GTGCTACAGTGCCACCGTCACCTTCTTCAAGGTGAAGTGGATCTTCTCCTCGGTGG TGGACCTGAAGCAGACCATCATCCCCGACTACAGGAACATGATCGGACAGGGGG CCTGApWF-521(SEQIDNO: 119) QSVLTQPPSVSAAPGQRVTISCSGTRSNIGSDYVSWYQHLPGTAPKLLVYGDNLRPSG IPDRFSASKSGTSATLGITGLQTGDEADYYCGTWDYTLNGVVFGGGTKLTVLGQPKA NPTVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADGSPVKAGVETTKPSKQS NNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECSGAGSGGNWSHPQ FEKGGSGGSGGSGGSNWSHPQFEKGGSGGSGGSGGSNWSHPQFEKGGSGGGRLGGG SVQVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSVIYSG GSSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARTSYLNHGDYWGQ GTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGV HTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHT CPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVE VHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA KGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPP VLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPELQLEESC AEAQDGELDGLWTTITIFITLFLLSVCYSATVTFFKVKWIFSSVVDLKQTIIPDYRNMIG QGA pWF-533(SEQIDNO: 120) CAGTCTGTGTTGACGCAGCCGCCCTCAGTGTCTGCGGCCCCAGGACAGAGGGTCA CCATCTCCTGCTCTGGAACCAGGTCCAACATTGGGAGTGATTATGTTTCCTGGTAC CAACACCTCCCAGGAACAGCCCCCAAACTCCTCGTTTATGGCGATAATCTGCGAC CCTCAGGGATTCCTGACCGATTCTCTGCCTCCAAGTCTGGCACGTCAGCCACCCTG GGCATCACCGGACTCCAGACTGGGGACGAGGCCGATTATTACTGCGGCACATGG GATTACACCCTGAATGGTGTGGTGTTCGGCGGAGGGACCAAGCTGACCGTCCTAtc ttcaGCCTCCACCAAGGGCCCATCGGTCTTCCCCCTGGCACCCTCCTCCAAGAGCAC CTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCG GTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGG CTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCC AGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAACCACAAGCCCAGCAAC ACCAAGGTGGACAAGAGAGTGGAGCCCAAGAGCTGC WO 2022/051556 PCT/US2021/048944 pWF-533(SEQIDNO: 121) QSVLTQPPSVSAAPGQRVTISCSGTRSNIGSDYVSWYQHLPGTAPKLLVYGDNLRPSG IPDRFSASKSGTSATLGITGLQTGDEADYYCGTWDYTLNGVVFGGGTKLTVLSSAST KGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSG LYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCpWF-534(SEQIDNO: 122) CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTG AGACTCTCCTGTGCAGCCTCTGGATTCACCTTTAGCAGCTATGCCATGAGCTGGGT CCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTCTCAGTTATTTATAGCGGTGGT AGTAGCACATACTATGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCAGAGATA ATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGAGAGCCGAGGACACGG CCGTATATTACTGTGCGCGCACTTCTTACCTGAACCATGGTGATTACTGGGGTCAA GGTACTCTGGTGACCGTGTCTAGCGCCTCCGTGGCTGCACCATCTGTCTTCATCTT CCCGCCATCTGATGAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGA ATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCA ATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGCACCTA CAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGT CTACGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTC AACAGGGGAGAGTGTGACAAGACCCACACCTGCCCCCCCTGCCCAGCCCCAGAG CTGCTGGGCGGACCCTCCGTGTTCCTGTTCCCCCCCAAGCCCAAGGACACCCTGA TGATCAGCAGGACCCCCGAGGTGACCTGCGTGGTGGTGGACGTGAGCCACGAGG ACCCAGAGGTGAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCACAACGCCA AGACCAAGCCCAGAGAGGAGCAGTACAACAGCACCTACAGGGTGGTGTCCGTGC TGACCGTGCTGCACCAGGACTGGCTGAACGGCAAGGAATACAAGTGCAAGGTCT CCAACAAGGCCCTGCCAGCCCCCATCGAAAAGACCATCAGCAAGGCCAAGGGCC AGCCACGGGAGCCCCAGGTGTACACCCTGCCCCCCTCCCGGGAGGAGATGACCA AGAACCAGGTGTCCCTGACCTGTCTGGTGAAGGGCTTCTACCCCAGCGACATCGC CGTGGAGTGGGAGAGCAACGGCCAGCCCGAGAACAACTACAAGACCACCCCCCC AGTGCTGGACAGCGACGGCAGCTTCTTCCTGTACAGCAAGCTGACCGTGGACAAG TCCAGGTGGCAGCAGGGCAACGTGTTCAGCTGCAGCGTGATGCACGAGGCCCTGC ACAACCACTACACCCAGAAGAGCCTGAGCCTGTCCCCCGAGCTGCAACTGGAGG AGAGCTGTGCGGAGGCGCAGGACGGGGAGCTGGACGGGCTGTGGACGACCATCA CCATCTTCATCACACTCTTCCTGTTAAGCGTGTGCTACAGTGCCACCGTCACCTTC TTCAAGGTGAAGTGGATCTTCTCCTCGGTGGTGGACCTGAAGCAGACCATCATCC CCGACTACAGGAACATGATCGGACAGGGGGCCTGA WO 2022/051556 PCT/US2021/048944 pWF-534(SEQIDNO: 123)QVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSVIYSGGSS TYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARTSYLNHGDYWGQGTL VTVSSASVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNS QESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGECDK THTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVD GVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIS KAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTT PPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPELQLEE SCAEAQDGELDGLWTTITIFITLFLLSVCYSATVTFFKVKWIFSSVVDLKQTIIPDYRN MIGQGAmu IL 15(SEQIDNO: 124) ATGAAAATTTTGAAACCATATATGAGGAATACATCCATCTCGTGCTACTTGTGTTT CCTTCTAAACAGTCACTTTTTAACTGAGGCTGGCATTCATGTCTTCATTTTGGGCT GTGTCAGTGTAGGTCTCCCTAAAACAGAGGCCAACTGGATAGATGTAAGATATGA CCTGGAGAAAATTGAAAGCCTTATTCAATCTATTCATATTGACACCACTTTATACA CTGACAGTGACTTTCATCCCAGTTGCAAAGTTACTGCAATGAACTGCTTTCTCCTG GAATTGCAGGTTATTTTACATGAGTACAGTAACATGACTCTTAATGAAACAGTAA GAAACGTGCTCTACCTTGCAAACAGCACTCTGTCTTCTAACAAGAATGTAGCAGA ATCTGGCTGCAAGGAATGTGAGGAGCTGGAGGAGAAAACCTTCACAGAGTTTTTG CAAAGCTTTATACGCATTGTCCAAATGTTCATCAACACGTCCmu IL 15(SEQIDNO: 125)MKILKPYMRNTSISCYLCFLLNSHFLTEAGIHVFILGCVSVGLPKTEANWIDVRYDLE KIESLIQSIHIDTTLYTDSDFHPSCKVTAMNCFLLELQVILHEYSNMTLNETVRNVLYL ANSTLSSNKNVAESGCKECEELEEKTFTEFLQSFIRIVQMFINTS INCORPORATION BY REFERENCE [0155]All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference. However, the citation of a reference herein should not be construed as an acknowledgement that such reference is prior art to the present invention. To the extent that any of the definitions or terms provided in the references incorporated by reference differ from the terms and discussion provided herein, the present terms and definitions control.

WO 2022/051556 PCT/US2021/048944 EQUIVALENTS [0156]The foregoing written specification is considered to be sufficient to enable one skilled in the art to practice the invention. The foregoing description and examples detail certain preferred embodiments of the invention and describe the best mode contemplated by the inventors. It will be appreciated, however, that no matter how detailed the foregoing may appear in text, the invention may be practiced in many ways and the invention should be construed in accordance with the appended claims and any equivalents thereof. [0157]The following examples, including the experiments conducted and results achieved, are provided for illustrative purposes only and are not to be construed as limiting the present invention. EXAMPLES Example 1 - Chimeric Antigen Receptor for B Cells (CAR-B) Constructs to Bind PSMA. [0158] DNA Constructs.Exemplary CAR-B constructs were designed to recognize Prostate Specific Membrane Antigen ("PSMA"). PSMA is an antigen that is expressed more highly on prostate cancer cells than on other non-cancerous cells. Various construct were made comprising an extracellular domain that comprised an scFv specific for PSMA, an extracellular hinge region from CDS, a CD28 transmembrane domain, and various intracellular signaling domains. A list of the constructs is provided in Table 6: TABLE 6 Construct Description pWF-82pTLPW-SFFV-XENP 14484 scFv-hCD8H-hCD28M-hCD19E (SEQ ID NOS. 39 and 40) pWF-83pTLPW-SFFV-XENP 14484 scFv-hCD8H-hCD28M-hCD40E (SEQ ID NOS. 41 and42) pWF-84pTLPW-SFFV-XENP 14484 scFv-hCD8H-hCD28M-h(CD40+CD79b)E (SEQ IDNOS. 43 and 44) pWF-85pTLPW-SFFV-XENP 14484 scFv-hCD8H-hCD28M-h(CD40+CD137)E (SEQ IDNOS. 45 and 46) pWF-86pTLPW-SFFV-XENP 14484 scFv-hCD8H-hCD28M-h(CD40+Fcyr2a)E (SEQ IDNOS. 47) pWF-87pTLPW-SFFV-XENP 14484 scFv-hCD8H-hCD28M-h(hMyd88+CD40)E (SEQ IDNOS. 48 and 49) pWF-88pTLPW-SFFV-XENP 14484 scFv-hCD8H-hCD28M-hCD79aE (SEQ ID NOS. and 51) pWF-89pTLPW-SFFV-XENP 14484 scFv-hCD8H-hCD28M-hCD79bE (SEQ ID NOS. and 53) WO 2022/051556 PCT/US2021/048944 id="p-159" id="p-159" id="p-159" id="p-159" id="p-159" id="p-159" id="p-159" id="p-159" id="p-159" id="p-159" id="p-159"

[0159] Expression of anti-PSMA CAR-B on HEK-293 Cells.The constructs encoding pWF82 to pWF89 were used to prepare lentivirus in Lentix cells using the Takara lentivirus preparation kit. Expression of the various CAR-B constructs was measured using flow cytometry using antibodies specific for PSMA (biotin-PSMA, Sinobiological and is depicted in FIG. 5. [0160] Expression of anti-PSMA CAR-B in Human B Cells.To measure expression and binding of anti-PSMA CAR-B’s in B cells, two additional constructs were made: TABLE 7 Construct Description pWF-391pMMLV(LTR)-hEFla promoter-anti hPSMA(XENP14484)-CBCR (SEQ ID NOS. and 55)pWF-394 pMMLV(LTR)-hEFla promoter-anti sarcoglycan CBCR1 (SEQ ID NOS. 56 and 57) id="p-161" id="p-161" id="p-161" id="p-161" id="p-161" id="p-161" id="p-161" id="p-161" id="p-161" id="p-161" id="p-161"

[0161]A MMLV based vector was used for the preparation of the retrovirus. The retrovirus was used to infect mouse B cells isolated from the spleen. After transduction, B cells were further expanded on feeder cells expressing CD40L and soluble IL-4. The expression of anti-PSMA CAR- B was detected by using recombinant biotin-PSMA. PE-labeled streptavidin was used to detect PSMA binding in HEK-293 cells. [0162] Results.The results of this experiment are depicted in FIG. 7 and demonstrate that it is possible to create mouse B cell that expresses a CAR-B that can bind with specificity to an antigen. For example, B cells expressing pWF391 bound to PSMA whereas the B cells expressing pWF3did not bind PSMA did not bind to PSMA (pWF394 was designed to bind sarcoglycan not PSMA). Example 2 - Chimeric Antigen Receptor on B cells (B-CAR) Constructs to Bind GPC3. [0163] DNA Construct.Exemplary cBCR constructs were designed to recognize glypican-(GPC-3). Glypican-3 is expressed on hepatocellular carcinoma cells but not on most non-cancer cells. Various construct were made comprising an extracellular domain that comprised an scFv specific for GPC-3, an extracellular hinge region from CD8, a CD28 transmembrane domain, and various intracellular signaling domains. An additional anti-PSMA CAR-B was constructed as a control for these experiments. A list of the constructs is provided in Table 8. TABLE 8 Construct Description pWF-396pMMLV(LTR)-hEFlapromoter-anti-GPC3 scFv-hCD8H-hCD28M-hCD79aE (SEQ ID NOS. 58 and 59) pWF-397pMMLV(LTR)-hEFlapromoter-anti-GPC3 scFv-hCD8H-hCD28M-hCD79bE (SEQ ID NOS. 60 and 61) pWF-398pMMLV(LTR)-hEFla promoter-anti-hPSMA(XENP14484) scFv-hCD8H-hCD28M- hCD79aE (SEQ ID NOS. 62 and 63) WO 2022/051556 PCT/US2021/048944 id="p-164" id="p-164" id="p-164" id="p-164" id="p-164" id="p-164" id="p-164" id="p-164" id="p-164" id="p-164" id="p-164"

[0164] Expression of anti-GPC-3 on HEK-293 Cell.Lentiviral transductions were used to express GPC3 CAR-B proteins on the surface of HEK293 cells. Expression was determined by flow cytometry with an anti-idiotype antibody specific for GPC-3 (Eureka Therapeutics). [0165] Expression of anti-GPC-3 CAR-B in Human B Cells.The CAR-B encoding pWF 396, 397 and 398 constructs were used to prepare MMLV retrovirus. This retrovirus was used to transduce mouse B cells isolated by negative selection (Stem Cell Technologies) and activated for hours by co-culture with HeLa cells expressing CD40L and the addition of soluble IL-4. hours post-transduction, expression was confirmed using flow cytometry. The expression of the CAR-B was detected using an anti-idiotype antibody against human GPC3. The anti-idiotype antibody was obtained from Eureka Therapeutics. [0166] Results.Mouse B cells expressing anti-GPC-3 CAR-Bs, pWF-396 and 397 where expressed and specifically bound anti-GPC3 idiotype antibody. Example 3 - Adenovirus Variant F35 Expressing GFP [0167]Adenovirus variant F35 expressing GFP was demonstrated to efficiently infect human B cells. Human B cells were isolated from the peripheral blood. The B cells were infected with adenovirus encoding GFP at volumes of 0, 1, 3, 10 pL. Example 4 - In Vivo Expression of CAR-B at Tumor Site [0168]Mouse B cells are transduced to express anti-GPC-3 CAR-B and then electroporated in vitro with mRNA encoding the luciferase reporter. These modified cells are introduced intravenously into immune-incompetent mice with established HepG2 tumor cells that express GPC-3. At multiple time points post-infusion mice are monitored by imaging with an IVIS instrument. Time- lapse imaging will measure accumulation of the modified B cells in the established tumor, to establish that expression of a CAR-B of defined specificity endows the B cells with the ability to home to and accumulate at the tumor expressing GPC-3. Example 5 - Delivering Payloads to Tumor Cells [0169]A large screening study was conducted to examine the effect of payloads on NIH3Tfibroblasts in a CT26 Model. Payloads included various immunomodulators, including cytokines and chemokines. First, BALB/c mice were injected with CT26 tumors into their left and right flank. See FIG. 8. Twelve and sixteen days later, mice were injected into the right flank tumor, with various combinations of 4-5 payloads. Tumor volume was measured for up to 35 days. [0170] Generation of the BALB/C CT26 tumor model.A total of 139 mice were injected with CT26 tumors into their left and right flanks. [0171] Selection of Payload.Twelve peptides were identified for their potential to (i) recruit and activate dendritic cells; (ii) initiate homing and guidance of dendritic cells and T cells into the tumor site; and (iii) activate effector T cells. The payloads screened are listed in Table 9.

WO 2022/051556 PCT/US2021/048944 TABLE 9 Payload SEQIDNO.FLT3L 70,71XCL1 72, 73TIM4-Fc 74, 75CXCL13 68, 69mCCL21 92, 93mCD80 - membrane bound 86, 87mCD40L - membrane bound 88, 89mlFNa A2 84, 85mlL-12 80, 81mlL-21 90, 91mLIGHT mutant 78, 79M4-lBBL-membrane bound 76, 77mIL-15 124, 125 id="p-172" id="p-172" id="p-172" id="p-172" id="p-172" id="p-172" id="p-172" id="p-172" id="p-172" id="p-172" id="p-172"

[0172]Each was either given a combination of 4-5 payloads, all 12 payloads, or 3T3 cells (without payload) or saline as a control. In total, there were twenty-seven groups (n = 5 mice/group). The experimental groups are identified in Table 10. TABLE 10 Group # Treatment FLT3L, XCL1, CXCL13, TIM4-Fc, TLRFLT3L, XCL1, CXCL13, CD80-MBFLT3L, XCL1, CXCL13, CD40L-MB, TLRFLT3L, XCL1, CXCL13, IL-12 and TMFLT3L, XCL1, CXCL13, 4-1BBL-MBFLT3L, XCL1, CXCL13, IFNa A2FLT3L, XCL1, LIGHT, TIM4-FcFLT3L, XCL1, LIGHT, CD80-MBFLT3L, XCL1, LIGHT, CD40L-MB, TLRFLT3L, XCL1, LIGHT, IL-12 and TMFLT3L, XCL1, LIGHT, 4-1BBL-MBFLT3L, XCL1, LIGHT, IFNa A2FLT3L, XCL1, IL-21, TIM4-FcFLT3L, XCL1, IL-21, CD80-MBFLT3L, XCL1, IL-21, CD40L-MB WO 2022/051556 PCT/US2021/048944 16 FLT3L, XCL1, IL-21, IL-12 and TMFLT3L, XCL1, IL-21, 4-1BBL-MBFLT3L, XCL1, IL-21, IFNa A2FLT3L, XCL1, CCL21, TIM4-FcFLT3L, XCL1, CCL21, CD80-MBFLT3L, XCL1, CCL21, CD40L-MBFLT3L, XCL1, CCL21, IL-12 and TMFLT3L, XCL1, CCL21, 4-1BBL-MBFLT3L, XCL1, CCL21, IFNa A2All PayloadsSaline3t3 cells (no payload) id="p-173" id="p-173" id="p-173" id="p-173" id="p-173" id="p-173" id="p-173" id="p-173" id="p-173" id="p-173" id="p-173"

[0173] Dosing.Tumor volume was between 100 mm3 and 150 mm3 at the time of the first injection. For the groups receiving 4 payloads, each pay load was delivered at 2.5 x 105 cells per injection for a total of 106 cells delivered. For the groups receiving 5 payloads, each pay load was delivered at [x] cells per injection for a total of 3 x 106 cells delivered. The fifth pay load was co- administered with P01y(I:C), which is a ds-RNA analogy. Payloads were injected intra-tumor. The volume of administration was 50 pL for all groups except the poly (I:C) group and the large 12-way group, where the volume was 150 pL. [0174] Payload Administration Procedures.Cells were harvested with versene (not in the presences of trypsin). Once collected, the cells were counted, spun and resuspended in a volume that could be adjusted to 20 x 10A/ml after the cells are recounted. All payloads were brought to x 10A6 per mL. TLR agonist (invivogen Cat#vac-pic) by resuspending lyophilized powder in water provided. TLR agonist was resuspended at 10 mg/ml and heated to 70degC and then let to sit at RT for 1 hour prior to using. The dose of TLR agonist is 50 pg in 50 pl. [0175] Results.The results are depicted in FIGS 9-11. Several combinations of payloads injected ipsilaterally demonstrated antitumor activity in the contralateral tumors manifested as delayed tumor growth in this model. Groups 3, 8 and 21 showed the most significant impairment of tumor growth over 30 days. Example 6 - Modified B Cells that Express and Secrete Payloads [0176] Experimental Design.A BALB/c mouse CT26 tumor model was used to evaluate the efficacy of modified B cells expressing various payload on tumor volume and survival. Mice were injected with tumor cells at a volume of 100 pL. On day 6 once tumors had reached a volume of 175mm3, mice were injected with modified B cells expressing various payloads as described below. Tumor volume and survival were measured for 17 days.

WO 2022/051556 PCT/US2021/048944 id="p-177" id="p-177" id="p-177" id="p-177" id="p-177" id="p-177" id="p-177" id="p-177" id="p-177" id="p-177" id="p-177"

[0177] Isolation of Mouse PBMCs.Mouse PBMCs or splenocytes are isolated from blood or spleen, respectively. PBMCs are isolated using Lympholyte-M (CedarLane, Cat#CL5030). Splenocytes are isolated by manual cell separation through a 70 micron nylon cell strainer. B cells are then isolated from PBMCs or splenocytes via immunomagnetic negative selection using EasySep® Mouse B cell Isolation Kit (Stem Cell Technologies, Cat #19854). [0178] Selection of Payloads.Nucleic acid sequences expressing payload peptides or proteins are transfected or transduced into isolated B cells. The following twelve peptides were identified for their potential to (i) recruit and activate dendritic cells; (ii) initiate homing and guidance of dendritic cells and T cells into the tumor site; and (iii) activate effector T cells. The payloads screened are listed in Table 9. [0179]Each mouse was either given a combination of 4-5 payloads, or isolated B cells (without payload) or saline as a control. In total, there were twenty-seven groups (n = 5 mice/group). The experimental groups are identified in Table 11. TABLE 11 Group # T reatment FLT3L, XCL1, CXCL13, CD40L-MB, TERFLT3L, XCL1, mLIGHT, CD80-MBFLT3L, XCL1, CCL21, CD40L-MBSalineB cells (no payload) id="p-180" id="p-180" id="p-180" id="p-180" id="p-180" id="p-180" id="p-180" id="p-180" id="p-180" id="p-180" id="p-180"

[0180]Generation of Payload Expressing B Cells. For transfection, purified or cultured B cells are washed and suspended in Cytoporation Medium T (BTX, Cat # 47-0002) at 5 x 106 to 25 x 106 cells per ml and mixed with 7.5 pg to 50 pg RNA (RNA constructs are designed and prepped in house or purchased from TriLink using CleanCap® and fully substituted with Pseudo-U). 200 pL cell/RNA suspension electroporated using BTX Agilpulse® Electroporation System. [0181] Dosing.Tumor volume was between 100 mm3 and 150 mm3 at the time of the first injection. For the groups receiving 4 payloads, each pay load was delivered at 2.5 x 105 cells per injection for a total of 106 cells delivered. For the groups receiving 5 payloads, each pay load was delivered at 2.5 x 105 cells per injection for a total of 1.25 x 106 cells delivered. Payloads were injected intra-tumor. The volume of administration was 50 pL for groups receiving 4 payloads, the volume of administration was 100 pL for groups receiving 5 payloads. [0182] Payload Administration Procedures.Cells were harvested with versene (not in the presence of trypsin). Once collected, the cells were counted, spun and resuspended in a volume that could be adjusted to 20 x 106/ml. All payloads were brought to 20 x 106 per mL. TER agonist (InvivoGen Cat#vac-pic) by resuspending lyophilized powder in water provided. TER agonist was WO 2022/051556 PCT/US2021/048944 resuspended at 10 mg/ml and heated to 70°C and then let to sit at RT for 1 hour prior to using. The dose of TLR agonist is 50 pg in 50 pl. Example 7 - Anti-tumor activity of intratumorally injected B cells [0183]Mouse splenocytes were obtained and isolated via manual cell separation utilizing a micron nylon cell strainer. Autologous (BALB/c) or allogeneic (C57B1/6) donor mice were used (data shown utilized allogeneic B cells). B cells were isolated from the splenocytes above using immunomagnetic negative selection via the EasySep® Mouse B Cell Isolation Kit (Stem Cell Technologies®, Cat #19854). [0184]B cells were then injected either (i) fresh or (ii) first stimulated for 16-24 hours in growth media (RPMI, 10% FBS, 1% Pen/Strep, 5ng/ml recombinant mouse IL-4, lOOuM beta- mercaptoethanol) with 5 pg/ml Lipopolysaccharide. 5X106 B cells were then intratumorally injected into the CT26 mouse model, and anti-tumor responses in the distal (abscopal) tumor where measured. Tumors were implanted at day 0, and at day 6 palpable tumor mass was observed.Treatment was initiated on day 6 intratumorally. The results are set for in Figure 12. Example 8 - Expression of chimeric antigen receptor (CAR) in B cells using RNA electroporation to make CAR B cells [0185]Mouse PBMCs or splenocytes were isolated from blood or spleen as follows. Mouse PBMCs were isolated using Lympholyte-M (CedarLane, Cat #CL5030), and splenocytes were isolated by manual cell separation via passage through a 70 micron nylon cell strainer. B cells were then isolated from PBMCs or splenocytes, respectively, via immunomagnetic negative selection using the EasySep® Mouse B Cell Isolation Kit (Stem Cell Technologies, Cat #19854). [0186]B cells were then stimulated for 16-24 hours in growth media (RPMI, 10% FBS, 1% Pen/Strep, 5ng/ml recombinant mouse IL-4, and lOOuM beta-mercaptoethanol) with 5-15 ug/ml lipopolysaccharide. B cells were then transduced or transfected using known techniques (viral transfection or electroporation) to achieve either stable or transient expression of cBCR (CAR-B). A strep II tag was incorporated for post-translational detection. Representative cBCRs (CAR-Bs) depicted are as follows:1. XENP PSMA CBCR (3X strep II tag)2. HyHEL 10 CBCR (3X strep II tag)3. D1.3-M3 HEL CBCR (3X strep II tag) [0187]For transfection, purified or cultured B cells were washed and suspended in Cytoporation Medium T (BTX, Cat #47-0002) at 5xl06 to 25xl06 cells per ml and mixed with 7.5ug to 50ug RNA (RNA constructs were designed and prepped either in-house or purchased from TriLink using CleanCap® and fully substituted with Pseudo-U). A 200ul cell/RNA suspension was obtained and electroporated using the BTX AgilePulse® Electroporation System. Cells were then washed in PBS and prepped for IV injection into immune-incompetent mice with established HepG2 tumor cells that express respective antigen (e.g. GPC3, HEL, PSMA). Translation and expression of protein of WO 2022/051556 PCT/US2021/048944 interest was then measured using an anti-Strep II tag antibody. The results are set forth in Figure 13. In Figure 13, the X axis shows strength of expression signal as measured by flow cytometry, and the Y axis sets forth percent of cells expressing the desired protein of interest (PSMA, HEL). [0188]This experiment demonstrates that the desired RNA sequence/s are successfully transfected or transduced (accordingly), the RNA is successfully translated, and the desired protein of interest is expressed on cell surface. Example 9 - Modified B cells expressing integrins and homing receptors [0189]Nucleic acid constructs expressing an integrin, a homing receptor, or both are constructed using known techniques. Mouse and Human B cells are transfected or transduced (accordingly) with the nucleic acid constructs to express the integrin, the homing receptor, or both. These modified cells are administered intravenously into mice or a human host. Time-lapse imaging will measure accumulation of the modified B cells at the site/target of interest, such as a homing or target tissue, an inflammatory site in a specific location or tissue, or a tumor or tumor microenvironment, to establish that expression of an integrin and/or a homing receptor of defined homing specificity endows the B cells with the ability to home to and accumulate at the site/target of interest where delivery of therapeutic payloads is desirable. A screening study is conducted according to the techniques of Example 5 to examine delivery and effect of payloads at the site/target of interest. Example 10 - Altering B cell trafficking [0190]Isolated B cells are cultured with a specific concentration of all-trans-retinoic acid (ATRA) or derivatives thereof that induce expression of a4p7 integrin and the homing receptor CCR9. Thereafter, the B cells are harvested and administered intravenously into mice. There are two experimental groups of the recipient mice. The first group of mice are pre-treated with DSS or TNBS to induce gut inflammation. The second group of mice are not treated with DSS or TNBS. Inflammation similar to that observed in human intestinal bowl diseases is induced by pretreatment with DSS or TNBS. Administered B cells treated with ATRA or derivative thereof will home to areas of inflammation consistent with their homing potential due to increased expression of a4pintegrin and the homing receptor CCR9. Example 11 - Modified B cells expressing immune inhibitory molecules [0191]Nucleic acid constructs expressing an immune inhibitory molecule selected from IL-10, TGF-P, PD-L1, PD-L2, LAG-3, and TIM-3, or any combinations thereof, are constructed using known techniques. Mouse and Human B cells are transfected or transduced (accordingly) with the nucleic acid constructs to express one or more of the immune inhibitory molecules listed above. These modified cells are administered intravenously into mice or a human host. Time-lapse imaging will measure accumulation of the modified B cells at a site/target of interest, such as a homing or target tissue, an inflammatory site in a specific location or tissue, or a tumor or tumor WO 2022/051556 PCT/US2021/048944 microenvironment, to establish that inflammation at the site and autoimmune activity of the B cells localized to the site are decreased, thereby leading to a positive therapeutic response. Example 12 - Activation of B cells with TLRs [0192]B cells are treated with TLR agonists and/or modified to express a constitutively active TLR for use in potentiating B cells for immune responses and producing potent effector B cells to increase antigen-specific immune responses in a subject. Isolated mouse or human B cells are treated in vitro with a TLR agonist at the same time or in advance of the administration of the B cells. In some instances, the mouse or human B cells are treated with more than one TLR agonists. [0193]A modified B cell, transfected or transduced with or without a CAR-B construct of the foregoing examples, is engineered to express one or more constitutively active TLRs. Each TLR is introduced into the modified B cell (transduced or transfected using known techniques) as a DNA construct under the control of a constitutively activated transcriptional pathway. A modified B cell, expressing one or more constitutively active TLRs (with or without a CAR-B construct), is also treated with one or more TLR agonists at the same time or in advance of the administration of the modified B cells to a subject or patient in need thereof. Time-lapse imaging and other known techniques will measure accumulation of the modified B cells in the desired location and confirm expression of the TLR(s) and any expressed CAR-B of a defined specificity. [0194]This experiment will demonstrate that the desired DNA sequence/s encoding specific TLR(s) of interest are successfully transfected or transduced (accordingly) into B cells with or without a CAR-B construct and treated with or without TLR agonist(s), the RNA is successfully translated, the desired TLR(s) are expressed in the B cells for producing potent effector B cells potentiating B cells for immune responses. Example 13 - Antigen presentation both in HLA Class I and Class II molecules using RNA electroporated B cells [0195] mRNA Constructs.Exemplary mRNA constructs are designed by fusing a specific antigen, e.g., a tumor antigen or an infectious disease antigen, to the targeting signal of a the lysosomal protein LAMP1, to target the specific antigen to the lysosomes and present the antigen simultaneously and efficiently in both HLA class I and class II molecules. Tumor antigens and infectious disease antigens are well known in the art, and can include any antigen of interest against which an immune response is desired. Various mRNA constructs are made encoding at least one specific antigen of interest fused to the targeting signal of LAMP 1 that is capable of presenting the specific antigen simultaneously and efficiently in both HLA class I and class II molecules when transfected into a suitable immune cell. [0196] Experimental Design.Isolated mouse or human B cells are electroporated in vitro with an mRNA construct described above (i.e., encoding a specific antigen of interest fused to the targeting signal of LAMP1) using known mRNA electroporation techniques. In some instances, the mouse or human B cells are also transduced or transfected using known techniques with a CAR-B construct

Claims

1.WO 2022/051556 PCT/US2021/048944 What is Claimed 1. An isolated modified B cell, capable of expressing an integrin, a homing antibody, protein, a receptor, or combinations thereof, wherein said integrin, homing antibody, protein, or receptor is not naturally expressed in a B cell or is expressed at higher levels than is naturally expressed in a B cell; and wherein said integrin, homing antibody, protein, receptor, or combinations thereof is attracted to a site or target of interest.

2. The isolated modified B cell of claim 82, wherein the integrin, homing antibody, protein, and receptor is selected from CLA (PSGL-1 glycoform), CLA (PSGL-1 glycoform), CCR10, CCR3, CCR4, CCR5, CCR6, CCR9, CD43E, CD44, c-Met, CXCR3, CXCR4, LFA-1, LFA-1 (aL02), selectin ligands, VLA-4, VLA-4 (a401), and a407, or combinations thereof.

3. The isolated modified B cell of claim 83, wherein the site of interest is a homing or target tissue, an inflammatory site in a specific location or tissue, or a tumor or tumor microenvironment, where delivery of payloads is desirable.

4. The isolated modified B cell of claim 84, wherein the homing or target tissue is selected from skin, gut (intestine, colon, mesenteric lymph nodes (mLN), Peyer’s Patch (PP), small intestine), liver, lung, bone marrow, heart, peripheral lymph node (LN), CNS, thymus, and bone marrow.

5. The isolated modified B cell of claim 85, wherein the target of interest is selected from CXCL16, CCL17, CCL17(22), CCL20 (MIP-3a), CCL21, CCL25, CCL27, CCL28, CCL4, CCL5, CD62E, CD62P, CXCL10, CXCL12, CXCL13, CXCL16, CXCL9/CXCL10, CXCR3, E/P-selectin, E-selectin, GPR15L, HGF, Hyaluronate, ICAM-1, ligands for CCR1, 2, 5, MAdCAM, MAdCAM-1, PNAd, VAP-1, VC AM, and VCAM-1, or combinations thereof.

6. A method of treating a patient comprising administering the isolated modified B cell of claim 82.

7. The method of claim 87, further comprising administering a compound or a derivative thereof, wherein the compound or derivative thereof is capable of increasing the expression of the integrin, homing antibody, protein, and receptor, or combinations thereof.

8. The method of claim 88, wherein the compound or a derivative thereof is capable of altering trafficking of B cells to a site or target of interest in the patient.

9. The method of claim 89, wherein the compound is all-trans-retinoic acid (ATRA) or a derivative thereof.

10. An isolated modified B cell, capable of expressing an immune inhibitory molecule, wherein said immune inhibitory molecule is not naturally expressed in a B cell or is expressed at higher levels than is naturally expressed in a B cell.

11. The isolated modified B cell of claim 91, wherein said immune inhibitory molecule is selected from IL-10, TGF-0, PD-L1, PD-L2, LAG-3, and TIM-3, or combinations thereof.

12. The isolated modified B cell of claim 92, wherein said immune inhibitory molecule is capable of decreasing inflammation and autoimmune activity of B cells at a site or target of interest in a WO 2022/051556 PCT/US2021/048944 patient.

13. A method of treating a patient comprising administering the isolated modified B cell of claim 91.

14. The method of claim 94, wherein said immune inhibitory molecule is selected from IL-10, TGF־P, PD-L1, PD-L2, LAG-3, and TIM-3, or combinations thereof.

15. The method of claim 95, wherein said immune inhibitory molecule is capable of decreasing inflammation and autoimmune activity of B cells at a site or target of interest in the patient.

16. The method of claim 96, further comprising administering a compound or a derivative thereof capable of increasing the expression of an integrin, a homing antibody, a protein, a receptor, or combinations thereof in the B cell.

17. The method of claim 97, wherein said compound or derivative thereof is capable of altering trafficking of B cells to a site or target of interest in the patient.

18. The method of claim 98, wherein said compound is all-trans-retinoic acid (ATRA) or a derivative thereof.

19. An isolated modified B cell, wherein the isolated modified B cell is treated with a compound or a derivative thereof, wherein said compound or derivative thereof is capable of increasing the expression of an integrin, a homing antibody, a protein, a receptor, or combinations thereof in B cells.

20. The isolated modified B cell of claim 100, wherein said compound or derivative thereof is capable of altering trafficking of B cells to a site or target of interest in the patient.

21. The isolated modified B cell of claim 101, wherein said compound is all-trans-retinoic acid (ATRA) or a derivative thereof

22. A method of treating a patient comprising administering the isolated modified B cell of claim 100, wherein said compound or derivative thereof is capable of (i) increasing the expression of an integrin, a homing antibody, a protein, a receptor, or combinations thereof in B cells, and (ii) altering trafficking of B cells to a site or target of interest in the patient.

23. The method of claim 103, wherein said compound is all-trans-retinoic acid (ATRA) or a derivative thereof.

24. An isolated modified B cell, capable of expressing at least one or more of a constitutively active Toll-like receptor (TLR), wherein said TLR is not naturally expressed in a B cell or is expressed at higher levels than is naturally expressed in a B cell.

25. The isolated modified B cell of claim 105, wherein said TLR is selected from TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9, TLR10, TLR11, TLR12, and TLR13, or combinations thereof.

26. The isolated modified B cell of claim 106, wherein said TLR is capable of potentiating B cells for increasing immune responses in a patient.Tl.

27.The isolated modified B cell of claim 107, wherein said TLR is capable of producing potent effector B cells for increasing immune responses in a patient. 100 WO 2022/051556 PCT/US2021/048944

28. A method of treating a patient comprising administering the isolated modified B cell of claim 105, wherein said immune inhibitory molecule is capable of decreasing inflammation and autoimmune activity of B cells at a site or target of interest in a patient.

29. The method of claim 109, wherein said TLR is selected from TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9, TLR10, TLR11, TLR12, and TLR13, or combinations thereof.

30. The method of claim 110, wherein said TLR is capable of (i) potentiating B cells, and (ii) producing potent effector B cells, for increasing immune responses in a patient.

31. The method of claim 111, further comprising administering at least one or more of a TLR agonist to the patient.

32. An isolated modified B cell, wherein the isolated modified B cell is treated with at least one or more of a TLR agonist.

33. The isolated modified B cell of claim 113, wherein said TLR agonist is capable of (i) potentiating B cells, and (ii) producing potent effector B cells, for increasing immune responses in a patient.

34. The isolated modified B cell of claim 114, wherein said TLR agonist binds to one or more TLRs selected from TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9, TLR10, TLR11, TLR12, and TLR13, or combinations thereof.

35. The isolated modified B cell of claim 115, wherein said TLR agonist is selected from CpG- rich oligonucleotides, double-stranded RNA mimic, polyinosinic acid:polycytidylic acid (poly-I:C).

36. The isolated modified B cell of claim 116, wherein said TLR agonist comprises CpG oligonucleotides.

37. A method of treating a patient comprising administering the isolated modified B cell of claim 113.

38. The method of claim 118, wherein said TLR agonist is capable of is capable of (i) potentiating B cells, and (ii) producing potent effector B cells, for increasing immune responses in the patient.

39. The method of claim 119, wherein said TLR agonist binds to one or more T LRs selected from TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9, TLR10, TLR11, TLR12, and TLR13, or combinations thereof.

40. The method of claim 120, wherein said TLR agonist is selected from CpG-rich oligonucleotides, double-stranded RNA mimic, polyinosinic acid:polycytidylic acid (poly-I:C).

41. The method of claim 121, wherein said TLR agonist comprises CpG oligonucleotides.

42. An isolated modified B cell, wherein said B cell is electroporated with an mRNA encoding at least one or more of an antigen fused to a targeting signal.

43. The isolated modified B cell of claim 123, wherein said antigen is (i) not naturally presented by a B cell, (ii) not presented by a B cell simultaneously in both HLA class I and class II molecules naturally, or (iii) not presented by a B cell with high efficiencies in both HLA class I and class II molecules naturally. 101 WO 2022/051556 PCT/US2021/048944

44. The isolated modified B cell of claim 124, wherein said targeting signal is targeting signal of a lysosomal protein.

45. The isolated modified B cell of claim 125, wherein said targeting signal is a targeting signal of lysosome-associated membrane protein-1 (LAMP1).

46. The isolated modified B cell of claim 126, wherein said antigen is capable of being targeted to the lysosomes and presented simultaneously and efficiently in both HLA class I and class II molecules.

47. The isolated modified B cell of claim 127, wherein said B cells is capable of increasing antigen-specific immune responses in a patient.

48. A method of treating a patient comprising administering the isolated modified B cell of claim 123.

49. The method of claim 129, wherein said antigen is (i) not naturally presented by a B cell, (ii) not presented by a B cell simultaneously in both HLA class I and class II molecules naturally, or (iii) not presented by a B cell with high efficiencies in both HLA class I and class II molecules naturally.

50. The method of claim 130, wherein said targeting signal is targeting signal of a lysosomal protein.

51. The method of claim 131, wherein said targeting signal is a targeting signal of lysosome- associated membrane protein-1 (LAMP1).

52. The method of claim 132, wherein said antigen is capable of being targeted to the lysosomes and presented simultaneously and efficiently in both HLA class I and class II molecules.

53. The method of claim 133, wherein said B cells is capable of increasing antigen-specific immune responses in the patient. 102